IRE1 Small Molecule Inhibitors

ABSTRACT

Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.

CROSS-REFERENCE

This application claims benefit of U.S. Provisional Patent ApplicationNo. 62/429,498 filed on Dec. 2, 2016, which is incorporated herein byreference in its entirety.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has beensubmitted electronically in ASCII format and is hereby incorporated byreference in its entirety. Said ASCII copy, created on Nov. 28, 2017, isnamed 51089-707_601_SL.txt and is 23,840 bytes in size.

BACKGROUND

Aggressive tumors have evolved strategies that enable them to thriveunder constant adverse conditions. For example, cancer cells respond tohypoxia, nutrient starvation, oxidative stress, and high metabolicdemand by adjusting their protein folding capacity via the endoplasmicreticulum (ER) stress response pathway. There exists a need for improvedmethods and compositions to target cancer cells and counter theirmechanisms of survival.

BRIEF SUMMARY

Provided in one aspect is a compound of Formula (I), or apharmaceutically acceptable salt, or solvate thereof:

wherein,

is an optionally substituted C₃-C₁₀ heterocyclyl containing at least oneN, O, S, S(═O), or S(═O)₂; wherein if

is substituted, then

is substituted with 0-3 R⁵;

is a substituted C₃-C₁₀ cycloalkyl that is substituted with 1-3R⁴ and0-3R⁵;

-   -   each R⁴ is independently —OR⁶, —SR⁶, —S(═O)R⁷, —S(═O)₂R⁷, or        —N(R⁶)₂;    -   each R⁵ is independently halogen, —CN, —OR⁸, —SR⁸, —S(═O)R⁹,        —S(═O)₂R⁹, —S(═O)₂N(R⁸)₂, —NR⁸S(═O)₂R⁹, —C(═O)R⁹, —OC(═O)R⁹,        —CO₂R⁸, —OCO₂R⁹, —N(R⁸)₂, —OC(═O)N(R⁸)₂, —NR⁸C(═O)R⁹,        —NR⁸C(═O)OR⁹, optionally substituted C₁-C₆alkyl, optionally        substituted C₁-C₆ fluoroalkyl, optionally substituted        C₁-C₆heteroalkyl, optionally substituted C₃-C₆cycloalkyl,        optionally substituted aryl, or optionally substituted        heteroaryl;    -   A¹ is N or CR^(A); A² is N or CR^(A); A³ is N or CR^(A); A⁴ is N        or CR^(A); A⁵ is N or CR^(A);    -   each R^(A) is independently H or optionally substituted        C₁-C₆alkyl;    -   R¹ and R² are each independently H or optionally substituted        C₁-C₆alkyl;    -   L¹ and L² are each independently —CHY—, —CH₂— or —NH—;    -   Y is optionally substituted C₁-C₆alkyl;

is optionally substituted aryl or optionally substituted heteroaryl,wherein if

is substituted, then

is substituted with 0-4 R^(c);

-   -   each R^(c) is independently H, halogen, —CN, —OR¹⁰, —SR¹⁰,        —S(═O)R¹¹, —S(═O)₂R¹¹, —S(═O)₂N(R¹⁰)₂, —NR¹⁰S(═O)₂R¹¹, —C(═O)R¹,        —OC(═O)R¹¹, —CO₂R¹⁰, —OCO₂R¹¹, —N(R¹⁰)₂, —OC(═O)N(R¹⁰)₂,        —NR¹¹C(═O)R¹¹, —NR¹⁰C(═O)OR¹¹, optionally substituted        C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl, optionally        substituted C₁-C₆heteroalkyl, optionally substituted        C₃-C₆cycloalkyl, optionally substituted aryl, or optionally        substituted heteroaryl;    -   each R³ is independently H or optionally substituted C₁-C₆alkyl;

or L^(D);

is optionally substituted heterocyclyl containing at least one N atom;wherein if

is substituted, then

is substituted with 0-4 R^(D);

-   -   L^(D) is —N(R¹²)-(optionally substituted C₁-C₆ alkyl),        —N(R¹³)-(optionally substituted C₁-C₆ alkylene)-N(R¹⁴)₂ or        -(optionally substituted C₁-C₆ alkylene)-N(R¹⁴)₂; wherein if        L^(D) is substituted, then L^(D) is substituted with 0-4 R^(D);    -   each R^(D) is independently halogen, —CN, —OR¹⁵, —SR¹⁵,        —S(═O)R¹⁶, —S(═O)₂R¹⁶, —S(═O)₂N(R¹⁵)₂, —NR¹⁵S(═O)₂R¹⁶,        —C(═O)R¹⁶, —OC(═O)R¹⁶, —CO₂R¹⁵, —OCO₂R¹⁶, —N(R¹⁵)₂,        —OC(═O)N(R¹)₂, —NR¹⁵C(═O)R¹⁶, —NR¹⁵C(═O)OR¹⁶, optionally        substituted C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl,        optionally substituted C₁-C₆heteroalkyl, optionally substituted        C₃-C₆cycloalkyl, optionally substituted aryl, or optionally        substituted heteroaryl;    -   each R⁶ is independently hydrogen, optionally substituted        C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl, optionally        substituted C₁-C₆heteroalkyl, optionally substituted        C₃-C₁₀cycloalkyl, optionally substituted C₂-C₁₀heterocycloalkyl,        optionally substituted aryl, or optionally substituted        heteroaryl; or    -   two R⁶ are taken together with the N atom to which they are        attached to form an optionally substituted heterocycle;    -   each R⁷ is independently optionally substituted C₁-C₆alkyl,        optionally substituted C₁-C₆fluoroalkyl, optionally substituted        C₁-C₆heteroalkyl, optionally substituted C₃-C₁₀cycloalkyl,        optionally substituted C₂-C₁₀heterocycloalkyl, optionally        substituted aryl, or optionally substituted heteroaryl;    -   each R⁸ is independently hydrogen, optionally substituted        C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl, optionally        substituted C₁-C₆heteroalkyl, optionally substituted        C₃-C₁₀cycloalkyl, optionally substituted C₂-C₁₀heterocycloalkyl,        optionally substituted aryl, or optionally substituted        heteroaryl; or    -   two R⁸ are taken together with the N atom to which they are        attached to form an optionally substituted heterocycle;    -   each R⁹ is independently optionally substituted C₁-C₆alkyl,        optionally substituted C₁-C₆fluoroalkyl, optionally substituted        C₁-C₆heteroalkyl, optionally substituted C₃-C₁₀cycloalkyl,        optionally substituted C₂-C₁₀heterocycloalkyl, optionally        substituted aryl, or optionally substituted heteroaryl;    -   each R¹⁰ is independently hydrogen, optionally substituted        C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl, optionally        substituted C₁-C₆heteroalkyl, optionally substituted        C₃-C₁₀cycloalkyl, optionally substituted C₂-C₁₀heterocycloalkyl,        optionally substituted aryl, or optionally substituted        heteroaryl; or    -   two R¹⁰ are taken together with the N atom to which they are        attached to form an optionally substituted heterocycle;    -   each R¹¹ is independently optionally substituted C₁-C₆alkyl,        optionally substituted C₁-C₆fluoroalkyl, optionally substituted        C₁-C₆heteroalkyl, optionally substituted C₃-C₁₀cycloalkyl,        optionally substituted C₂-C₁₀heterocycloalkyl, optionally        substituted aryl, or optionally substituted heteroaryl;    -   each R¹² and R¹³ is independently H or optionally substituted        C₁-C₆alkyl;    -   each R¹⁴ is independently H or optionally substituted        C₁-C₆alkyl; or    -   two R¹⁴ are taken together with the N atom to which they are        attached to form an optionally substituted heterocycle;    -   each R¹⁵ is independently hydrogen, optionally substituted        C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl, optionally        substituted C₁-C₆heteroalkyl, optionally substituted        C₃-C₁₀cycloalkyl, optionally substituted C₂-C₁₀heterocycloalkyl,        optionally substituted aryl, or optionally substituted        heteroaryl; or    -   two R¹⁵ are taken together with the N atom to which they are        attached to form an optionally substituted heterocycle; and    -   each R¹⁶ is independently optionally substituted C₁-C₆alkyl,        optionally substituted C₁-C₆fluoroalkyl, optionally substituted        C₁-C₆heteroalkyl, optionally substituted C₃-C₁₀cycloalkyl,        optionally substituted C₂-C₁₀heterocycloalkyl, optionally        substituted aryl, or optionally substituted heteroaryl.

Also provided herein in another aspect is a compound of Formula (II), ora pharmaceutically acceptable salt, or solvate thereof:

wherein,

Z is H,

is optionally substituted C₃-C₁₀ heterocyclyl containing at least one N,O, S, S(═O), or S(═O)₂; wherein if

is substituted, then

is substituted with 0-3 R⁵;

is a substituted C₃-C₁₀ cycloalkyl that is substituted with 1-3R⁴ and0-3R⁵;

-   -   each R⁴ is independently —OR⁶, —SR⁶, —S(═O)R⁷, —S(═O)₂R⁷, or        —N(R⁶)₂;    -   each R⁵ is independently halogen, —CN, —OR⁸, —SR⁸, —S(═O)R⁹,        —S(═O)₂R⁹, —S(═O)₂N(R⁸)₂, —NR⁸S(═O)₂R⁹, —C(═O)R⁹, —OC(═O)R⁹,        —CO₂R⁸, —OCO₂R⁹, —N(R⁸)₂, —OC(═O)N(R⁸)₂, —NR⁸C(═O)R⁹,        —NR⁸C(═O)OR⁹, optionally substituted C₁-C₆alkyl, optionally        substituted C₁-C₆fluoroalkyl, optionally substituted        C₁-C₆heteroalkyl, optionally substituted C₃-C₆cycloalkyl,        optionally substituted aryl, or optionally substituted        heteroaryl;    -   A¹ is N or CR^(A); A² is N or CR^(A); A⁴ is N or CR^(A); A⁵ is N        or CR^(A);    -   each R^(A) is independently H or optionally substituted        C₁-C₆alkyl;    -   R^(A′) is optionally substituted C₁-C₆alkyl;    -   R¹ and R² are each independently H or optionally substituted        C₁-C₆alkyl;    -   L¹ and L² are each independently —CHY—, —CH₂— or —NH—;    -   Y is optionally substituted C₁-C₆alkyl;

is optionally substituted aryl or optionally substituted heteroaryl,wherein if

is substituted, then

is substituted with 0-4 R^(c);

-   -   each R^(c) is independently H, halogen, —CN, —OR¹⁰, —SR¹⁰,        —S(═O)R¹¹, —S(═O)₂R¹¹, —S(═O)₂N(R¹⁰)₂, —NR¹⁰S(═O)₂R¹¹,        —C(═O)R¹¹, —OC(═O)R¹¹, —CO₂R¹⁰, —OCO₂R¹¹, —N(R¹⁰)₂,        —OC(═O)N(R¹⁰)₂, —NR¹⁰C(═O)R¹¹, —NR¹¹C(═O)OR¹¹, optionally        substituted C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl,        optionally substituted C₁-C₆heteroalkyl, optionally substituted        C₃-C₆cycloalkyl, optionally substituted aryl, or optionally        substituted heteroaryl;    -   each R³ is independently H or optionally substituted C₁-C₆alkyl;

or L^(D);

is optionally substituted heterocyclyl containing at least one N atom;wherein if

is substituted, then

is substituted with 0-4 R^(D);

-   -   L^(D) is —N(R¹²)-(optionally substituted C₁-C₆ alkyl),        —N(R¹³)-(optionally substituted C₁-C₆ alkylene)-N(R¹⁴)₂ or        -(optionally substituted C₁-C₆ alkylene)-N(R¹⁴)₂; wherein if        L^(D) is substituted, then L^(D) is substituted with 0-4 R^(D);    -   each R^(D) is independently halogen, —CN, —OR¹⁵, —SR¹⁵,        —S(═O)R¹⁶, —S(═O)₂R¹⁶, —S(═O)₂N(R¹⁵)₂, —NR¹⁵S(═O)₂R¹⁶,        —C(═O)R¹⁶, —OC(═O)R¹⁶, —CO₂R¹⁵, —OCO₂R¹⁶, —N(R¹⁵)₂,        —OC(═O)N(R¹)₂, —NR¹⁵C(═O)R¹⁶, —NR¹⁵C(═O)OR¹⁶, optionally        substituted C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl,        optionally substituted C₁-C₆heteroalkyl, optionally substituted        C₃-C₆cycloalkyl, optionally substituted aryl, or optionally        substituted heteroaryl;    -   each R⁶ is independently hydrogen, optionally substituted        C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl, optionally        substituted C₁-C₆heteroalkyl, optionally substituted        C₃-C₁₀cycloalkyl, optionally substituted C₂-C₁₀heterocycloalkyl,        optionally substituted aryl, or optionally substituted        heteroaryl; or    -   two R⁶ are taken together with the N atom to which they are        attached to form an optionally substituted heterocycle;    -   each R⁷ is independently optionally substituted C₁-C₆alkyl,        optionally substituted C₁-C₆fluoroalkyl, optionally substituted        C₁-C₆heteroalkyl, optionally substituted C₃-C₁₀cycloalkyl,        optionally substituted C₂-C₁₀heterocycloalkyl, optionally        substituted aryl, or optionally substituted heteroaryl;    -   each R⁸ is independently hydrogen, optionally substituted        C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl, optionally        substituted C₁-C₆heteroalkyl, optionally substituted        C₃-C₁₀cycloalkyl, optionally substituted C₂-C₁₀heterocycloalkyl,        optionally substituted aryl, or optionally substituted        heteroaryl; or    -   two R⁸ are taken together with the N atom to which they are        attached to form an optionally substituted heterocycle;    -   each R⁹ is independently optionally substituted C₁-C₆alkyl,        optionally substituted C₁-C₆fluoroalkyl, optionally substituted        C₁-C₆heteroalkyl, optionally substituted C₃-C₁₀cycloalkyl,        optionally substituted C₂-C₁₀heterocycloalkyl, optionally        substituted aryl, or optionally substituted heteroaryl;    -   each R¹⁰ is independently hydrogen, optionally substituted        C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl, optionally        substituted C₁-C₆heteroalkyl, optionally substituted        C₃-C₁₀cycloalkyl, optionally substituted C₂-C₁₀heterocycloalkyl,        optionally substituted aryl, or optionally substituted        heteroaryl; or    -   two R¹⁰ are taken together with the N atom to which they are        attached to form an optionally substituted heterocycle;    -   each R¹¹ is independently optionally substituted C₁-C₆alkyl,        optionally substituted C₁-C₆fluoroalkyl, optionally substituted        C₁-C₆heteroalkyl, optionally substituted C₃-C₁₀cycloalkyl,        optionally substituted C₂-C₁₀heterocycloalkyl, optionally        substituted aryl, or optionally substituted heteroaryl;    -   each R¹² and R¹³ is independently H or optionally substituted        C₁-C₆alkyl;    -   each R¹⁴ is independently H or optionally substituted        C₁-C₆alkyl; or    -   two R¹⁴ are taken together with the N atom to which they are        attached to form an optionally substituted heterocycle;    -   each R¹⁵ is independently hydrogen, optionally substituted        C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl, optionally        substituted C₁-C₆heteroalkyl, optionally substituted        C₃-C₁₀cycloalkyl, optionally substituted C₂-C₁₀heterocycloalkyl,        optionally substituted aryl, or optionally substituted        heteroaryl; or    -   two R¹⁵ are taken together with the N atom to which they are        attached to form an optionally substituted heterocycle; and    -   each R¹⁶ is independently optionally substituted C₁-C₆alkyl,        optionally substituted C₁-C₆fluoroalkyl, optionally substituted        C₁-C₆heteroalkyl, optionally substituted C₃-C₁₀cycloalkyl,        optionally substituted C₂-C₁₀heterocycloalkyl, optionally        substituted aryl, or optionally substituted heteroaryl.

Also provided herein in another aspect is a compound of Formula (III),or a pharmaceutically acceptable salt, or solvate thereof:

wherein,

Z is H,

is an optionally substituted C₃-C₁₀ heterocyclyl containing at least oneN, O, S, S(═O), or S(═O)₂; wherein if

is substituted, then

is substituted with 0-3 R⁵;

is a substituted C₃-C₁₀ cycloalkyl that is substituted with 1-3R⁴ and0-3R⁵;

-   -   each R⁴ is independently —OR⁶, —SR⁶, —S(═O)R⁷, —S(═O)₂R⁷, or        —N(R⁶)₂;    -   each R⁵ is independently halogen, —CN, —OR⁸, —SR⁸, —S(═O)R⁹,        —S(═O)₂R⁹, —S(═O)₂N(R⁸)₂, —NR⁸S(═O)₂R⁹, —C(═O)R⁹, —OC(═O)R⁹,        —CO₂R⁸, —OCO₂R⁹, —N(R⁸)₂, —OC(═O)N(R⁸)₂, —NR⁸C(═O)R⁹,        —NR⁸C(═O)OR⁹, optionally substituted C₁-C₆alkyl, optionally        substituted C₁-C₆fluoroalkyl, optionally substituted        C₁-C₆heteroalkyl, optionally substituted C₃-C₆cycloalkyl,        optionally substituted aryl, or optionally substituted        heteroaryl;    -   A¹ is N or CR^(A); A² is N or CR^(A); A³ is N or CR^(A); A⁴ is N        or CR^(A); A⁵ is N or CR^(A);    -   each R^(A) is independently H or optionally substituted        C₁-C₆alkyl;    -   R¹ and R² are each independently H or optionally substituted        C₁-C₆alkyl;    -   L¹ and L² are each independently —CHY—, —CH₂— or —NH—;    -   Y is optionally substituted C₁-C₆alkyl;

is optionally substituted aryl or optionally substituted heteroaryl,wherein if

is substituted, then

is substituted with 0-4 R^(c);

-   -   each R^(c) is independently H, halogen, —CN, —OR¹⁰, —SR¹⁰,        —S(═O)R¹¹, —S(═O)₂R¹¹, —S(═O)₂N(R¹⁰)₂, —NR¹⁰S(═O)₂R¹¹,        —C(═O)R¹¹, —OC(═O)R¹¹, —CO₂R¹⁰, —OCO₂R¹¹, —N(R¹⁰)₂,        —OC(═O)N(R¹⁰)₂, —NR¹⁰C(═O)R¹¹, —NR¹⁰C(═O)OR¹¹, optionally        substituted C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl,        optionally substituted C₁-C₆heteroalkyl, optionally substituted        C₃-C₆cycloalkyl, optionally substituted aryl, or optionally        substituted heteroaryl;    -   each R³ is independently H or optionally substituted C₁-C₆alkyl;    -   L^(D) is —N(R¹²)-(optionally substituted C₁-C₆ alkyl),        —N(R¹³)-(optionally substituted C₁-C₆ alkylene)-N(R¹⁴)₂ or        -(optionally substituted C₁-C₆ alkylene)-N(R¹⁴)₂; wherein if        L^(D) is substituted, then L^(D) is substituted with 0-4 R^(D);    -   each R^(D) is independently halogen, —CN, —OR¹⁵, —SR¹⁵,        —S(═O)R¹⁶, —S(═O)₂R¹⁶, —S(═O)₂N(R¹⁵)₂, —NR¹⁵S(═O)₂R¹⁶,        —C(═O)R¹⁶, —OC(═O)R¹⁶, —CO₂R¹⁵, —OCO₂R¹⁶, —N(R¹⁵)₂,        —OC(═O)N(R¹)₂, —NR¹⁵C(═O)R¹⁶, —NR¹⁵C(═O)OR¹⁶, optionally        substituted C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl,        optionally substituted C₁-C₆heteroalkyl, optionally substituted        C₃-C₆cycloalkyl, optionally substituted aryl, or optionally        substituted heteroaryl;    -   each R⁶ is independently hydrogen, optionally substituted        C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl, optionally        substituted C₁-C₆heteroalkyl, optionally substituted        C₃-C₁₀cycloalkyl, optionally substituted C₂-C₁₀heterocycloalkyl,        optionally substituted aryl, or optionally substituted        heteroaryl; or    -   two R⁶ are taken together with the N atom to which they are        attached to form an optionally substituted heterocycle;    -   each R⁷ is independently optionally substituted C₁-C₆alkyl,        optionally substituted C₁-C₆fluoroalkyl, optionally substituted        C₁-C₆heteroalkyl, optionally substituted C₃-C₁₀cycloalkyl,        optionally substituted C₂-C₁₀heterocycloalkyl, optionally        substituted aryl, or optionally substituted heteroaryl;    -   each R⁸ is independently hydrogen, optionally substituted        C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl, optionally        substituted C₁-C₆heteroalkyl, optionally substituted        C₃-C₁₀cycloalkyl, optionally substituted C₂-C₁₀heterocycloalkyl,        optionally substituted aryl, or optionally substituted        heteroaryl; or    -   two R⁸ are taken together with the N atom to which they are        attached to form an optionally substituted heterocycle;    -   each R⁹ is independently optionally substituted C₁-C₆alkyl,        optionally substituted C₁-C₆fluoroalkyl, optionally substituted        C₁-C₆heteroalkyl, optionally substituted C₃-C₁₀cycloalkyl,        optionally substituted C₂-C₁₀heterocycloalkyl, optionally        substituted aryl, or optionally substituted heteroaryl;    -   each R¹⁰ is independently hydrogen, optionally substituted        C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl, optionally        substituted C₁-C₆heteroalkyl, optionally substituted        C₃-C₁₀cycloalkyl, optionally substituted C₂-C₁₀heterocycloalkyl,        optionally substituted aryl, or optionally substituted        heteroaryl; or    -   two R¹⁰ are taken together with the N atom to which they are        attached to form an optionally substituted heterocycle;    -   each R¹¹ is independently optionally substituted C₁-C₆alkyl,        optionally substituted C₁-C₆fluoroalkyl, optionally substituted        C₁-C₆heteroalkyl, optionally substituted C₃-C₁₀cycloalkyl,        optionally substituted C₂-C₁₀heterocycloalkyl, optionally        substituted aryl, or optionally substituted heteroaryl;    -   R¹² is independently H or optionally substituted C₃-C₆alkyl;    -   R¹³ is H or optionally substituted C₁-C₆alkyl; Each R¹⁴ is        independently H or optionally substituted C₁-C₆alkyl; or    -   two R¹⁴ are taken together with the N atom to which they are        attached to form an optionally substituted heterocycle;    -   each R¹⁵ is independently hydrogen, optionally substituted        C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl, optionally        substituted C₁-C₆heteroalkyl, optionally substituted        C₃-C₁₀cycloalkyl, optionally substituted C₂-C₁₀heterocycloalkyl,        optionally substituted aryl, or optionally substituted        heteroaryl; or    -   two R¹⁵ are taken together with the N atom to which they are        attached to form an optionally substituted heterocycle; and    -   each R¹⁶ is independently optionally substituted C₁-C₆alkyl,        optionally substituted C₁-C₆fluoroalkyl, optionally substituted        C₁-C₆heteroalkyl, optionally substituted C₃-C₁₀cycloalkyl,        optionally substituted C₂-C₁₀heterocycloalkyl, optionally        substituted aryl, or optionally substituted heteroaryl.

In some embodiments, the compound or pharmaceutically acceptable salt,or solvate thereof, selectively binds to IRE1α at one or more bindingsites. In some embodiments, the IRE1α comprises an RNase domain, akinase domain, or any combination thereof. In some embodiments, thekinase domain is an auto-transphosphorylation kinase domain. In someembodiments, the kinase domain comprises an ATP-binding pocket. In someembodiments, the kinase domain comprises an activation loop. In someembodiments, at least one binding site is within the RNase domain. Insome embodiments, at least one binding site is within the kinase domain.In some embodiments, the at least one binding site is within theATP-binding pocket of the kinase domain. In some embodiments, In someembodiments, the at least one binding site is within the activation loopof the kinase domain. In some embodiments, binding occurs at a firstbinding site. In some embodiments, the first binding site is locatedwithin the RNase domain, kinase domain, ATP-binding pocket, oractivation loop. In some embodiments, the first binding site comprisesat least one amino acid residue of within amino acid residues 465-977 ofSEQ ID NO: 1. In some embodiments, the first binding site comprises atleast one amino acid residue within amino acid residues 568-833 of SEQID NO: 1. In some embodiments, the first binding site comprises at leastone amino acid residue within amino acid residues 577-586, 597, 599,626, 642-643, 645, 648, 688, 692-693, 695, or 711 of SEQ ID NO: 1. Insome embodiments, the first binding site comprises at least one aminoacid residue within amino acid residues 710-725 or 729-736 of SEQ IDNO: 1. In some embodiments, the first binding site comprises at leastone amino acid residue within amino acid residues 835-963 of SEQ IDNO: 1. In some embodiments, binding further occurs at a second bindingsite. In some embodiments, the second binding site is located within theRNase domain, the kinase domain, the ATP-binding pocket, or theactivation loop. In some embodiments, the second binding site comprisesat least one amino acid residue of within amino acid residues 465-977 ofSEQ ID NO: 1. In some embodiments, the second binding site comprises atleast one amino acid residue within amino acid residues 568-833 of SEQID NO: 1. In some embodiments, the second binding site comprises atleast one amino acid residue within amino acid residues 577-586, 597,599, 626, 642-643, 645, 648, 688, 692-693, 695, or 711 of SEQ ID NO: 1.In some embodiments, the second binding site comprises at least oneamino acid residue within amino acid residues 710-725 or 729-736 of SEQID NO: 1. In some embodiments, the second binding site comprises atleast one amino acid residue within amino acid residues 835-963 of SEQID NO: 1. In some embodiments, binding occurs when the IRE1α is in ahomo-dimerized conformation. In some embodiments, binding occurs whenthe IRE1α is in an oligomerized conformation. In some embodiments,binding occurs when the IRE1α is in a non-oligomerized or non-dimerizedconformation. In some embodiments, binding occurs when the IRE1α is inan ATP-bound state. In some embodiments, binding occurs when the IRE1αis in a non-ATP-bound state. In some embodiments, the compoundselectively binds to a first IRE1a. In some embodiments, selectivelybinding to the first IRE1α blocks dimerization of the first IRE1α to asecond IRE a. In some embodiments, selectively binding to the firstIRE1α blocks auto-transphosphorylation of the first IRE1a. In someembodiments, selectively binding to the first IRE1α blocksauto-transphosphorylation of a second IRE1α to which the first IRE1α isdimerized. In some embodiments, selectively binding to the first IRE1αblocks activation of the first IRE1a. In some embodiments, selectivelybinding to the first IRE1α blocks activation a second IRE1α to which thefirst IRE1α is dimerized. In some embodiments, selectively binding tothe first IRE1α blocks kinase activity of the first IRE1a. In someembodiments, selectively binding to the first IRE1α blocks kinaseactivity of a second IRE1α to which the first IRE1α is dimerized. Insome embodiments, selectively binding to the first IRE1α blocks RNaseactivity of the first IRE1a. In some embodiments, selectively binding tothe first IRE1α blocks RNase activity of a second IRE1α to which thefirst IRE1α is dimerized.

In another aspect, provided herein is a compound that selectively bindsa first IRE1α at two or more sites, wherein when the compound is boundto the first IRE1α protein, the compound binds to an ATP-binding pocketof the first IRE1α and blocks the binding of ATP to the first IRE1α. Insome embodiments, the ATP binding pocket is comprised within a kinasedomain. In some embodiments, the ATP binding pocket is comprised withinamino acid residues 465-977 of SEQ ID NO: 1 In some embodiments, the ATPbinding pocket is comprised within amino acid residues 568-833 of SEQ IDNO: 1. In some embodiments, the ATP binding pocket comprises one or moreof amino acid resides 577-586, 597, 599, 626, 642-643, 645, 648, 688,692-693, 695, or 711 of SEQ ID NO: 1.

In another aspect, provided herein is a pharmaceutical compositioncomprising any one of the compounds described herein, or apharmaceutically acceptable salt or solvate thereof. In someembodiments, the pharmaceutical composition further comprises one ormore pharmaceutically acceptable excipients.

In another aspect, provided herein is a method for treating orameliorating the effects of a disease associated with altered IRE1signaling, the method comprising administering to a subject in needthereof a pharmaceutical composition, wherein the pharmaceuticalcomposition comprises the compound of any one of the compounds describedherein. In some embodiments, the disease is cancer. In some embodiments,the cancer is a solid cancer or a hematologic cancer. In someembodiments, the cancer is ovarian cancer, breast cancer, or triplenegative breast cancer (TNBC).

In another aspect, provided herein is a method for treating orameliorating a cell proliferative disorder, the method comprisingadministering a pharmaceutical composition comprising a compound, or apharmaceutically acceptable salt, or solvate thereof, that selectivelybinds to at least one amino acid residue of a IRE1 family proteincomprising an RNase domain and kinase domain. In some embodiments, theIRE1 family protein is IRE1α. In some embodiments, the compound binds toan ATP-binding site of IRE1α. In some embodiments, the cellproliferative disorder is cancer. In some embodiments, the cancer is asolid cancer or a hematologic cancer.

BRIEF DESCRIPTION OF THE DRAWINGS

The novel features of the invention are set forth with particularity inthe appended claims. A better understanding of the features andadvantages of the present invention will be obtained by reference to thefollowing detailed description that sets forth illustrative embodiments,in which the principles of the invention are utilized, and theaccompanying drawings of which:

FIG. 1 shows an example diagram of the domain structure of IRE1α. Asignal peptide (P) and transmembrane (TM) region are indicated.

FIGS. 2A-2E shows an example alignment of the C-terminal half IRE1orthologues from yeast (ScIre1) (SEQ ID NO: 4), human (HsIre1) (SEQ IDNO: 5), mouse (MmIre1) (SEQ ID NO: 6), and rat (RnIRE1) (SEQ ID NO: 7).Stars indicate kinase domain dimer interface residues. Circles indicateKinase extension nuclease (KEN) domain dimer interface residues.Triangles indicate putative nuclease active site residues. Yellowhighlighted residues are highly conserved in Ire1 orthologues. Greenhighlighted residues are invariant in all analyzed Ire1 orthologues.Blue highlighted residues are invariant in analyzed RNaseL and Ire1orthologues.

DETAILED DESCRIPTION Certain Terminology

Unless otherwise stated, the following terms used in this applicationhave the definitions given below. The use of the term “including” aswell as other forms, such as “include”, “includes,” and “included,” isnot limiting. The section headings used herein are for organizationalpurposes only and are not to be construed as limiting the subject matterdescribed.

As used herein and in the appended claims, the singular forms “a,”“and,” and “the” include plural referents unless the context clearlydictates otherwise. Thus, for example, reference to “an agent” includesa plurality of such agents, and reference to “the cell” includesreference to one or more cells (or to a plurality of cells) andequivalents thereof known to those skilled in the art, and so forth.When ranges are used herein for physical properties, such as molecularweight, or chemical properties, such as chemical formulae, allcombinations and subcombinations of ranges and specific embodimentstherein are intended to be included. The term “about” when referring toa number or a numerical range means that the number or numerical rangereferred to is an approximation within experimental variability (orwithin statistical experimental error), and thus the number or numericalrange may vary between 1% and 15% of the stated number or numericalrange. The term “comprising” (and related terms such as “comprise” or“comprises” or “having” or “including”) is not intended to exclude thatin other certain embodiments, for example, an embodiment of anycomposition of matter, composition, method, or process, or the like,described herein, may “consist of” or “consist essentially of” thedescribed features.

Definitions

As used in the specification and appended claims, unless specified tothe contrary, the following terms have the meaning indicated below.

“Amino” refers to the —NH₂ radical.

“Cyano” refers to the —CN radical.

“Nitro” refers to the —NO₂ radical.

“Oxa” refers to the —O— radical.

“Oxo” refers to the ═O radical.

“Thioxo” refers to the =S radical.

“Imino” refers to the =N—H radical.

“Oximo” refers to the =N—OH radical.

As used herein, C₁-C_(x) includes C₁-C₂, C₁-C₃ . . . C₁-C_(x). By way ofexample only, a group designated as “C₁-C₄” indicates that there are oneto four carbon atoms in the moiety, i.e. groups containing 1 carbonatom, 2 carbon atoms, 3 carbon atoms or 4 carbon atoms. Thus, by way ofexample only, “C₁-C₄ alkyl” indicates that there are one to four carbonatoms in the alkyl group, i.e., the alkyl group is selected from amongmethyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, andt-butyl.

An “alkyl” group refers to an aliphatic hydrocarbon group. The alkylgroup is branched or straight chain. In some embodiments, the “alkyl”group has 1 to 10 carbon atoms, i.e. a C₁-C₁₀alkyl. Whenever it appearsherein, a numerical range such as “1 to 10” refers to each integer inthe given range; e.g., “1 to 10 carbon atoms” means that the alkyl groupconsist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbonatoms, 5 carbon atoms, 6 carbon atoms, etc., up to and including 10carbon atoms, although the present definition also covers the occurrenceof the term “alkyl” where no numerical range is designated. In someembodiments, an alkyl is a C₁-C₆alkyl. In one aspect the alkyl ismethyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, ort-butyl. Typical alkyl groups include, but are in no way limited to,methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tertiarybutyl, pentyl, neopentyl, or hexyl.

An “alkylene” group refers to a divalent alkyl radical. Any of the abovementioned monovalent alkyl groups may be an alkylene by abstraction of asecond hydrogen atom from the alkyl. In some embodiments, an alkelene isa C₁-C₆alkylene. In other embodiments, an alkylene is a C₁-C₄alkylene.In certain embodiments, an alkylene comprises one to four carbon atoms(e.g., C₁-C₄ alkylene). In other embodiments, an alkylene comprises oneto three carbon atoms (e.g., C₁-C₃ alkylene). In other embodiments, analkylene comprises one to two carbon atoms (e.g., C₁-C₂ alkylene). Inother embodiments, an alkylene comprises one carbon atom (e.g., C₁alkylene). In other embodiments, an alkylene comprises two carbon atoms(e.g., C₂ alkylene). In other embodiments, an alkylene comprises two tofour carbon atoms (e.g., C₂-C₄ alkylene). Typical alkylene groupsinclude, but are not limited to, —CH₂—, —CH(CH₃)—, —C(CH₃)₂—, —CH₂CH₂—,—CH₂CH(CH₃)—, —CH₂C(CH₃)₂—, —CH₂CH₂CH₂—, —CH₂CH₂CH₂CH₂—, and the like.

The term “alkenyl” refers to a type of alkyl group in which at least onecarbon-carbon double bond is present. In one embodiment, an alkenylgroup has the formula —C(R)═CR₂, wherein R refers to the remainingportions of the alkenyl group, which may be the same or different. Insome embodiments, R is H or an alkyl. In some embodiments, an alkenyl isselected from ethenyl (i.e., vinyl), propenyl (i.e., allyl), butenyl,pentenyl, pentadienyl, and the like. Non-limiting examples of an alkenylgroup include —CH═CH₂, —C(CH₃)=CH₂, —CH═CHCH₃, —C(CH₃)=CHCH₃, and—CH₂CH═CH₂.

The term “alkynyl” refers to a type of alkyl group in which at least onecarbon-carbon triple bond is present. In one embodiment, an alkenylgroup has the formula —C═C—R, wherein R refers to the remaining portionsof the alkynyl group. In some embodiments, R is H or an alkyl.

In some embodiments, an alkynyl is selected from ethynyl, propynyl,butynyl, pentynyl, hexynyl, and the like. Non-limiting examples of analkynyl group include —C≡CH, —C≡CCH₃—C≡CCH₂CH₃, —CH₂C≡CH.

An “alkoxy” group refers to a (alkyl)O— group, where alkyl is as definedherein.

The term “alkylamine” refers to the —N(alkyl)_(x)H_(y) group, where x is0 and y is 2, or where x is 1 and y is 1, or where x is 2 and y is 0.

The term “aromatic” refers to a planar ring having a delocalizedit-electron system containing 4n+2π electrons, where n is an integer.The term “aromatic” includes both carbocyclic aryl (“aryl”, e.g.,phenyl) and heterocyclic aryl (or “heteroaryl” or “heteroaromatic”)groups (e.g., pyridine). The term includes monocyclic or fused-ringpolycyclic (i.e., rings which share adjacent pairs of carbon atoms)groups.

The term “carbocyclic” or “carbocycle” refers to a ring or ring systemwhere the atoms forming the backbone of the ring are all carbon atoms.The term thus distinguishes carbocyclic from “heterocyclic” rings or“heterocycles” in which the ring backbone contains at least one atomwhich is different from carbon. In some embodiments, at least one of thetwo rings of a bicyclic carbocycle is aromatic. In some embodiments,both rings of a bicyclic carbocycle are aromatic. Carbocycle includescycloalkyl and aryl.

As used herein, the term “aryl” refers to an aromatic ring wherein eachof the atoms forming the ring is a carbon atom. In one aspect, aryl isphenyl or a naphthyl. In some embodiments, an aryl is a phenyl. In someembodiments, an aryl is a C₆-C₁₀aryl. Depending on the structure, anaryl group is a monoradical or a diradical (i.e., an arylene group).

The term “cycloalkyl” refers to a monocyclic or polycyclic aliphatic,non-aromatic radical, wherein each of the atoms forming the ring (i.e.skeletal atoms) is a carbon atom. In some embodiments, cycloalkyls arespirocyclic or bridged compounds. In some embodiments, cycloalkyls areoptionally fused with an aromatic ring, and the point of attachment isat a carbon that is not an aromatic ring carbon atom. In someembodiments, cycloalkyl groups include groups having from 3 to 10 ringatoms. In some embodiments, cycloalkyl groups include groups having from3 to 6 ring atoms. In some embodiments, cycloalkyl groups are selectedfrom among cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl,cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, spiro[2.2]pentyl,norbornyl and bicycle[1.1.1]pentyl. In some embodiments, a cycloalkyl isa C₃-C₆cycloalkyl. In some embodiments, a cycloalkyl is a monocycliccycloalkyl. Monocyclic cycloalkyls include, but are not limited to,cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, andcyclooctyl. Polycyclic cycloalkyls include, for example, adamantyl,norbornyl (i.e., bicyclo[2.2.1]heptanyl), norbornenyl, decalinyl,7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like.

The term “cycloalkylene” refers to a monocyclic or polycyclic aliphatic,non-aromatic divalent radical, wherein each of the atoms forming thering (i.e. skeletal atoms) is a carbon atom. In some embodiments,cycloalkylene are spirocyclic or bridged compounds. In some embodiments,cycloalkylenes are optionally fused with an aromatic ring, and the pointof attachment is at a carbon that is not an aromatic ring carbon atom.In some embodiments, cycloalkylene groups include groups having from 3to 10 ring atoms. In some embodiments, cycloalkylene groups includegroups having from 3 to 6 ring atoms.

The term “halo” or, alternatively, “halogen” or “halide” means fluoro,chloro, bromo or iodo. In some embodiments, halo is fluoro, chloro, orbromo.

The term “haloalkyl” refers to an alkyl in which one or more hydrogenatoms are replaced by a halogen atom. In one aspect, a fluoralkyl is aC₁-C₆fluoroalkyl.

The term “fluoroalkyl” refers to an alkyl in which one or more hydrogenatoms are replaced by a fluorine atom. In one aspect, a fluoralkyl is aC₁-C₆fluoroalkyl. In some embodiments, a fluoroalkyl is selected fromtrifluoromethyl, difluoromethyl, fluoromethyl, 2,2,2-trifluoroethyl,1-fluoromethyl-2-fluoroethyl, and the like.

The term “heteroalkyl” refers to an alkyl group in which one or moreskeletal atoms of the alkyl are selected from an atom other than carbon,e.g., oxygen, nitrogen (e.g. —NH—, —N(alkyl)-, sulfur, or combinationsthereof. A heteroalkyl is attached to the rest of the molecule at acarbon atom of the heteroalkyl. In one aspect, a heteroalkyl is aC₁-C₆heteroalkyl.

The term “heteroalkylene” refers to an alkylene group in which one ormore skeletal atoms of the alkylene are selected from an atom other thancarbon, e.g., oxygen, nitrogen (e.g. —NH—, —N(alkyl)-, sulfur, orcombinations thereof. In some embodiments, a heteroalkylene is attachedto the rest of the molecule at a carbon atom of the heteroalkylene. Inone aspect, a heteroalkylene is a C₁-C₆heteroalkylene.

As used herein, the term “heteroatom” refers to an atom of any elementother than carbon or hydrogen. In some embodiments, the heteroatom isnitrogen, oxygen, or sulfur. In some embodiments, the heteroatom isnitrogen or oxygen. In some embodiments, the heteroatom is nitrogen.

The term “heterocycle” or “heterocyclic” refers to heteroaromatic rings(also known as heteroaryls) and heterocycloalkyl rings (also known asheteroalicyclic groups) containing one to four heteroatoms in thering(s), where each heteroatom in the ring(s) is selected from O, S andN, wherein each heterocyclic group has from 3 to 10 atoms in its ringsystem, and with the proviso that any ring does not contain two adjacentO or S atoms. In some embodiments, heterocycles are monocyclic,bicyclic, polycyclic, spirocyclic or bridged compounds. Non-aromaticheterocyclic groups (also known as heterocycloalkyls) include ringshaving 3 to 10 atoms in its ring system and aromatic heterocyclic groupsinclude rings having 5 to 10 atoms in its ring system. The heterocyclicgroups include benzo-fused ring systems. Examples of non-aromaticheterocyclic groups are pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl,tetrahydrothienyl, oxazolidinonyl, tetrahydropyranyl, dihydropyranyl,tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl,thioxanyl, piperazinyl, aziridinyl, azetidinyl, oxetanyl, thietanyl,homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl,thiazepinyl, 1,2,3,6-tetrahydropyridinyl, pyrrolin-2-yl, pyrrolin-3-yl,indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl,pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl,dihydrofuranyl, pyrazolidinyl, imidazolinyl, imidazolidinyl,3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl, 3H-indolyl,indolin-2-onyl, isoindolin-1-onyl, isoindoline-1,3-dionyl,3,4-dihydroisoquinolin-1(2H)-onyl, 3,4-dihydroquinolin-2(1H)-onyl,isoindoline-1,3-dithionyl, benzo[d]oxazol-2(3H)-onyl,1H-benzo[d]imidazol-2(3H)-onyl, benzo[d]thiazol-2(3H)-onyl, andquinolizinyl. Examples of aromatic heterocyclic groups are pyridinyl,imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl,furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl,quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl,cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl,triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl,furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl,benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, andfuropyridinyl. The foregoing groups are either C-attached (or C-linked)or N-attached where such is possible. For instance, a group derived frompyrrole includes both pyrrol-1-yl (N-attached) or pyrrol-3-yl(C-attached).

Further, a group derived from imidazole includes imidazol-1-yl orimidazol-3-yl (both N-attached) or imidazol-2-yl, imidazol-4-yl orimidazol-5-yl (all C-attached). The heterocyclic groups includebenzo-fused ring systems. Non-aromatic heterocycles are optionallysubstituted with one or two oxo (═O) moieties, such as pyrrolidin-2-one.In some embodiments, at least one of the two rings of a bicyclicheterocycle is aromatic. In some embodiments, both rings of a bicyclicheterocycle are aromatic.

The terms “heteroaryl” or, alternatively, “heteroaromatic” refers to anaryl group that includes one or more ring heteroatoms selected fromnitrogen, oxygen and sulfur. Illustrative examples of heteroaryl groupsinclude monocyclic heteroaryls and bicyclic heteroaryls. Monocyclicheteroaryls include pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl,triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl,oxazolyl, isothiazolyl, pyrrolyl, pyridazinyl, triazinyl, oxadiazolyl,thiadiazolyl, and furazanyl. Bicyclic heteroaryls include indolizine,indole, benzofuran, benzothiophene, indazole, benzimidazole, purine,quinolizine, quinoline, isoquinoline, cinnoline, phthalazine,quinazoline, quinoxaline, 1,8-naphthyridine, and pteridine. In someembodiments, a heteroaryl contains 0-4 N atoms in the ring. In someembodiments, a heteroaryl contains 1-4 N atoms in the ring. In someembodiments, a heteroaryl contains 0-4 N atoms, 0-1 O atoms, and 0-1 Satoms in the ring. In some embodiments, a heteroaryl contains 1-4 Natoms, 0-1 O atoms, and 0-1 S atoms in the ring. In some embodiments,heteroaryl is a C₁-C₉heteroaryl. In some embodiments, monocyclicheteroaryl is a C₁-C₅heteroaryl. In some embodiments, monocyclicheteroaryl is a 5-membered or 6-membered heteroaryl. In someembodiments, bicyclic heteroaryl is a C₆-C₉heteroaryl.

A “heterocycloalkyl” or “heteroalicyclic” group refers to a cycloalkylgroup that includes at least one heteroatom selected from nitrogen,oxygen and sulfur. In some embodiments, a heterocycloalkyl is aspirocyclic or bridged compound. In some embodiments, a heterocycloalkylis fused with an aryl or heteroaryl. In some embodiments, theheterocycloalkyl is oxazolidinonyl, pyrrolidinyl, tetrahydrofuranyl,tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl,piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl,piperidin-2-onyl, pyrrolidine-2,5-dithionyl, pyrrolidine-2,5-dionyl,pyrrolidinonyl, imidazolidinyl, imidazolidin-2-onyl, orthiazolidin-2-onyl. The term heteroalicyclic also includes all ringforms of the carbohydrates, including but not limited to themonosaccharides, the disaccharides and the oligosaccharides. In oneaspect, a heterocycloalkyl is a C₂-C₁₀heterocycloalkyl. In anotheraspect, a heterocycloalkyl is a C₄-C₁₀heterocycloalkyl. In someembodiments, a heterocycloalkyl contains 0-2 N atoms in the ring. Insome embodiments, a heterocycloalkyl contains 0-2 N atoms, 0-2 O atomsand 0-1 S atoms in the ring.

The term “bond” or “single bond” refers to a chemical bond between twoatoms, or two moieties when the atoms joined by the bond are consideredto be part of larger substructure. In one aspect, when a group describedherein is a bond, the referenced group is absent thereby allowing a bondto be formed between the remaining identified groups.

The term “moiety” refers to a specific segment or functional group of amolecule. Chemical moieties are often recognized chemical entitiesembedded in or appended to a molecule.

The term “optionally substituted” or “substituted” means that thereferenced group is optionally substituted with one or more additionalgroup(s) individually and independently selected from D, halogen, —CN,—NH₂, —NH(alkyl), —CH₂N(alkyl)₂, —N(alkyl)₂, —OH, —CO₂H, —CO₂alkyl,—CH₂NH₂, —C(═O)NH₂, —C(═O)NH(alkyl), —C(═O)N(alkyl)₂, —S(═O)₂NH₂,—S(═O)₂NH(alkyl), —S(═O)₂N(alkyl)₂, alkyl, cycloalkyl, fluoroalkyl,heteroalkyl, alkoxy, fluoroalkoxy, heterocycloalkyl, aryl, heteroaryl,aryloxy, alkylthio, arylthio, alkylsulfoxide, arylsulfoxide,alkylsulfone, and arylsulfone. In some other embodiments, optionalsubstituents are independently selected from D, halogen, —CN, —NH₂,—NH(CH₃), —N(CH₃)₂, —OH, —CO₂H, —CO₂(C₁-C₄alkyl), —CH₂NH₂, —C(═O)NH₂,—C(═O)NH(C₁-C₄alkyl), —C(═O)N(C₁-C₄alkyl)₂, —S(═O)₂NH₂,—S(═O)₂NH(C₁-C₄alkyl), —S(═O)₂N(C₁-C₄alkyl)₂, C₁-C₄alkyl,C₃-C₆cycloalkyl, C₁-C₄fluoroalkyl, C₁-C₄heteroalkyl, C₁-C₄alkoxy,C₁-C₄fluoroalkoxy, —SC₁-C₄alkyl, —S(═O)C₁-C₄alkyl, and—S(═O)₂C₁-C₄alkyl. In some embodiments, optional substituents areindependently selected from D, halogen, —CN, —NH₂, —OH, —NH(CH₃),—N(CH₃)₂, —CH₃, —CH₂CH₃, —CH₂NH₂, —CF₃, —OCH₃, and —OCF₃. In someembodiments, substituted groups are substituted with one or two of thepreceding groups. In some embodiments, an optional substituent on analiphatic carbon atom (acyclic or cyclic) includes oxo (═O).

A “tautomer” refers to a molecule wherein a proton shift from one atomof a molecule to another atom of the same molecule is possible. Thecompounds presented herein may, in certain embodiments, exist astautomers. In circumstances where tautomerization is possible, achemical equilibrium of the tautomers will exist. The exact ratio of thetautomers depends on several factors, including physical state,temperature, solvent, and pH. Some examples of tautomeric equilibriuminclude:

“Optional” or “optionally” means that a subsequently described event orcircumstance may or may not occur and that the description includesinstances when the event or circumstance occurs and instances in whichit does not. For example, “optionally substituted aryl” means that thearyl radical may or may not be substituted and that the descriptionincludes both substituted aryl radicals and aryl radicals having nosubstitution.

“Pharmaceutically acceptable salt” includes both acid and base additionsalts. A pharmaceutically acceptable salt of any one of the pyrazolecompounds described herein is intended to encompass any and allpharmaceutically suitable salt forms. Preferred pharmaceuticallyacceptable salts of the compounds described herein are pharmaceuticallyacceptable acid addition salts and pharmaceutically acceptable baseaddition salts.

“Pharmaceutically acceptable acid addition salt” refers to those saltswhich retain the biological effectiveness and properties of the freebases, which are not biologically or otherwise undesirable, and whichare formed with inorganic acids such as hydrochloric acid, hydrobromicacid, sulfuric acid, nitric acid, phosphoric acid, hydroiodic acid,hydrofluoric acid, phosphorous acid, and the like. Also included aresalts that are formed with organic acids such as aliphatic mono- anddicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoicacids, alkanedioic acids, aromatic acids, aliphatic and. aromaticsulfonic acids, etc. and include, for example, acetic acid,trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid,oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid,tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid,methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid,salicylic acid, and the like. Exemplary salts thus include sulfates,pyrosulfates, bisulfates, sulfites, bisulfites, nitrates, phosphates,monohydrogenphosphates, dihydrogenphosphates, metaphosphates,pyrophosphates, chlorides, bromides, iodides, acetates,trifluoroacetates, propionates, caprylates, isobutyrates, oxalates,malonates, succinate suberates, sebacates, fumarates, maleates,mandelates, benzoates, chlorobenzoates, methylbenzoates,dinitrobenzoates, phthalates, benzenesulfonates, toluenesulfonates,phenylacetates, citrates, lactates, malates, tartrates,methanesulfonates, and the like. Also contemplated are salts of aminoacids, such as arginates, gluconates, and galacturonates (see, forexample, Berge S. M. et al., “Pharmaceutical Salts,” Journal ofPharmaceutical Science, 66:1-19 (1997)). Acid addition salts of basiccompounds may be prepared by contacting the free base forms with asufficient amount of the desired acid to produce the salt according tomethods and techniques with which a skilled artisan is familiar.

“Pharmaceutically acceptable base addition salt” refers to those saltsthat retain the biological effectiveness and properties of the freeacids, which are not biologically or otherwise undesirable. These saltsare prepared from addition of an inorganic base or an organic base tothe free acid. Pharmaceutically acceptable base addition salts may beformed with metals or amines, such as alkali and alkaline earth metalsor organic amines. Salts derived from inorganic bases include, but arenot limited to, sodium, potassium, lithium, ammonium, calcium,magnesium, iron, zinc, copper, manganese, aluminum salts and the like.Salts derived from organic bases include, but are not limited to, saltsof primary, secondary, and tertiary amines, substituted amines includingnaturally occurring substituted amines, cyclic amines and basic ionexchange resins, for example, isopropylamine, trimethylamine,diethylamine, triethylamine, tripropylamine, ethanolamine,diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol,dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine,N,N-dibenzylethylenediamine, chloroprocaine, hydrabamine, choline,betaine, ethylenediamine, ethylenedianiline, N-methylglucamine,glucosamine, methylglucamine, theobromine, purines, piperazine,piperidine, N-ethylpiperidine, polyamine resins and the like. See Bergeet al., supra.

“Prodrug” is meant to indicate a compound that may be converted underphysiological conditions or by solvolysis to a biologically activecompound described herein. Thus, the term “prodrug” refers to aprecursor of a biologically active compound that is pharmaceuticallyacceptable. A prodrug may be inactive when administered to a subject,but is converted in vivo to an active compound, for example, byhydrolysis. The prodrug compound often offers advantages of solubility,tissue compatibility or delayed release in a mammalian organism (see,e.g., Bundgard, H., Design of Prodrugs (1985), pp. 7-9, 21-24 (Elsevier,Amsterdam).

A discussion of prodrugs is provided in Higuchi, T., et al., “Pro-drugsas Novel Delivery Systems,” A.C.S. Symposium Series, Vol. 14, and inBioreversible Carriers in Drug Design, ed. Edward B. Roche, AmericanPharmaceutical Association and Pergamon Press, 1987.

The term “prodrug” is also meant to include any covalently bondedcarriers, which release the active compound in vivo when such prodrug isadministered to a mammalian subject. Prodrugs of an active compound, asdescribed herein, may be prepared by modifying functional groups presentin the active compound in such a way that the modifications are cleaved,either in routine manipulation or in vivo, to the parent activecompound. Prodrugs include compounds wherein a hydroxy, amino ormercapto group is bonded to any group that, when the prodrug of theactive compound is administered to a mammalian subject, cleaves to forma free hydroxy, free amino or free mercapto group, respectively.Examples of prodrugs include, but are not limited to, acetate, formateand benzoate derivatives of alcohol or amine functional groups in theactive compounds and the like.

The term “acceptable” with respect to a formulation, composition oringredient, as used herein, means having no persistent detrimentaleffect on the general health of the subject being treated.

The term “modulate” as used herein, means to interact with a targeteither directly or indirectly so as to alter the activity of the target,including, by way of example only, to enhance the activity of thetarget, to inhibit the activity of the target, to limit the activity ofthe target, or to extend the activity of the target.

The term “modulator” as used herein, refers to a molecule that interactswith a target either directly or indirectly. The interactions include,but are not limited to, the interactions of an agonist, partial agonist,an inverse agonist, antagonist, degrader, or combinations thereof. Insome embodiments, a modulator is an agonist.

The terms “administer,” “administering”, “administration,” and the like,as used herein, refer to the methods that may be used to enable deliveryof compounds or compositions to the desired site of biological action.These methods include, but are not limited to oral routes, intraduodenalroutes, parenteral injection (including intravenous, subcutaneous,intraperitoneal, intramuscular, intravascular or infusion), topical andrectal administration. Those of skill in the art are familiar withadministration techniques that can be employed with the compounds andmethods described herein. In some embodiments, the compounds andcompositions described herein are administered orally.

The terms “co-administration” or the like, as used herein, are meant toencompass administration of the selected therapeutic agents to a singlepatient, and are intended to include treatment regimens in which theagents are administered by the same or different route of administrationor at the same or different time.

The terms “effective amount” or “therapeutically effective amount,” asused herein, refer to a sufficient amount of an agent or a compoundbeing administered, which will relieve to some extent one or more of thesymptoms of the disease or condition being treated. The result includesreduction and/or alleviation of the signs, symptoms, or causes of adisease, or any other desired alteration of a biological system. Forexample, an “effective amount” for therapeutic uses is the amount of thecomposition comprising a compound as disclosed herein required toprovide a clinically significant decrease in disease symptoms. Anappropriate “effective” amount in any individual case is optionallydetermined using techniques, such as a dose escalation study.

The terms “enhance” or “enhancing,” as used herein, means to increase orprolong either in potency or duration a desired effect. Thus, in regardto enhancing the effect of therapeutic agents, the term “enhancing”refers to the ability to increase or prolong, either in potency orduration, the effect of other therapeutic agents on a system. An“enhancing-effective amount,” as used herein, refers to an amountadequate to enhance the effect of another therapeutic agent in a desiredsystem.

The term “pharmaceutical combination” as used herein, means a productthat results from the mixing or combining of more than one activeingredient and includes both fixed and non-fixed combinations of theactive ingredients. The term “fixed combination” means that the activeingredients, e.g. a compound described herein, or a pharmaceuticallyacceptable salt thereof, and a co-agent, are both administered to apatient simultaneously in the form of a single entity or dosage. Theterm “non-fixed combination” means that the active ingredients, e.g. acompound described herein, or a pharmaceutically acceptable saltthereof, and a co-agent, are administered to a patient as separateentities either simultaneously, concurrently or sequentially with nospecific intervening time limits, wherein such administration provideseffective levels of the two compounds in the body of the patient. Thelatter also applies to cocktail therapy, e.g. the administration ofthree or more active ingredients.

The terms “kit” and “article of manufacture” are used as synonyms.

The term “subject” or “patient” encompasses mammals. Examples of mammalsinclude, but are not limited to, any member of the Mammalian class:humans, non-human primates such as chimpanzees, and other apes andmonkey species; farm animals such as cattle, horses, sheep, goats,swine; domestic animals such as rabbits, dogs, and cats; laboratoryanimals including rodents, such as rats, mice and guinea pigs, and thelike. In one aspect, the mammal is a human.

As used herein, “treatment” or “treating” or “palliating” or“ameliorating” are used interchangeably herein. These terms refers to anapproach for obtaining beneficial or desired results including but notlimited to therapeutic benefit and/or a prophylactic benefit. By“therapeutic benefit” is meant eradication or amelioration of theunderlying disorder being treated. Also, a therapeutic benefit isachieved with the eradication or amelioration of one or more of thephysiological symptoms associated with the underlying disorder such thatan improvement is observed in the patient, notwithstanding that thepatient may still be afflicted with the underlying disorder. Forprophylactic benefit, the compositions may be administered to a patientat risk of developing a particular disease, or to a patient reportingone or more of the physiological symptoms of a disease, even though adiagnosis of this disease may not have been made.

Compounds

Compounds described herein, including pharmaceutically acceptable salts,and pharmaceutically acceptable solvates thereof, that modulate IRE1mediated signaling, directly or indirectly.

Provided herein is a compound of Formula (I), or a pharmaceuticallyacceptable salt, or solvate thereof:

wherein,

is an optionally substituted C₃-C₁₀ heterocyclyl containing at least oneN, O, S, S(═O), or S(═O)₂; wherein if

is substituted, then

is substituted with 0-3 R⁵;

is a substituted C₃-C₁₀ cycloalkyl that is substituted with 1-3R⁴ and0-3R⁵;

-   -   each R⁴ is independently —OR⁶, —SR⁶, —S(═O)R⁷, —S(═O)₂R⁷, or        —N(R⁶)₂;    -   each R⁵ is independently halogen, —CN, —OR⁸, —SR⁸, —S(═O)R⁹,        —S(═O)₂R⁹, —S(═O)₂N(R⁸)₂, —NR⁸S(═O)₂R⁹, —C(═O)R⁹, —OC(═O)R⁹,        —CO₂R⁸, —OCO₂R⁹, —N(R⁸)₂, —OC(═O)N(R⁸)₂, —NR⁸C(═O)R⁹,        —NR⁸C(═O)OR⁹, optionally substituted C₁-C₆alkyl, optionally        substituted C₁-C₆fluoroalkyl, optionally substituted        C₁-C₆heteroalkyl, optionally substituted C₃-C₆cycloalkyl,        optionally substituted aryl, or optionally substituted        heteroaryl;    -   A¹ is N or CR^(A); A² is N or CR^(A); A³ is N or CR^(A); A⁴ is N        or CR^(A); A⁵ is N or CR^(A);    -   each R^(A) is independently H or optionally substituted        C₁-C₆alkyl;    -   R¹ and R² are each independently H or optionally substituted        C₁-C₆alkyl;    -   L¹ and L² are each independently —CHY—, —CH₂— or —NH—;    -   Y is optionally substituted C₁-C₆alkyl;

is optionally substituted aryl or optionally substituted heteroaryl,wherein if

is substituted, then

is substituted with 0-4 R^(c);

-   -   each R^(c) is independently H, halogen, —CN, —OR¹⁰, —SR¹⁰,        —S(═O)R¹¹, —S(═O)₂R¹¹, —S(═O)₂N(R¹⁰)₂, —NR¹⁰S(═O)₂R¹¹,        —C(═O)R¹¹, —OC(═O)R¹¹, —CO₂R¹⁰, —OCO₂R¹¹, —N(R¹⁰)₂,        —OC(═O)N(R¹⁰)₂, —NR¹⁰C(═O)R¹¹, —NR¹⁰C(═O)OR¹¹, optionally        substituted C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl,        optionally substituted C₁-C₆heteroalkyl, optionally substituted        C₃-C₆cycloalkyl, optionally substituted aryl, or optionally        substituted heteroaryl;    -   each R³ is independently H or optionally substituted C₁-C₆alkyl;

or L^(D);

is optionally substituted heterocyclyl containing at least one N atom;wherein if

is substituted, then

is substituted with 0-4 R^(D);

-   -   L^(D) is —N(R¹²)-(optionally substituted C₁-C₆ alkyl),        —N(R¹³)-(optionally substituted C₁-C₆ alkylene)-N(R¹⁴)₂ or        -(optionally substituted C₁-C₆ alkylene)-N(R¹⁴)₂; wherein if        L^(D) is substituted, then L^(D) is substituted with 0-4 R^(D);    -   each R^(D) is independently halogen, —CN, —OR¹⁵, —SR¹⁵,        —S(═O)R¹⁶, —S(═O)₂R¹⁶, —S(═O)₂N(R¹⁵)₂, —NR¹⁵S(═O)₂R¹⁶,        —C(═O)R¹⁶, —OC(═O)R¹⁶, —CO₂R¹⁵, —OCO₂R¹⁶, —N(R¹⁵)₂,        —OC(═O)N(R¹⁵)₂, —NR¹⁵C(═O)R¹⁶, —NR¹⁵C(═O)OR¹⁶, optionally        substituted C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl,        optionally substituted C₁-C₆heteroalkyl, optionally substituted        C₃-C₆cycloalkyl, optionally substituted aryl, or optionally        substituted heteroaryl;    -   each R⁶ is independently hydrogen, optionally substituted        C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl, optionally        substituted C₁-C₆heteroalkyl, optionally substituted        C₃-C₁₀cycloalkyl, optionally substituted C₂-C₁₀heterocycloalkyl,        optionally substituted aryl, or optionally substituted        heteroaryl; or    -   two R⁶ are taken together with the N atom to which they are        attached to form an optionally substituted heterocycle;    -   each R⁷ is independently optionally substituted C₁-C₆alkyl,        optionally substituted C₁-C₆fluoroalkyl, optionally substituted        C₁-C₆heteroalkyl, optionally substituted C₃-C₁₀cycloalkyl,        optionally substituted C₂-C₁₀heterocycloalkyl, optionally        substituted aryl, or optionally substituted heteroaryl;    -   each R⁸ is independently hydrogen, optionally substituted        C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl, optionally        substituted C₁-C₆heteroalkyl, optionally substituted        C₃-C₁₀cycloalkyl, optionally substituted C₂-C₁₀heterocycloalkyl,        optionally substituted aryl, or optionally substituted        heteroaryl; or    -   two R⁸ are taken together with the N atom to which they are        attached to form an optionally substituted heterocycle;    -   each R⁹ is independently optionally substituted C₁-C₆alkyl,        optionally substituted C₁-C₆fluoroalkyl, optionally substituted        C₁-C₆heteroalkyl, optionally substituted C₃-C₁₀cycloalkyl,        optionally substituted C₂-C₁₀heterocycloalkyl, optionally        substituted aryl, or optionally substituted heteroaryl;    -   each R¹⁰ is independently hydrogen, optionally substituted        C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl, optionally        substituted C₁-C₆heteroalkyl, optionally substituted        C₃-C₁₀cycloalkyl, optionally substituted C₂-C₁₀heterocycloalkyl,        optionally substituted aryl, or optionally substituted        heteroaryl; or    -   two R¹⁰ are taken together with the N atom to which they are        attached to form an optionally substituted heterocycle;    -   each R¹¹ is independently optionally substituted C₁-C₆alkyl,        optionally substituted C₁-C₆fluoroalkyl, optionally substituted        C₁-C₆heteroalkyl, optionally substituted C₃-C₁₀cycloalkyl,        optionally substituted C₂-C₁₀heterocycloalkyl, optionally        substituted aryl, or optionally substituted heteroaryl;    -   each R¹² and R¹³ is independently H or optionally substituted        C₁-C₆alkyl;    -   each R¹⁴ is independently H or optionally substituted        C₁-C₆alkyl; or    -   two R¹⁴ are taken together with the N atom to which they are        attached to form an optionally substituted heterocycle;    -   each R¹⁵ is independently hydrogen, optionally substituted        C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl, optionally        substituted C₁-C₆heteroalkyl, optionally substituted        C₃-C₁₀cycloalkyl, optionally substituted C₂-C₁₀heterocycloalkyl,        optionally substituted aryl, or optionally substituted        heteroaryl; or    -   two R¹⁵ are taken together with the N atom to which they are        attached to form an optionally substituted heterocycle; and    -   each R¹⁶ is independently optionally substituted C₁-C₆alkyl,        optionally substituted C₁-C₆fluoroalkyl, optionally substituted        C₁-C₆heteroalkyl, optionally substituted C₃-C₁₀cycloalkyl,        optionally substituted C₂-C₁₀heterocycloalkyl, optionally        substituted aryl, or optionally substituted heteroaryl.

In some embodiments,

In some embodiments,

is optionally substituted C₄-C₇ heterocyclyl containing at least one N,O, S, S(═O), or S(═O)₂; wherein if

is substituted, then

is substituted with 0-3 R⁵.

In some embodiments, is

o is 0, 1, or 2; and p is 0, 1, 2, or 3.

In some embodiments,

and o is 0, 1, or 2.

In some embodiments,

In some embodiments,

is substituted C₄-C₇ cycloalkyl that is substituted with 1-3R⁴ and0-3R⁵.

In some embodiments,

and

q is 0, 1, 2, or 3.

In some embodiments,

and

q is 0, 1, 2, or 3.

In some embodiments, A¹ is CH; A² is N or CR^(A); A³ is N or CR^(A); A⁴is CH; and A⁵ is CH. In some embodiments, A² is N. In some embodiments,A² is CR^(A). In some embodiments, A³ is CR^(A). In some embodiments,R^(A) is optionally substituted C₁-C₆alkyl. In some embodiments, R^(A)is methyl, ethyl, propyl or butyl. In some embodiment, R^(A) is ethyl,propyl or butyl. In some embodiments, R¹ is optionally substitutedC₁-C₆alkyl. In some embodiments, R¹ is methyl. In some embodiments, R²is H. In some embodiments, L¹ and L² are each —NH—. In some embodiments,L¹ is —CH₂— and L² is —NH—. In some embodiments, L¹ is —NH— and L² is—CH₂-. In some embodiments, L¹ is —CHY—. In some embodiments, L² is—CHY—. In some embodiments, Y is optionally substituted C₁-C₃alkyl.

In some embodiments,

is optionally substituted aryl, wherein if

is substituted, then

is substituted with 0-4 R^(c).

In some embodiments,

is optionally substituted heteroaryl wherein if

is substituted, then

is substituted with 0-4 R^(c).

In some embodiments,

C¹ is N or CR^(C); C² is N or CR^(C); C³ is N or CR^(C); and C⁴ is N orCR^(C).

In some embodiments, C¹ is CR^(C); C² is CR^(C); C³ is CR^(C); and C⁴ isCR^(C). In some embodiments, C¹ is CR^(C); C² is CH; C³ is CH; and C⁴ isCH. In some embodiments, R^(c) is optionally substitutedC₁-C₆fluoroalkyl. In some embodiments, R^(c) is —CF₃. In someembodiments, each R³ is independently H.

In some embodiments,

In some embodiments,

is optionally substituted heterocyclyl containing at least one N atom;and if

is substituted, then

is substituted with 0-4 R^(D).

In some embodiments,

is optionally substituted heterocyclyl containing one N atom; and if

is substituted, then

is substituted with 0-4 R^(D).

In some embodiments,

is optionally substituted heterocyclyl containing two N atoms; and if

is substituted, then

is substituted with 0-4 R^(D).

In some embodiments, is

and

r is 0, 1, or 2.

In some embodiments,

and r is 0, 1, or 2.

In some embodiments,

is L^(D)

In some embodiments, L^(D) is —N(R¹²)-(optionally substituted C₁-C₆alkyl), —N(R¹³)-(optionally substituted C₁-C₆ alkylene)-N(R¹⁴)₂ or-(optionally substituted C₁-C₆ alkylene)-N(R¹⁴)₂; and if L^(D) issubstituted, then L^(D) is substituted with 0-4 R^(D). In someembodiments, L^(D) is —N(R¹²)-(optionally substituted C₁-C₆ alkyl), andif L^(D) is substituted, then L^(D) is substituted with 0-4 R^(D). Insome embodiments, L^(D) is —N(R¹²)—CH₂—CH₂—CH₂—CH₃, —N(R¹²)—CH₂—CH₂—CH₃,—N(R¹²)—CH₂—CH₃, or —N(R¹²)—CH₃. In some embodiments, R¹² is H orC₁-C₄alkyl. In some embodiments, R¹² is H or C₃-C₄alkyl. In someembodiments, L^(D) is —N(R¹³)-(optionally substituted C₁-C₆alkylene)-N(R¹⁴)₂, and if L^(D) is substituted, then L^(D) issubstituted with 0-4 R^(D). In some embodiments, L^(D) is—N(R¹³)—CH₂—CH₂—CH₂—CH₂—N(R¹⁴)₂, —N(R¹³)—CH₂—CH₂—CH₂—N(R¹⁴)₂,—N(R¹³)—CH₂—CH₂—N(R¹⁴)₂, or —N(R¹³)—CH₂—N(R¹⁴)₂. In some embodiments,each R¹³ and R¹⁴ is independently H or C₁-C₄alkyl. In some embodiments,L^(D) is or -(optionally substituted C₁-C₆ alkylene)—N(R¹⁴)₂; and ifL^(D) is substituted, then L^(D) is substituted with 0-4 R^(D). In someembodiments, L^(D) is —CH₂—CH₂—CH₂—CH₂—N(R¹⁴)₂, —CH₂—CH₂—CH₂—N(R¹⁴)₂,—CH₂—CH₂—N(R¹⁴)₂, or —CH₂—N(R¹⁴)₂. In some embodiments, each R¹⁴ isindependently H or C₁-C₄alkyl.

In some embodiments, the compound has the structure of formula (Ia)

wherein,

C¹ is N or CR^(C); C² is N or CR^(C); C³ is N or CR^(C); and C⁴ is N orCR^(C).

In some embodiments, the compound has the structure of formula (Ib)

wherein,

C¹ is N or CR^(C); C² is N or CR^(C); C³ is N or CR^(C); and C⁴ is N orCR^(C).

In some embodiments, the compound has the structure of formula (Ic)

wherein,

C¹ is N or CR^(C); C² is N or CR^(C); C³ is N or CR^(C); and C⁴ is N orCR^(C).

In some embodiments, the compound has the structure of formula (Id)

wherein,

C¹ is N or CR^(C); C² is N or CR_(C); C³ is N or CR_(C); and C⁴ is N orCR_(C).

In some embodiments, the compound has the structure of formula (Ie)

wherein,

C¹ is N or CR^(C); C² is N or CR^(C); C³ is N or CR^(C); and C⁴ is N orCR_(C).

In some embodiments, the compound has the structure of formula (If)

In some embodiments, the compound has the structure of formula (Ig)

In some embodiments, the compound has the structure of formula (Ih)

In some embodiments, the compound has the structure of formula (li)

In another aspect, provided herein is a compound of Formula (II), or apharmaceutically acceptable salt, or solvate thereof:

wherein

Z is H,

is an optionally substituted C₃-C₁₀ heterocyclyl containing at least oneN, O, S, S(═O), or S(═O)₂; wherein if

is substituted, then

is substituted with 0-3 R⁵;

is a substituted C₃-C₁₀ cycloalkyl that is substituted with 1-3R⁴ and0-3R⁵;

-   -   each R⁴ is independently —OR⁶, —SR⁶, —S(═O)R⁷, —S(═O)₂R⁷, or        —N(R⁶)₂;    -   each R⁵ is independently halogen, —CN, —OR⁸, —SR⁸, —S(═O)R⁹,        —S(═O)₂R⁹, —S(═O)₂N(R⁸)₂, —NR⁸S(═O)₂R⁹, —C(═O)R⁹, —OC(═O)R⁹,        —CO₂R⁸, —OCO₂R⁹, —N(R⁸)₂, —OC(═O)N(R⁸)₂, —NR⁸C(═O)R⁹,        —NR⁸C(═O)OR⁹, optionally substituted C₁-C₆alkyl, optionally        substituted C₁-C₆fluoroalkyl, optionally substituted        C₁-C₆heteroalkyl, optionally substituted C₃-C₆cycloalkyl,        optionally substituted aryl, or optionally substituted        heteroaryl;    -   A¹ is N or CR^(A); A² is N or CR^(A); A⁴ is N or CR^(A); A⁵ is N        or CR^(A);    -   each R^(A) is independently H or optionally substituted        C₁-C₆alkyl;    -   R^(A′) is optionally substituted C₁-C₆alkyl;    -   R¹ and R² are each independently H or optionally substituted        C₁-C₆alkyl;    -   L¹ and L² are each independently —CHY—, —CH₂— or —NH—;    -   Y is optionally substituted C₁-C₆alkyl;

is optionally substituted aryl or optionally substituted heteroaryl,wherein if

is substituted, then

is substituted with 0-4 R^(c);

-   -   each R^(c) is independently H, halogen, —CN, —OR¹⁰, —SR¹⁰,        —S(═O)R¹¹, —S(═O)₂R¹¹, —S(═O)₂N(R¹⁰)₂, —NR¹⁰S(═O)₂R¹¹,        —C(═O)R¹¹, —OC(═O)R¹¹, —CO₂R¹⁰, —OCO₂R¹¹, —N(R¹⁰)₂,        —OC(═O)N(R¹⁰)₂, —NR¹⁰C(═O)R¹¹, —NR¹⁰C(═O)OR¹¹, optionally        substituted C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl,        optionally substituted C₁-C₆heteroalkyl, optionally substituted        C₃-C₆cycloalkyl, optionally substituted aryl, or optionally        substituted heteroaryl;    -   each R³ is independently H or optionally substituted C₁-C₆alkyl;

or L^(D);

is optionally substituted heterocyclyl containing at least one N atom;wherein if

is substituted, then

is substituted with 0-4 R^(D);

-   -   L^(D) is —N(R¹²)-(optionally substituted C₁-C₆ alkyl),        —N(R¹³)-(optionally substituted C₁-C₆ alkylene)—N(R¹⁴)₂ or        -(optionally substituted C₁-C₆ alkylene)—N(R¹⁴)₂; wherein if        L^(D) is substituted, then L^(D) is substituted with 0-4 R^(D);    -   each R^(D) is independently halogen, —CN, —OR¹⁵, —SR¹⁵,        —S(═O)R¹⁶, —S(═O)₂R¹⁶, —S(═O)₂N(R¹⁵)₂, —NR¹⁵S(═O)₂R¹⁶,        —C(═O)R¹⁶, —OC(═O)R¹⁶, —CO₂R¹⁵, —OCO₂R¹⁶, —N(R¹⁵)₂,        —OC(═O)N(R¹)₂, —NR¹⁵C(═O)R¹⁶, —NR¹⁵C(═O)OR¹⁶, optionally        substituted C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl,        optionally substituted C₁-C₆heteroalkyl, optionally substituted        C₃-C₆cycloalkyl, optionally substituted aryl, or optionally        substituted heteroaryl;    -   each R⁶ is independently hydrogen, optionally substituted        C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl, optionally        substituted C₁-C₆heteroalkyl, optionally substituted        C₃-C₁₀cycloalkyl, optionally substituted C₂-C₁₀heterocycloalkyl,        optionally substituted aryl, or optionally substituted        heteroaryl; or    -   two R⁶ are taken together with the N atom to which they are        attached to form an optionally substituted heterocycle;    -   each R⁷ is independently optionally substituted C₁-C₆alkyl,        optionally substituted C₁-C₆fluoroalkyl, optionally substituted        C₁-C₆heteroalkyl, optionally substituted C₃-C₁₀cycloalkyl,        optionally substituted C₂-C₁₀heterocycloalkyl, optionally        substituted aryl, or optionally substituted heteroaryl;    -   each R⁸ is independently hydrogen, optionally substituted        C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl, optionally        substituted C₁-C₆heteroalkyl, optionally substituted        C₃-C₁₀cycloalkyl, optionally substituted C₂-C₁₀heterocycloalkyl,        optionally substituted aryl, or optionally substituted        heteroaryl; or    -   two R⁸ are taken together with the N atom to which they are        attached to form an optionally substituted heterocycle;    -   each R⁹ is independently optionally substituted C₁-C₆alkyl,        optionally substituted C₁-C₆fluoroalkyl, optionally substituted        C₁-C₆heteroalkyl, optionally substituted C₃-C₁₀cycloalkyl,        optionally substituted C₂-C₁₀heterocycloalkyl, optionally        substituted aryl, or optionally substituted heteroaryl;    -   each R¹⁰ is independently hydrogen, optionally substituted        C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl, optionally        substituted C₁-C₆heteroalkyl, optionally substituted        C₃-C₁₀cycloalkyl, optionally substituted C₂-C₁₀heterocycloalkyl,        optionally substituted aryl, or optionally substituted        heteroaryl; or    -   two R¹⁰ are taken together with the N atom to which they are        attached to form an optionally substituted heterocycle;    -   each R¹¹ is independently optionally substituted C₁-C₆alkyl,        optionally substituted C₁-C₆fluoroalkyl, optionally substituted        C₁-C₆heteroalkyl, optionally substituted C₃-C₁₀cycloalkyl,        optionally substituted C₂-C₁₀heterocycloalkyl, optionally        substituted aryl, or optionally substituted heteroaryl;    -   each R¹² and R¹³ is independently H or optionally substituted        C₁-C₆alkyl;    -   each R¹⁴ is independently H or optionally substituted        C₁-C₆alkyl; or    -   two R¹⁴ are taken together with the N atom to which they are        attached to form an optionally substituted heterocycle;    -   each R¹⁵ is independently hydrogen, optionally substituted        C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl, optionally        substituted C₁-C₆heteroalkyl, optionally substituted        C₃-C₁₀cycloalkyl, optionally substituted C₂-C₁₀heterocycloalkyl,        optionally substituted aryl, or optionally substituted        heteroaryl; or    -   two R¹⁵ are taken together with the N atom to which they are        attached to form an optionally substituted heterocycle, and    -   each R¹⁶ is independently optionally substituted C₁-C₆alkyl,        optionally substituted C₁-C₆fluoroalkyl, optionally substituted        C₁-C₆heteroalkyl, optionally substituted C₃-C₁₀cycloalkyl,        optionally substituted C₂-C₁₀heterocycloalkyl, optionally        substituted aryl, or optionally substituted heteroaryl.

In some embodiments, Z is H. In some embodiments, Z is

In some embodiments,

is optionally substituted C₄-C₇ heterocyclyl containing at least one N,O, S, S(═O), or S(═O)₂; wherein if

is substituted, then

is substituted with 0-3 R⁵.

In some embodiments, is

o is 0, 1, or 2; and p is 0, 1, 2, or 3.

In some embodiments,

and o is 0, 1, or 2.

In some embodiments, Z is

In some embodiments,

is substituted C₄-C₇ cycloalkyl that is substituted with 1-3R⁴ and0-3R⁵.

In some embodiments, is

and

q is 0, 1, 2, or 3.

In some embodiments,

and

q is 0, 1, 2, or 3.

In some embodiments, A¹ is CH; A² is N or CR^(A); A⁴ is CH; and A⁵ isCH. In some embodiments, A² is N. In some embodiments, A² is CR^(A). Insome embodiments, R^(A′) is optionally substituted C₁-C₄alkyl. In someembodiments, R^(A′) is methyl, ethyl, propyl, and butyl. In someembodiments, R^(A′) ethyl, propyl, and butyl. In some embodiments, R¹ isoptionally substituted C₁-C₆alkyl. In some embodiments, R¹ is methyl. Insome embodiments, R² is H. In some embodiments, L¹ and L² are each —NH—.In some embodiments, L¹ is —CH₂— and L² is —NH—. In some embodiments, L¹is —NH— and L² is —CH₂-. In some embodiments, L¹ is —CHY—. In someembodiments, L² is —CHY—. In some embodiments, Y is optionallysubstituted C₁-C₃alkyl.

In some embodiments,

is optionally substituted aryl, wherein if

is substituted, then

is substituted with 0-4 R^(c).

In some embodiments,

is optionally substituted heteroaryl wherein if

is substituted, then

is substituted with 0-4 R^(c).

In some embodiments,

C¹ is N or CR^(C); C² is N or CR^(C); C³ is N or CR^(C); and C⁴ is N orCR^(C)

In some embodiments, C¹ is CR^(C); C² is CR^(C); C³ is CR^(C); and C⁴ isCR^(C). In some embodiments, C¹ is CR^(C); C² is CH; C³ is CH; and C⁴ isCH. In some embodiments, R^(c) is optionally substitutedC₁-C₆fluoroalkyl. In some embodiments, R^(c) is —CF₃. In someembodiments, each R³ is independently H.

In some embodiments, Z is

In some embodiments,

is optionally substituted heterocyclyl containing at least one N atom;and if

is substituted, then

is substituted with 0-4 R^(D).

In some embodiments,

is optionally substituted heterocyclyl containing one N atom; and if

is substituted, then

is substituted with 0-4 R^(D).

In some embodiments,

is optionally substituted heterocyclyl containing two N atoms; and if

is substituted, then

is substituted with 0-4 R^(D).

In some embodiments,

and

r is 0, 1, or 2.

In some embodiments,

and r is 0, 1, or 2.

In some embodiments,

is L^(D).

In some embodiments, L^(D) is —N(R¹²)-(optionally substituted C₁-C₆alkyl), —N(R¹³)-(optionally substituted C₁-C₆ alkylene)—N(R¹⁴)₂ or-(optionally substituted C₁-C₆ alkylene)—N(R¹⁴)₂; and if L^(D) issubstituted, then L^(D) is substituted with 0-4 R^(D). In someembodiments, L^(D) is —N(R¹²)-(optionally substituted C₁-C₆ alkyl), andif L^(D) is substituted, then L^(D) is substituted with 0-4 R^(D). Insome embodiments, L^(D) is —N(R¹²)—CH₂—CH₂—CH₂—CH₃, —N(R¹²)—CH₂—CH₂—CH₃,—N(R¹²)—CH₂—CH₃, or —N(R¹²)—CH₃. In some embodiments, R¹² is H orC₁-C₄alkyl. In some embodiments, R¹² is H or C₃-C₄alkyl. In someembodiments, L^(D) is —N(R¹³)-(optionally substituted C₁-C₆alkylene)—N(R¹⁴)₂, and if L^(D) is substituted, then L^(D) issubstituted with 0-4 R^(D). In some embodiments, L^(D) is—N(R¹³)—CH₂—CH₂—CH₂—CH₂—N(R¹⁴)₂, —N(R¹³)—CH₂—CH₂—CH₂—N(R¹⁴)₂,—N(R¹³)—CH₂—CH₂—N(R¹⁴)₂, or —N(R¹³)—CH₂—N(R¹⁴)₂. In some embodiments,each R¹³ and R¹⁴ is independently H or C₁-C₄alkyl. In some embodiments,L^(D) is or -(optionally substituted C₁-C₆ alkylene)—N(R¹⁴)₂; and ifL^(D) is substituted, then L^(D) is substituted with 0-4 R^(D). In someembodiments, L^(D) is —CH₂—CH₂—CH₂—CH₂—N(R¹⁴)₂, —CH₂—CH₂—CH₂—N(R¹⁴)₂,—CH₂—CH₂—N(R¹⁴)₂, or —CH₂—N(R¹⁴)₂. In some embodiments, each R¹⁴ isindependently H or C₁-C₄alkyl.

In some embodiments, the compound has the structure of formula (IIa)

wherein,

C¹ is N or CR^(C); C² is N or CR^(C); C³ is N or CR^(C); and C⁴ is N orCR^(C).

In some embodiments, the compound has the structure of formula (IIb)

wherein,

C¹ is N or CR^(C); C² is N or CR^(C); C³ is N or CR^(C); and C⁴ is N orCR^(C).

In some embodiments, the compound has the structure of formula (IIc)

wherein,

C¹ is N or CR^(C); C² is N or CR^(C); C³ is N or CR^(C); and C⁴ is N orCR^(C).

In some embodiments, the compound has the structure of formula (IId)

wherein,

C¹ is N or CR^(C); C² is N or CR^(C); C³ is N or CR^(C); and C⁴ is N orCR^(C).

In some embodiments, the compound has the structure of formula (IIe)

wherein,

C¹ is N or CR^(C); C² is N or CR^(C); C³ is N or CR^(C); and C⁴ is N orCR^(C).

In some embodiments, the compound has the structure of formula (IIf)

wherein,

C¹ is N or CR^(C); C² is N or CR^(C); C³ is N or CR^(C); and C⁴ is N orCR^(C).

In some embodiments, the compound has the structure of formula (IIg)

wherein,

C¹ is N or CR^(C); C² is N or CR^(C); C³ is N or CR^(C); and C⁴ is N orCR^(C).

In some embodiments, the compound has the structure of formula (IIh)

In some embodiments, the compound has the structure of formula (IIi)

In some embodiments, the compound has the structure of formula (IIj)

In some embodiments, the compound has the structure of formula (IIk)

In some embodiments, the compound has the structure of formula (IIl)

In some embodiments, the compound has the structure of formula (IIm)

In another aspect, provided herein is a compound of Formula (III), or apharmaceutically acceptable salt, or solvate thereof:

wherein,

Z is H

is an optionally substituted C₃-C₁₀ heterocyclyl containing at least oneN, O, S, S(═O), or S(═O)₂; wherein if

is substituted, then

is substituted with 0-3 R⁵;

is a substituted C₃-C₁₀ cycloalkyl that is substituted with 1-3R⁴ and0-3R⁵;

-   -   each R⁴ is independently —OR⁶, —SR⁶, —S(═O)R⁷, —S(═O)₂R⁷, or        —N(R⁶)₂;    -   each R⁵ is independently halogen, —CN, —OR⁸, —SR⁸, —S(═O)R⁹,        —S(═O)₂R⁹, —S(═O)₂N(R⁸)₂, —NR⁸S(═O)₂R⁹, —C(═O)R⁹, —OC(═O)R⁹,        —CO₂R⁸, —OCO₂R⁹, —N(R⁸)₂, —OC(═O)N(R⁸)₂, —NR⁸C(═O)R⁹,        —NR⁸C(═O)OR⁹, optionally substituted C₁-C₆alkyl, optionally        substituted C₁-C₆fluoroalkyl, optionally substituted        C₁-C₆heteroalkyl, optionally substituted C₃-C₆cycloalkyl,        optionally substituted aryl, or optionally substituted        heteroaryl;    -   A¹ is N or CR^(A); A² is N or CR^(A); A³ is N or CR^(A); A⁴ is N        or CR^(A); A⁵ is N or CR^(A);    -   each R^(A) is independently H or optionally substituted        C₁-C₆alkyl;    -   R¹ and R² are each independently H or optionally substituted        C₁-C₆alkyl;    -   L¹ and L² are each independently —CHY—, —CH₂— or —NH—;    -   Y is optionally substituted C₁-C₆alkyl;

is optionally substituted aryl or optionally substituted heteroaryl,wherein if

is substituted, then

is substituted with 0-4 R^(c);

-   -   each R^(c) is independently H, halogen, —CN, —OR¹⁰, —SR¹⁰,        —S(═O)R¹¹, —S(═O)₂R¹¹, —S(═O)₂N(R¹⁰)₂, —NR¹⁰S(═O)₂R¹¹,        —C(═O)R¹¹, —OC(═O)R¹¹, —CO₂R¹⁰, —OCO₂R¹¹, —N(R¹⁰)₂,        —OC(═O)N(R¹⁰)₂, —NR¹⁰C(═O)R¹¹, —NR¹⁰C(═O)OR¹¹, optionally        substituted C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl,        optionally substituted C₁-C₆heteroalkyl, optionally substituted        C₃-C₆cycloalkyl, optionally substituted aryl, or optionally        substituted heteroaryl;    -   each R³ is independently H or optionally substituted C₁-C₆alkyl;        L^(D) is —N(R¹²)-(optionally substituted C₁-C₆ alkyl),        —N(R¹³)-(optionally substituted C₁-C₆ alkylene)—N(R¹⁴)₂ or        -(optionally substituted C₁-C₆ alkylene)—N(R¹⁴)₂; wherein if        L^(D) is substituted, then L^(D) is substituted with 0-4 R^(D);    -   each R^(D) is independently halogen, —CN, —OR¹⁵, —SR¹⁵,        —S(═O)R¹⁶, —S(═O)₂R¹⁶, —S(═O)₂N(R¹⁵)₂, —NR¹⁵S(═O)₂R¹⁶,        —C(═O)R¹⁶, —OC(═O)R¹⁶, —CO₂R¹⁵, —OCO₂R¹⁶, —N(R¹⁵)₂,        —OC(═O)N(R¹⁵)₂, —NR¹⁵C(═O)R¹⁶, —NR¹⁵C(═O)OR¹⁶, optionally        substituted C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl,        optionally substituted C₁-C₆heteroalkyl, optionally substituted        C₃-C₆cycloalkyl, optionally substituted aryl, or optionally        substituted heteroaryl;    -   each R⁶ is independently hydrogen, optionally substituted        C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl, optionally        substituted C₁-C₆heteroalkyl, optionally substituted        C₃-C₁₀cycloalkyl, optionally substituted C₂-C₁₀heterocycloalkyl,        optionally substituted aryl, or optionally substituted        heteroaryl; or    -   two R⁶ are taken together with the N atom to which they are        attached to form an optionally substituted heterocycle, each R⁷        is independently optionally substituted C₁-C₆alkyl, optionally        substituted C₁-C₆fluoroalkyl, optionally substituted        C₁-C₆heteroalkyl, optionally substituted C₃-C₁₀cycloalkyl,        optionally substituted C₂-C₁₀heterocycloalkyl, optionally        substituted aryl, or optionally substituted heteroaryl;    -   each R⁸ is independently hydrogen, optionally substituted        C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl, optionally        substituted C₁-C₆heteroalkyl, optionally substituted        C₃-C₁₀cycloalkyl, optionally substituted C₂-C₁₀heterocycloalkyl,        optionally substituted aryl, or optionally substituted        heteroaryl; or    -   two R⁸ are taken together with the N atom to which they are        attached to form an optionally substituted heterocycle, each R⁹        is independently optionally substituted C₁-C₆alkyl, optionally        substituted C₁-C₆fluoroalkyl, optionally substituted        C₁-C₆heteroalkyl, optionally substituted C₃-C₁₀cycloalkyl,        optionally substituted C₂-C₁₀heterocycloalkyl, optionally        substituted aryl, or optionally substituted heteroaryl;    -   each R¹⁰ is independently hydrogen, optionally substituted        C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl, optionally        substituted C₁-C₆heteroalkyl, optionally substituted        C₃-C₁₀cycloalkyl, optionally substituted C₂-C₁₀heterocycloalkyl,        optionally substituted aryl, or optionally substituted        heteroaryl; or    -   two R¹⁰ are taken together with the N atom to which they are        attached to form an optionally substituted heterocycle, each R¹¹        is independently optionally substituted C₁-C₆alkyl, optionally        substituted C₁-C₆fluoroalkyl, optionally substituted        C₁-C₆heteroalkyl, optionally substituted C₃-C₁₀cycloalkyl,        optionally substituted C₂-C₁₀heterocycloalkyl, optionally        substituted aryl, or optionally substituted heteroaryl;    -   R¹² is independently H or optionally substituted C₃-C₆alkyl;    -   R¹³ is H or optionally substituted C₁-C₆alkyl;    -   each R¹⁴ is independently H or optionally substituted        C₁-C₆alkyl; or    -   two R¹⁴ are taken together with the N atom to which they are        attached to form an optionally substituted heterocycle;    -   each R¹⁵ is independently hydrogen, optionally substituted        C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl, optionally        substituted C₁-C₆heteroalkyl, optionally substituted        C₃-C₁₀cycloalkyl, optionally substituted C₂-C₁₀heterocycloalkyl,        optionally substituted aryl, or optionally substituted        heteroaryl; or    -   two R¹⁵ are taken together with the N atom to which they are        attached to form an optionally substituted heterocycle, and each        R¹⁶ is independently optionally substituted C₁-C₆alkyl,        optionally substituted C₁-C₆fluoroalkyl, optionally substituted        C₁-C₆heteroalkyl, optionally substituted C₃-C₁₀cycloalkyl,        optionally substituted C₂-C₁₀heterocycloalkyl, optionally        substituted aryl, or optionally substituted heteroaryl.

In some embodiments, Z is H. In some embodiments, Z is

In some embodiments,

is optionally substituted C₄-C₇ heterocyclyl containing at least one N,O, S, S(═O), or S(═O)₂; wherein if

is substituted, then

is substituted with 0-3 R⁵.

In some embodiments,

o is 0, 1, or 2; and p is 0, 1, 2, or 3.

In some embodiments,

and o is 0, 1, or 2.

In some embodiments, Z is

In some embodiments,

is substituted C₄-C₇ cycloalkyl that is substituted with 1-3R⁴ and0-3R⁵.

In some embodiments,

and

q is 0, 1, 2, or 3.

In some embodiments,

and

q is 0, 1, 2, or 3.

In some embodiments, A¹ is CH; A² is N or CR^(A); A³ is N or CR^(A); A⁴is CH; and A⁵ is CH. In some embodiments, A² is N. In some embodiments,A² is CR^(A). In some embodiments, A³ is CR^(A). In some embodiments,R^(A) is optionally substituted C₁-C₆alkyl. In some embodiments, R^(A)is methyl, ethyl, propyl or butyl. In some embodiments, R^(A) is methyl,propyl or butyl. In some embodiments, R¹ is optionally substitutedC₁-C₆alkyl. In some embodiments, R¹ is methyl. In some embodiments, R²is H. In some embodiments, L¹ and L² are each —NH—. In some embodiments,L¹ is —CH₂— and L² is —NH—. In some embodiments, L¹ is —NH— and L² is—CH₂—. In some embodiments, L¹ is —CHY—. In some embodiments, L² is—CHY—. In some embodiments, Y is optionally substituted C₁-C₃alkyl.

In some embodiments,

is optionally substituted aryl, wherein if

is substituted, then

is substituted with 0-4 R^(c).

In some embodiments,

is optionally substituted heteroaryl wherein if

is substituted, then

is substituted with 0-4 R^(c).

In some embodiments,

C¹ is N or CR^(C); C² is N or CR^(C); C³ is N or CR^(C); and C⁴ is N orCR^(C).

In some embodiments, C¹ is CR^(C); C² is CR^(C); C³ is CR^(C); and C⁴ isCR^(C). In some embodiments, C¹ is CR^(C); C² is CH; C³ is CH; and C⁴ isCH. In some embodiments, R^(c) is optionally substitutedC₁-C₆fluoroalkyl. In some embodiments, R^(c) is —CF₃. In someembodiments, each R³ is independently H. In some embodiments, L^(D) is—N(R¹²)-(optionally substituted C₁-C₆ alkyl), —N(R¹³)-(optionallysubstituted C₁-C₆ alkylene)—N(R¹⁴)₂ or -(optionally substituted C₁-C₆alkylene)—N(R¹⁴)₂; and if L^(D) is substituted, then L^(D) issubstituted with 0-4 R^(D). In some embodiments, L^(D) is—N(R¹²)-(optionally substituted C₁-C₆ alkyl), and if L^(D) issubstituted, then L^(D) is substituted with 0-4 R^(D). In someembodiments, L^(D) is —N(R¹²)—CH₂—CH₂—CH₂—CH₃, —N(R¹²)—CH₂—CH₂—CH₃,—N(R¹²)—CH₂—CH₃, or —N(R₁₂)—CH₃. In some embodiments, R¹² is H orC₃-C₄alkyl. In some embodiments, L^(D) is —N(R¹³)-(optionallysubstituted C₁-C₆ alkylene)—N(R¹⁴)₂, and if L^(D) is substituted, thenL^(D) is substituted with 0-4 R^(D). In some embodiments, L^(D) is—N(R¹³CH)—CH₂—CH₂—CH₂—N(R¹⁴)₂, —N(R¹³)—CH₂—CH₂—CH₂—N(R¹⁴)₂,—N(R¹³)—CH₂—CH₂—N(R¹⁴)₂, or —N(R¹³)—CH₂—N(R¹⁴)₂. In some embodiments,each R¹³ and R¹⁴ is independently H or C₁-C₄alkyl. In some embodiments,L^(D) is or -(optionally substituted C₁-C₆ alkylene)—N(R¹⁴)₂; and ifL^(D) is substituted, then L^(D) is substituted with 0-4 R^(D). In someembodiments, L^(D) is —CH₂—CH₂—CH₂—CH₂—N(R¹⁴)₂, —CH₂—CH₂—CH₂—N(R¹⁴)₂,—CH₂—CH₂—N(R¹⁴)₂, or —CH₂—N(R¹⁴)₂. In some embodiments, each R¹⁴ isindependently H or C₁-C₄alkyl.

In some embodiments, the compound has the structure of formula (IIIa)

wherein,

C¹ is N or CR^(C); C² is N or CR^(C); C³ is N or CR^(C); and C⁴ is N orCR^(C).

In some embodiments, the compound has the structure of formula (IIIb)

wherein,

C¹ is N or CR^(C); C² is N or CR^(C); C³ is N or CR^(C); and C⁴ is N orCR^(C).

In some embodiments, the compound has the structure of formula (IIIc)

wherein,

C¹ is N or CR^(C); C² is N or CR^(C); C³ is N or CR^(C); and C⁴ is N orCR^(C).

In some embodiments, the compound has the structure of formula (IIId)

wherein,

C¹ is N or CR^(C); C² is N or CR^(C); C³ is N or CR^(C); and C⁴ is N orCR^(C).

In some embodiments, the compound has the structure of formula (IIIe)

In some embodiments, the compound has the structure of formula (IIIf)

In some embodiments, the compound has the structure of formula (IIIg)

In some embodiments, the compound has the structure of formula (IIIh)

In some embodiments, a compound described herein is selected from anyone of the compounds from the following tables, Tables 1-3:

TABLE 1 Compound. No Structure Name 51

1-(1-methyl-5-(2- (piperidin-4-ylamino) quinazolin-6-yl)-1H-pyrazol-3-yl)-3- (5-((4- methylpiperazin-1- yl)methyl)-4-(trifluoromethyl) pyridin-2-yl)urea 50

1-(5-(2-((azetidin-3- ylmethyl)amino) quinazolin-6-yl)-1-methyl-1H-pyrazol- 3-yl)-3-(4-((4- methylpiperazin-1- yl)methyl)-3-(trifluoromethyl) phenyl)urea 49

1-(5-(8-ethyl-2- (((1r,4r)-4- hydroxycyclohexyl) amino)quinazolin-6-yl)-1-methyl-1H- pyrazol-3- yl)-3-(4-((4- methylpiperazin-1-yl)methyl)-3- (trifluoromethyl) phenyl)urea 46

N-(5-(2-(((1r,4r)-4- aminocyclohexyl) amino)-8- ethylquinazolin-6-yl)-1-methyl-1H- pyrazol- 3-yl)-2-(4-((4- methylpiperazin-1-yl)methyl)-3- trifluoromethyl) phenyl) acetamide 45

1-(4-((dimethylamino) methyl)-3- (trifluoromethyl) phenyl)-3-(1-methyl-5-(2-(piperidin-4- ylamino)quinazolin- 6-yl)-1H- pyrazol-3-yl)urea 44

1-(5-(2-(((1r,4r)-4- aminocyclohexyl) amino)quinazolin-6-yl)-1-methyl-1H- pyrazol-3-yl)-3-(4- ((4-(methylamino) piperidin-1-yl)methyl)-3- (trifluoromethyl) phenyl)urea 43

1-(5-(2-(((1r,4r)-4- aminocyclohexyl) amino)quinazolin-6-yl)-1-methyl-1H- pyrazol-3-yl)-3-(4- ((methyl(2- (methylamino)ethyl)amino)methyl)-3- (trifluoromethyl) phenyl)urea 42

1-(5-(2-(((1r,4r)-4- aminocyclohexyl) amino)quinazolin-6-yl)-1-methyl-1H- pyrazol-3-yl)-3-(4- (1-(4- methylpiperazin-1-yl)ethyl)-3- (trifluoromethyl) phenyl)urea 41

1-(5-(2-((4,4- difluorocyclohexyl) amino)quinazolin-6- yl)-1-methyl-1H-pyrazol-3-yl)-3- (4-((4- methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl) phenyl)urea 40

1-(1-methyl-5-(2- (((S)-piperidin- 3-yl)amino) quinazolin-6-yl)-1H-pyrazol-3- yl)-3-(4-(1-(4- methylpiperazin- 1-yl)ethyl)-3-(trifluoromethyl) phenyl)urea 39

(S)-1-(1-methyl-5-(2- (pyrrolidin-3 ylamino)quinazolin-6-yl)-1H-pyrazol-3- yl)-3-(4-((4- methylpiperazin-1- yl)methyl)-3-(trifluoromethyl) phenyl)urea 38

1-(5-(2-((3- aminopropyl)amino) quinazolin-6-yl)-1- methyl-1H-pyrazol-3-yl)-3-(4-((4- methylpiperazin-1- yl)methyl)-3- (trifluoromethyl)phenyl)urea 36

(R)-1-(1-methyl-5-(2- (pyrrolidin-3- ylamino)quinazolin-6-yl)-1H-pyrazol-3- yl)-3-(4-((4- methylpiperazin-1- yl)methyl)-3-(trifluoromethyl) phenyl)urea 35

1-(4-(((2- (dimethylamino) ethyl)(methyl) amino)methyl)-3-(trifluoromethyl) phenyl)-3-(1-methyl- 5-(2-(piperidin-4-ylamino)quinazolin- 6-yl)-1H- pyrazol-3-yl)urea 34

1-(5-(2-(((1S,3R)-3- aminocyclohexyl) amino)quinazolin-6-yl)-1-methyl-1H- pyrazol-3-yl)-3- (4-((4- methylpiperazin-1-yl)methyl)-3- (trifluoromethyl) phenyl)urea 33

1-(5-(2-(((1R,3R)-3- aminocyclohexyl) amino)quinazolin-6-yl)-1-methyl-1H- pyrazol-3-yl)-3- (4-((4- methylpiperazin-1-yl)methyl)-3- (trifluoromethyl) phenyl)urea 32

1-(5-(2-(((1r,4r)-4- aminocyclohexyl) amino)quinazolin-6-yl)-1-methyl-1H- pyrazol-3-yl)-3- (4-((4- aminopiperidin-1-yl)methyl)-3- (trifluoromethyl) phenyl)urea 31

1-(5-(2-(((1r,4r)-4- aminocyclohexyl) amino)-8- ethylquinazolin-6-yl)-1-methyl-1H- pyrazol-3-yl)-3- (4-((4- methylpiperazin-1-yl)methyl)-3- (trifluoromethyl) phenyl)urea 29

1-(5-(2-(((1s,4s)-4- aminocyclohexyl) amino)quinazolin-6-yl)-1-methyl-1H- pyrazol-3-yl)-3- (4-((4- methylpiperazin-1-yl)methyl)-3- (trifluoromethyl) phenyl)urea 26

1-(5-(2-(((1r,4r)-4- hydroxycyclohexyl) amino)quinazolin-6-yl)-1-methyl-1H- pyrazol-3-yl)-3- (4-((4- methylpiperazin-1-yl)methyl)-3- (trifluoromethyl) phenyl)urea 23

1-(4-((5-methyl-2,5- diazabicyclo[2.2.2] octan-2-yl)methyl)-3-(trifluoromethyl) phenyl)-3- (1-methyl-5-(2- (piperidin-4-ylamino)quinazolin- 6-yl)-1H- pyrazol-3-yl)urea 22

1-(1-methyl-5-(2- (piperidin-4- ylamino) quinazolin-6-yl)-1H-pyrazol-3-yl)-3- (4-(1-(4- methylpiperazin- 1-yl)ethyl)-3-(trifluoromethyl) phenyl)urea 21

1-(1-methyl-5-(2- (piperidin-4- ylamino) quinazolin-6-yl)-1H-pyrazol-3-yl)- 3-(3-((4- methylpiperazin-1- yl)methyl)-5-(trifluoromethyl) phenyl)urea 20

1-(1-methyl-5-(2- (piperidin-4- ylamino)quinazolin- 6-yl)-1H-pyrazol-3-yl)-3- (4-((4- methylpiperazin-1- yl)methyl)-3-(trifluoromethyl) phenyl)urea 19

1-(4-((3-methyl-3,8- diazabicyclo[3.2.1] octan-8- yl)methyl)-3-(trifluoromethyl) phenyl)-3- (1-methyl-5-(2- (piperidin-4-ylamino)quinazolin-6-yl)-1H- pyrazol-3-yl)urea 17

(S)-1-(1-methyl-5-(2- (piperidin-3- ylamino)quinazolin- 6-yl)-1H-pyrazol-3-yl)-3-(4-((4- methylpiperazin-1- yl)methyl)-3-(trifluoromethyl) phenyl)urea 15

(R)-1-(1-methyl-5-(2- (piperidin-3- ylamino)quinazolin- 6-yl)-1H-pyrazol-3-yl)-3-(4-((4- methylpiperazin-1- yl)methyl)-3-(trifluoromethyl) phenyl)urea 14

N-(1-methyl-5-(2- (piperidin-4- ylamino)quinazolin- 6-yl)-1H-pyrazol-3-yl)-2-(4-((4- methylpiperazin-1- yl)methyl)-3-(trifluoromethyl) phenyl)acetamide 5

1-(5-(2- (cyclohexylamino) quinazolin-6-yl)- 1-methyl-1H-pyrazol-3-yl)-3-(4-((4- methylpiperazin-1- yl)methyl)-3- (trifluoromethyl)phenyl)urea 4

1-(5-(3- (cyclohexylamino) isoquinolin-7-yl)- 1-methyl-1H-pyrazol-3-yl)-3-(4-((4- methylpiperazin-1- yl)methyl)-3- (trifluoromethyl)phenyl)urea 3

1-(5-(2-(((1r,4r)-4- aminocyclohexyl) amino)quinazolin-6-yl)-1-methyl-1H- pyrazol-3-yl)-3- (4-((4- methylpiperazin-1-yl)methyl)-3- (trifluoromethyl) phenyl)urea 2

1-(1-methyl-5-(2- (piperidin-4- ylamino) quinazolin-6-yl)-1H-pyrazol-3-yl)- 3-(4-((4- methylpiperazin-1- yl)methyl)-3-(trifluoromethyl) phenyl)urea 1

1-(1-methyl-5-(2- (piperidin-3- ylamino) quinazolin-6-yl)-1H-pyrazol-3-yl)- 3-(4-((4- methylpiperazin-1- yl)methyl)-3-(trifluoromethyl) phenyl)urea

TABLE 2 Compound No. Structure Name 12

1-(5-(2-amino-8- methylquinazolin-6-yl)-1- methyl-1H-pyrazol-3-yl)-3-(4-((4-methylpiperazin-1- yl)methyl)-3- (trifluoromethyl)phenyl)urea 11

N-(5-(2-aminoquinazolin-6-yl)- 1-methyl-1H-pyrazol-3-yl)-2-(4-((4-methylpiperazin-1- yl)methyl)-3- (trifluoromethyl)phenyl)acetamide 6

1-(5-(2-amino-8- ethylquinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)-3-(4-((4- methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea

TABLE 3 Compound No. Structure Name 10

1-(5-(2-aminoquinazolin-6- yl)-1-methyl-1H-pyrazol-3-yl)-3-(4-((methyl(2- (methylamino)ethyl)amino) methyl)-3-(trifluoromethyl)phenyl)urea 9

1-(4-(((2- aminoethyl)(methyl)amino) methyl)-3-(trifluoromethyl)phenyl)-3-(5- (2-aminoquinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)urea

In some embodiments, the compound is:

-   1-(1-methyl-5-(2-(piperidin-4-ylamino)quinazolin-6-yl)-1H-pyrazol-3-yl)-3-(5-((4-methylpiperazin-1-yl)methyl)-4-(trifluoromethyl)pyridin-2-yl)urea;-   1-(5-(8-ethyl-2-(((1r,4r)-4-hydroxycyclohexyl)amino)quinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)-3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea;-   N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-ethyl    quinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)-2-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)acetamide;-   1-(4-((dimethylamino)methyl)-3-(trifluoromethyl)phenyl)-3-(1-methyl-5-(2-(piperidin-4-yl    amino)quinazolin-6-yl)-1H-pyrazol-3-yl)urea;-   1-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)quinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)-3-(4-((4-(methylamino)piperidin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea;-   1-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)quinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)-3-(4-((methyl(2-(methylamino)ethyl)amino)methyl)-3-(trifluoromethyl)phenyl)urea;-   1-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)quinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)-3-(4-(1-(4-methylpiperazin-1-yl)ethyl)-3-(trifluoromethyl)phenyl)urea;-   1-(5-(2-((4,4-difluorocyclohexyl)amino)quinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)-3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea;-   1-(1-methyl-5-(2-(((S)-piperidin-3-yl)amino)quinazolin-6-yl)-1H-pyrazol-3-yl)-3-(4-(1-(4-methylpiperazin-1-yl)ethyl)-3-(trifluoromethyl)phenyl)urea;-   (S)-1-(1-methyl-5-(2-(pyrrolidin-3-ylamino)quinazolin-6-yl)-1H-pyrazol-3-yl)-3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea;-   (R)-1-(1-methyl-5-(2-(pyrrolidin-3-ylamino)quinazolin-6-yl)-1H-pyrazol-3-yl)-3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea;-   1-(4-(((2-(dimethylamino)ethyl)(methyl)amino)methyl)-3-(trifluoromethyl)phenyl)-3-(1-methyl-5-(2-(piperidin-4-ylamino)quinazolin-6-yl)-1H-pyrazol-3-yl)urea;-   1-(5-(2-(((1    S,3R)-3-aminocyclohexyl)amino)quinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)-3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea;-   1-(5-(2-(((1R,3R)-3-aminocyclohexyl)amino)quinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)-3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea;-   1-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)quinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)-3-(4-((4-aminopiperidin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea;-   1-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-ethyl    quinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)-3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea;-   1-(5-(2-(((1s,4s)-4-aminocyclohexyl)amino)quinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)-3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea;-   1-(5-(2-(((1r,4r)-4-hydroxycyclohexyl)amino)quinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)-3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea;-   1-(4-((5-methyl-2,5-diazabicyclo[2.2.2]octan-2-yl)methyl)-3-(trifluoromethyl)phenyl)-3-(1-methyl-5-(2-(piperidin-4-ylamino)quinazolin-6-yl)-1H-pyrazol-3-yl)urea;-   1-(1-methyl-5-(2-(piperidin-4-ylamino)quinazolin-6-yl)-1H-pyrazol-3-yl)-3-(4-(1-(4-methylpiperazin-1-yl)ethyl)-3-(trifluoromethyl)phenyl)urea;-   1-(1-methyl-5-(2-(piperidin-4-ylamino)quinazolin-6-yl)-1H-pyrazol-3-yl)-3-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)urea;-   1-(1-methyl-5-(2-(piperidin-4-ylamino)quinazolin-6-yl)-1H-pyrazol-3-yl)-3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea;-   1-(4-((3-methyl-3,8-diazabicyclo[3.2.1]octan-8-yl)methyl)-3-(trifluoromethyl)phenyl)-3-(1-methyl-5-(2-(piperidin-4-ylamino)quinazolin-6-yl)-1H-pyrazol-3-yl)urea;-   (S)-1-(1-methyl-5-(2-(piperidin-3-ylamino)quinazolin-6-yl)-1H-pyrazol-3-yl)-3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea;-   (R)-1-(1-methyl-5-(2-(piperidin-3-ylamino)quinazolin-6-yl)-1H-pyrazol-3-yl)-3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea;-   N-(1-methyl-5-(2-(piperidin-4-ylamino)quinazolin-6-yl)-1H-pyrazol-3-yl)-2-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)acetamide;-   1-(5-(2-(cyclohexylamino)quinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)-3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea;-   1-(5-(3-(cyclohexylamino)isoquinolin-7-yl)-1-methyl-1H-pyrazol-3-yl)-3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea;-   1-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)quinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)-3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea;-   1-(1-methyl-5-(2-(piperidin-4-ylamino)quinazolin-6-yl)-1H-pyrazol-3-yl)-3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea;    or-   1-(1-methyl-5-(2-(piperidin-3-ylamino)quinazolin-6-yl)-1H-pyrazol-3-yl)-3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea.

In some embodiments, the compound is:

-   1-(5-(2-((azetidin-3-ylmethyl)amino)quinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)-3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea;    or-   1-(5-(2-((3-aminopropyl)amino)quinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)-3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea.

In some embodiments, the compound is:

-   1-(5-(2-amino-8-methylquinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)-3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea;    or-   1-(5-(2-amino-8-ethylquinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)-3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea.

In some embodiments, the compound is:

-   N-(5-(2-aminoquinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)-2-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)acetamide.

In some embodiments, the compound is:

-   1-(5-(8-ethyl-2-(((1r,4r)-4-hydroxycyclohexyl)amino)quinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)-3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea;-   N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)-2-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)acetamide;-   1-(5-(2-amino-8-methylquinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)-3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea;-   1-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-ethyl    quinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)-3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea;    or-   1-(5-(2-amino-8-ethylquinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)-3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea.

In some embodiments, the compound is:

-   1-(5-(2-aminoquinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)-3-(4-((methyl(2-(methylamino)ethyl)amino)methyl)-3-(trifluoromethyl)phenyl)urea;    or-   1-(4-(((2-aminoethyl)(methyl)amino)methyl)-3-(trifluoromethyl)phenyl)-3-(5-(2-aminoquinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)urea.

IRE1-Like Family of Proteins

In some embodiments, a compound disclosed herein selectively binds to aprotein of the IRE1 family of proteins. Exemplary IRE1 family proteinsinclude IRE1, IRE1α, or ERN1. Other exemplary IRE1 family proteinsinclude IRE1 homologues or orthologues in other organisms. Exemplaryorganisms include human, non-human primate, mouse, rat, chicken, fruitfly, yeast, and others listed in Table 4. In some embodiments, the IRE1protein is human IRE1α.

TABLE 4 Organism Accession # Homo sapiens NP_001424.3 Mus musculusNP_076402.1 Rattus norvegicus XP_006247696.1

In some embodiments, a compound disclosed herein selectively binds to anIRE1 family protein comprising a kinase domain and/or an RNase domain.In some embodiments, the kinase domain is a trans-autophosphorylationkinase domain. In some embodiments, the IRE1 family protein is IRE1α. Anexample arrangement of domains within an IRE1α protein is depicted inFIG. 1. An example alignment of IRE1 family protein orthologues isdepicted in FIGS. 2A-2E.

In some embodiments, a compound disclosed herein selectively binds to atrans-autophosphorylation kinase domain region of IRE1α. In someembodiments, a compound disclosed herein selectively binds to atrans-autophosphorylation kinase domain region of IRE1α, for examplewithin amino acid residues 568-833 of SEQ ID NO: 1, or equivalent aminoacid residues thereof.

In some embodiments, a compound disclosed herein selectively binds to anATP-binding pocket within a trans-autophosphorylation kinase domainregion of IRE1α. In some embodiments, a compound disclosed hereinselectively binds to an ATP-binding pocket within atrans-autophosphorylation kinase domain region of IRE1α, for example,one or more of amino acid resides 577-711, 577-586, 597, 599, 626,642-643, 645, 648, 688, 692-693, 695, or 711 of SEQ ID NO: 1, orequivalent amino acid residues thereof.

In some embodiments, a compound disclosed herein selectively binds to anactivation loop within a trans-autophosphorylation kinase domain regionof IRE1α. In some embodiments, a compound disclosed herein selectivelybinds to an activation loop within a trans-autophosphorylation kinasedomain region of IRE1α, for example, one or more of amino acid residues710-736, 710-725, or 729-736 of SEQ ID NO: 1, or equivalent amino acidresidues thereof.

In some embodiments, a compound disclosed herein selectively binds to anRNase domain region of IRE1α. In some embodiments, a compound disclosedherein selectively binds to an RNase domain region of IRE1α, for examplewithin amino acid residues 835-963 of SEQ ID NO: 1, or equivalent aminoacid residues thereof.

In some embodiments, a compound disclosed herein selectively binds to akinase domain dimer interface amino acid residue. In some embodiments, acompound disclosed herein selectively binds to a kinase domain dimerinterface amino acid residue, such as one or more of amino acid residues569-701, 569, 591, 592, 594, 617, 620, 627, 628, 631, 674, 678, or 701of SEQ ID NO: 1.

In some embodiments, a compound disclosed herein selectively binds to afirst IRE1α and blocks dimerization between kinase domain dimerinterface amino acid residues of the first IRE1α and a second IRE1α. Insome embodiments, a compound disclosed herein selectively binds to afirst IRE1α, and inhibit dimerization at one or more of amino acidresidues 569-701, 569, 591, 592, 594, 617, 620,627, 628, 631, 674, 678,or 701 of SEQ ID NO: 1.

In some embodiments, a compound disclosed herein selectively binds to akinase-extension nuclease (KEN) domain dimer interface amino acidresidue of an IRE1α. In some embodiments, a compound disclosed hereinselectively binds to a KEN domain dimer interface amino acid residue,such as one or more of amino acid residues 840-925, 840, 844, 851, 908,912, or 925 of SEQ ID NO: 1.

In some embodiments, a compound disclosed herein selectively binds toamino acid residues of a nuclease active site. In some embodiments, acompound disclosed herein selectively binds to amino acid residues of anuclease active site, such as one or more of amino acid residues847-910, 847, 850, 886, 888, 889, 890, 892, 902, 905, 906, or 910 of SEQID NO: 1.

In some embodiments, a compound disclosed herein selectively binds to anRNase domain and a trans-autophosphorylation kinase domain region ofIRE1α. In some embodiments, a compound disclosed herein selectivelybinds to an RNase domain and an ATP-binding pocket within atrans-autophosphorylation kinase domain region of IRE1α. In someembodiments, a compound disclosed herein selectively binds to an RNasedomain and an activation loop within a trans autophosphorylation kinasedomain region of IRE1α.

In some embodiments, a compound disclosed herein selectively binds toIRE1α at two sites located in an RNase domain, trans-autophosphorylationkinase domain region, ATP-binding pocket, activation loop, or anycombination thereof. In some embodiments, a compound disclosed hereinselectively binds to IRE1α at two or more sites. In some embodiments, acompound disclosed herein selectively binds to IRE1α at two or moresites located in an RNase domain, trans-autophosphorylation kinasedomain region, ATP-binding pocket, activation loop, or any combinationthereof. In some embodiments, a compound disclosed herein selectivelybinds to IRE1α at three sites located in an RNase domain,trans-autophosphorylation kinase domain region, ATP-binding pocket,activation loop, or any combination thereof.

In some embodiments, a compound disclosed herein selectively binds toIRE1α at a first site located in an RNase domain,trans-autophosphorylation kinase domain region, ATP-binding pocket, oractivation loop. In some embodiments, a first site comprises one or moreof any amino acid residue within amino acid residues 465-977 of SEQ IDNO: 1. In some embodiments, a compound disclosed herein selectivelybinds to IRE1α at a second site located in an RNase domain,trans-autophosphorylation kinase domain region, ATP-binding pocket, oractivation loop. In some examples, the first site is located within thesame domain or region as the second site. In some examples, the firstsite is located within a different domain or region as the second site.

In some embodiments, a compound disclosed herein selectively binds tofirst IRE1α, thereby blocking dimerization of the first IRE1α to asecond IRE1α. In some embodiments, a compound disclosed hereinselectively binds to first IRE1α, thereby blockingauto-transphosphorylation of the first IRE1α or a second IRE1α to whichthe first IRE1α is dimerized.

In some embodiments, a compound disclosed herein selectively binds to afirst IRE1α, thereby blocking activation of the first IRE1α or a secondIRE1α to which the first IRE1α is dimerized.

In some embodiments, a compound disclosed herein selectively binds to afirst IRE1α, thereby blocking kinase activity of the first IRE1α or asecond IRE1α to which the first IRE1α is dimerized. In some embodiments,a compound disclosed herein selectively binds to a first IRE1α, therebyblocking RNase activity of the first IRE1α or a second IRE1α to whichthe first IRE1α is dimerized.

In some embodiments, a compound disclosed herein selectively binds toIRE1α when in a homo-dimerized conformation. In some embodiments, acompound disclosed herein selectively binds to IRE1α when in anoligomerized conformation. In some embodiments, a compound disclosedherein selectively binds to IRE1α when in a non-oligomerized ornon-dimerized conformation. In some embodiments, a compound disclosedherein selectively binds to IRE1α when in an ATP-bound state. In someembodiments, a compound disclosed herein selectively binds to a IRE1family protein when in a non-ATP-bound state. In some embodiments, thecompound is a pharmaceutically acceptable salt, or solvate thereof.

IRE1 Signaling Pathway

In some embodiments, a compound disclosed herein selectively binds to anIRE1 family protein and alters a downstream signaling pathway. In someembodiments, a compound disclosed herein selectively binds to an IRE1family protein and alters signaling of immunoglobulin heavy-chainbinding protein (BIP), protein kinase R (PKR)-like endoplasmic reticulumkinase (PERK), glucose regulate protein 78 (Grp78), eukaryotictranslation initiation factor 2α (eIF2α), X-box binding protein 1(XBP1), activating transcription factor 6α (ATF6α), C/EBP homologousprotein (CHOP), growth arrest and DNA damage-inducible protein 34(GADD34), tumor necrosis factor receptor-associated factor 2 (TRAF2),JUN N-terminal kinase (JNK), regulated IRE1-dependent decay (RIDD),transcriptionally active XBP1 (XBP1s), or unspliced XBP1 (XBP1u). Insome embodiments, a compound disclosed herein selectively binds to anIRE1 family protein and alters a downstream cellular process. In someembodiments, an IRE1 family protein is IRE1, IRE1α, or ERN1.

In some embodiments, a compound disclosed herein selectively binds to anIRE1 family protein and decreases or blocks a downstream signalingpathway. In some embodiments, a compound disclosed herein selectivelybinds to an IRE1 family protein and decreases or blocks activity orsignaling of TXNIP, Caspase 1, Interleukin 1-beta, JNK, Bim, cytochromeC, Caspase 3, Caspase 8, mRNA degradation, miRNA degradation,apoptotosis-inducing proteins, or inflammation-inducing proteins. Insome embodiments, a compound disclosed herein selectively binds to anIRE1 family protein and decreases XBP1 mRNA levels. In some embodiments,a compound disclosed herein selectively binds to an IRE1 family proteinand decreases transcriptionally active XBP1 (XBP1s) mRNA levels. In someembodiments, a compound disclosed herein selectively binds to an IRE1family protein and decreases spliced XBP1 mRNA levels. In someembodiments, an IRE1 family protein is IRE1, IRE1α, or ERN1.

In some embodiments, a compound disclosed herein selectively binds to anIRE1 family protein and increases, activates, or removes a block of adownstream signaling pathway. In some embodiments, a compound disclosedherein selectively binds to an IRE1 family protein and increases,activates, or removes a block of activity or signaling of Bcl2, Bcl-XL,Mcl-1, Bax, Bak, other anti-apoptotic proteins, or an mRNA transloconproteins. In some embodiments, an IRE1 family protein is IRE1, IRE1α, orERN1.

In some embodiments, a compound disclosed herein selectively binds to anIRE1family protein and disrupts binding with an effector protein. Insome cases, the effector protein binds to the IRE1 family protein whenin a dimerized or oligomerized state. In some cases, the effectorprotein binds to the IRE1 family protein when in a non-dimerized ornon-oligomerized state. In some cases, the effector protein isimmunoglobulin heavy-chain binding protein (BIP), protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK), glucose regulate protein78 (Grp78), tumor necrosis factor receptor-associated factor 2 (TRAF2),JUN N-terminal kinase (JNK), transcriptionally active XBP1 (XBP1s),unspliced XBP1 (XBP1u), regulated IRE1-dependent decay (RIDD), Heatshock protein 90 kDa alpha (HSP 90-alpha), or misfolded protein. In someembodiments, an IRE1 family protein is IRE1, IRE1α, or ERN1.

In some embodiments, a compound disclosed herein selectively binds to anIRE1 family protein and alters activity of a cellular process orcellular function, such as regulated IRE1-dependent decay (RIDD), RNAdecay, translation, autophagy, cell survival, ER protein folding, ERAD,reactive oxygen species generation, transport, ER-associated proteindegradation (ERAD), protein synthesis, or apoptosis. In someembodiments, where an altered or lack of a cellular process or cellularfunction is associate with a disease state, selective binding of acompound disclosed herein results in inhibiting or alleviating thedisease state, or inhibiting a deleterious activity associated with thedisease state. In some embodiments, an IRE1 family protein is IRE1,IRE1α, or ERN1.

Diseases Associated with Altered IRE1 Pathway Signaling

In some cases, a compound disclosed herein is used to treat orameliorate a disease associated with altered IRE1α pathway signalingwhen administered to a subject in need thereof. In some cases, acompound disclosed herein is used to treat or ameliorate the effects ofa disease associated with altered IRE1α pathway signaling whenadministered to a subject in need thereof. Exemplary disease associatedwith altered IRE1α signaling include cancer. In some cases, a compounddisclosed herein is used to treat or ameliorate a cancer whenadministered to a subject in need thereof. Exemplary cancers includetumors, solid and hematologic cancers. In some cases, a compounddisclosed herein is used to treat or ameliorate a cell proliferativedisorder when administered to a subject in need thereof. In some cases,the cell proliferative disorder is a cancer. In some cases, the canceris ovarian cancer, breast cancer, triple negative breast cancer (TNBC).

An IRE1α pathway can be involved in a variety of pathologicalconditions, including neurodegenerative diseases, inflammation,metabolic disorders, liver dysfunction, brain ischemia, heart ischemia,autoimmune diseases, and cancer. In some cases, modulation of thispathway provides therapeutic methods useful for treatment of suchdiseases.

In some instances, a compound disclosed herein is used to reinforceanti-tumor mechanisms. In some cases, an anti-tumor mechanism comprisesdirect inhibition of tumor growth. In some cases, an anti-tumormechanism comprises induction of anti-tumor immunity. In some cases,anti-tumor mechanisms comprise direct inhibition of tumor growth andsimultaneous induction of anti-tumor immunity. In some cases, a compounddisclosed herein can prevent lipid accumulation in myeloid cells exposedto ovarian cancer-derived ascites supernatants. In some cases, acompound disclosed herein can block myeloid cell immunosuppressionmediated by tumor-associated factors. In some cases, a compounddisclosed herein can be employed as therapeutic compound that enhancesdendritic cell and T cell anti-tumor activity in mammals. For example,the compounds disclosed herein can be used to treat murine and humanovarian cancers.

Methods of Dosing and Treatment Regimens

In one embodiment, the compounds described herein, or a pharmaceuticallyacceptable salt thereof, are used in the preparation of medicaments forthe treatment of diseases or conditions in a mammal that would benefitfrom administration of any one of the compounds disclosed. Methods fortreating any of the diseases or conditions described herein in a mammalin need of such treatment, involves administration of pharmaceuticalcompositions that include at least one compound described herein or apharmaceutically acceptable salt, active metabolite, prodrug, orpharmaceutically acceptable solvate thereof, in therapeuticallyeffective amounts to said mammal.

In certain embodiments, the compositions containing the compound(s)described herein are administered for prophylactic and/or therapeutictreatments. In certain therapeutic applications, the compositions areadministered to a patient already suffering from a disease or condition,in an amount sufficient to cure or at least partially arrest at leastone of the symptoms of the disease or condition. Amounts effective forthis use depend on the severity and course of the disease or condition,previous therapy, the patient's health status, weight, and response tothe drugs, and the judgment of the treating physician. Therapeuticallyeffective amounts are optionally determined by methods including, butnot limited to, a dose escalation and/or dose ranging clinical trial.

In prophylactic applications, compositions containing the compoundsdescribed herein are administered to a patient susceptible to orotherwise at risk of a particular disease, disorder or condition. Suchan amount is defined to be a “prophylactically effective amount ordose.” In this use, the precise amounts also depend on the patient'sstate of health, weight, and the like. When used in patients, effectiveamounts for this use will depend on the severity and course of thedisease, disorder or condition, previous therapy, the patient's healthstatus and response to the drugs, and the judgment of the treatingphysician. In one aspect, prophylactic treatments include administeringto a mammal, who previously experienced at least one symptom of thedisease being treated and is currently in remission, a pharmaceuticalcomposition comprising a compound described herein, or apharmaceutically acceptable salt thereof, in order to prevent a returnof the symptoms of the disease or condition.

In certain embodiments wherein the patient's condition does not improve,upon the doctor's discretion the administration of the compounds areadministered chronically, that is, for an extended period of time,including throughout the duration of the patient's life in order toameliorate or otherwise control or limit the symptoms of the patient'sdisease or condition.

In certain embodiments wherein a patient's status does improve, the doseof drug being administered is temporarily reduced or temporarilysuspended for a certain length of time (e.g., a “drug holiday”). Inspecific embodiments, the length of the drug holiday is between 2 daysand 1 year, including by way of example only, 2 days, 3 days, 4 days, 5days, 6 days, 7 days, 10 days, 12 days, 15 days, 20 days, 28 days, ormore than 28 days. The dose reduction during a drug holiday is, by wayof example only, by 10%-100%, including by way of example only 10%, 15%,20%, 25%), 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%,90%, 95%, and 100%.

Once improvement of the patient's conditions has occurred, a maintenancedose is administered if necessary. Subsequently, in specificembodiments, the dosage or the frequency of administration, or both, isreduced, as a function of the symptoms, to a level at which the improveddisease, disorder or condition is retained. In certain embodiments,however, the patient requires intermittent treatment on a long-termbasis upon any recurrence of symptoms.

The amount of a given agent that corresponds to such an amount variesdepending upon factors such as the particular compound, diseasecondition and its severity, the identity (e.g., weight, sex) of thesubject or host in need of treatment, but nevertheless is determinedaccording to the particular circumstances surrounding the case,including, e.g., the specific agent being administered, the route ofadministration, the condition being treated, and the subject or hostbeing treated.

In general, however, doses employed for adult human treatment aretypically in the range of 0.01 mg to 5000 mg per day. In one aspect,doses employed for adult human treatment are from about 1 mg to about1000 mg per day. In one embodiment, the desired dose is convenientlypresented in a single dose or in divided doses administeredsimultaneously or at appropriate intervals, for example as two, three,four or more sub-doses per day.

In one embodiment, the daily dosages appropriate for the compounddescribed herein, or a pharmaceutically acceptable salt thereof, arefrom about 0.01 to about 50 mg/kg per body weight. In some embodiments,the daily dosage or the amount of active in the dosage form are lower orhigher than the ranges indicated herein, based on a number of variablesin regard to an individual treatment regime. In various embodiments, thedaily and unit dosages are altered depending on a number of variablesincluding, but not limited to, the activity of the compound used, thedisease or condition to be treated, the mode of administration, therequirements of the individual subject, the severity of the disease orcondition being treated, and the judgment of the practitioner.

Toxicity and therapeutic efficacy of such therapeutic regimens aredetermined by standard pharmaceutical procedures in cell cultures orexperimental animals, including, but not limited to, the determinationof the LD50 and the ED50. The dose ratio between the toxic andtherapeutic effects is the therapeutic index and it is expressed as theratio between LD50 and ED50. In certain embodiments, the data obtainedfrom cell culture assays and animal studies are used in formulating thetherapeutically effective daily dosage range and/or the therapeuticallyeffective unit dosage amount for use in mammals, including humans. Insome embodiments, the daily dosage amount of the compounds describedherein lies within a range of circulating concentrations that includethe ED50 with minimal toxicity. In certain embodiments, the daily dosagerange and/or the unit dosage amount varies within this range dependingupon the dosage form employed and the route of administration utilized.

In any of the aforementioned aspects are further embodiments in whichthe effective amount of the compound described herein, or apharmaceutically acceptable salt thereof, is: (a) systemicallyadministered to the mammal; and/or (b) administered orally to themammal; and/or (c) intravenously administered to the mammal; and/or (d)administered by injection to the mammal; and/or (e) administeredtopically to the mammal; and/or (f) administered non-systemically orlocally to the mammal.

In any of the aforementioned aspects are further embodiments comprisingsingle administrations of the effective amount of the compound,including further embodiments in which (i) the compound is administeredonce a day; or (ii) the compound is administered to the mammal multipletimes over the span of one day, e.g., two, three, four or more timesdaily.

In any of the aforementioned aspects are further embodiments comprisingmultiple administrations of the effective amount of the compound,including further embodiments in which (i) the compound is administeredcontinuously or intermittently: as in a single dose; (ii) the timebetween multiple administrations is every 6 hours; (iii) the compound isadministered to the mammal every 8 hours; (iv) the compound isadministered to the mammal every 12 hours; (v) the compound isadministered to the mammal every 24 hours. In further or alternativeembodiments, the method comprises a drug holiday, wherein theadministration of the compound is temporarily suspended or the dose ofthe compound being administered is temporarily reduced; at the end ofthe drug holiday, dosing of the compound is resumed. In one embodiment,the length of the drug holiday varies from 2 days to 1 year.

In certain instances, it is appropriate to administer at least onecompound described herein, or a pharmaceutically acceptable saltthereof, in combination with one or more other therapeutic agents. Inone embodiment, the therapeutic effectiveness of one of the compoundsdescribed herein is enhanced by administration of an adjuvant {i.e., byitself the adjuvant has minimal therapeutic benefit, but in combinationwith another therapeutic agent, the overall therapeutic benefit to thepatient is enhanced). Or, in some embodiments, the benefit experiencedby a patient is increased by administering one of the compoundsdescribed herein with another agent (which also includes a therapeuticregimen) that also has therapeutic benefit.

It is understood that the dosage regimen to treat, prevent, orameliorate the condition(s) for which relief is sought, is modified inaccordance with a variety of factors (e.g. the disease, disorder orcondition from which the subject suffers; the age, weight, sex, diet,and medical condition of the subject). Thus, in some instances, thedosage regimen actually employed varies and, in some embodiments,deviates from the dosage regimens set forth herein.

For combination therapies described herein, dosages of theco-administered compounds vary depending on the type of co-drugemployed, on the specific drug employed, on the disease or conditionbeing treated and so forth. In additional embodiments, whenco-administered with one or more other therapeutic agents, the compoundprovided herein is administered either simultaneously with the one ormore other therapeutic agents, or sequentially.

In combination therapies, the multiple therapeutic agents (one of whichis one of the compounds described herein) are administered in any orderor even simultaneously. If administration is simultaneous, the multipletherapeutic agents are, by way of example only, provided in a single,unified form, or in multiple forms (e.g., as a single pill or as twoseparate pills).

The compounds described herein, or a pharmaceutically acceptable saltthereof, as well as combination therapies, are administered before,during or after the occurrence of a disease or condition, and the timingof administering the composition containing a compound varies. Thus, inone embodiment, the compounds described herein are used as aprophylactic and are administered continuously to subjects with apropensity to develop conditions or diseases in order to prevent theoccurrence of the disease or condition. In another embodiment, thecompounds and compositions are administered to a subject during or assoon as possible after the onset of the symptoms. In specificembodiments, a compound described herein is administered as soon as ispracticable after the onset of a disease or condition is detected orsuspected, and for a length of time necessary for the treatment of thedisease. In some embodiments, the length required for treatment varies,and the treatment length is adjusted to suit the specific needs of eachsubject. For example, in specific embodiments, a compound describedherein or a formulation containing the compound is administered for atleast 2 weeks, about 1 month to about 5 years.

EXAMPLES Example A1: Synthesis of tert-butyl((1r,4r)-4-((6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazolin-2-yl)amino)cyclohexyl)carbamate(1A)

Step 1: 6-bromoquinazolin-2-amine (1A-2)

To a solution of 5-bromo-2-fluoro-benzaldehyde (20.0 g, 98.5 mmol) inDMA (700 mL) was added guanidine-carbonic acid (26.6 g, 147.7 mmol). Themixture was stirred at 160° C. for 0.5 h, cooled to rt and concentrated.The residue was diluted with H₂O (300 mL) and extracted with ethylacetate (200 mL×3). The combined organic layers were washed with brine(100 mL×3), dried over Na₂SO₄, filtered and concentrated under reducedpressure to give a residue. The residue was washed with DCM (300 mL) toget compound 1A-2 (4.0 g).

Step 2: 6-bromo-2-iodoquinazoline (1A-3)

To a solution of compound 1A-2 (2.0 g, 8.9 mmol) in THF (20.0 mL) underN₂ were added of isoamylnitrite (3.1 g, 26.8 mmol, 3.6 mL),diiodomethane (11.9 g, 44.7 mmol, 3.6 mL) and CuI (1.7 g, 8.9 mmol). Themixture was stirred at 80° C. for 2 h, cooled to rt, quenched byaddition of ice water (100 mL), and extracted with ethyl acetate (100mL×3). The combined organic layers were washed with brine (100 mL×3),dried over anhydrous Na₂SO₄, filtered and concentrated. The residue waspurified by column chromatography (SiO₂) to afford compound 1A-3 (2.1g).

Step 3: 1-tert-butyl((1r,4r)-4-((6-bromoquinazolin-2-yl)amino)cyclohexyl)carbamate (lA-4)

To a solution of compound 1A-3 (4.0 g, 11.9 mmol) in IPA (120.0 mL) wasadded DIEA (4.6 g, 35.8 mmol, 6.2 mL) and tert-butyl((1r,4r)-4-aminocyclohexyl)carbamate (7.6 g, 35.8 mmol). The mixture wasstirred at 80° C. for 12 h, cooled to rt and filtered. The collectedsolid was washed with Dichloromethane/Methanol (10/1, 60 mL). Thecombined filtrate was concentrated to give a residue which was purifiedby column chromatography (SiO₂) to afford compound 1A-4 (3.6 g, 6.8mmol, 57.2% yield). M+H+=421.1 (LCMS); ¹H NMR (CHLOROFORM-d, 400 MHz) δ8.87 (s, 1H), 7.78 (d, J=1.8 Hz, 1H), 7.71 (dd, J=2.0, 9.0 Hz, 1H), 7.44(d, J=9.2 Hz, 1H), 5.19 (br d, J=7.9 Hz, 1H), 4.43 (br s, 1H), 3.93 (brd, J=7.5 Hz, 1H), 3.49 (br s, 1H), 2.27-2.00 (m, 4H), 1.46 (s, 9H),1.40-1.29 (m, 4H).

Step 4: tert-butyl((1r,4r)-4-((6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazolin-2-yl)amino)cyclohexyl)carbamate(1A)

A mixture of compound 1A-4 (2.0 g, 4.7 mmol),4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane(1.3 g, 5.2 mmol), AcOK (1.4 g, 14.2 mmol) and Pd(dppf)Cl₂ (347 mg,474.6 umol) in dioxane (50 mL) was degassed and purged with N₂ for 3times, and heated at 90° C. for 12 h under N₂. The reaction was cooledto rt and concentrated to give a residue. The residue was purified bycolumn chromatography (SiO₂) to afford compound 1A (2.7 g, crude).M+H⁺=469.2 (LCMS).

Example A2: Synthesis of tert-butyl4-((6-(3-amino-1-methyl-1H-pyrazol-5-yl)quinazolin-2-yl)(tert-butoxycarbonyl)amino)piperidine-1-carboxylate(2A)

Step 1: tert-butyl4-((6-bromoquinazolin-2-yl)amino)piperidine-1-carboxylate (2-1)

To a solution of compound 1A-3 (200 mg, 597.1 umol) in isopropanol (3.0mL) was added tert-butyl 4-aminopiperidine-1-carboxylate (598 mg, 3.0mmol) and DIEA (232 mg, 1.8 mmol, 312.9 uL). The mixture was stirred at80° C. for 2 h, cooled to rt and concentrated. The residue was purifiedby prep-TLC (SiO₂) to afford compound 2A-1 (131 mg).

Step 2: tert-butyl4-((6-bromoquinazolin-2-yl)(tert-butoxycarbonyl)amino)piperidine-1-carboxylate(2A-2)

To a mixture of compound 2A-1 (200 mg, 916.3 umol) and triethylamine(278 mg, 2.7 mmol, 381.0 uL) in dichloromethane (4 mL) were addedtert-butoxycarbonyl tert-butyl carbonate (600 mg, 2.8 mmol) and DMAP(111 mg, 916.3 umol). The mixture was stirred at 25° C. for 12 h,concentrated to get crude residue to which dioxane (2 mL) was added. Themixture was stirred at 90° C. for 12 h, cooled to rt and concentrated.The residue was purified by column chromatography (SiO₂) to afford 2A-2(400 mg).

Step 3: tert-butyl4-((tert-butoxycarbonyl)(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazolin-2-yl)amino)piperidine-1-carboxylate(2A-3)

To a solution of compound 2A-2 (400 mg, 394.1 umol) and KOAc (58 mg,591.2 umol) in dioxane (10 mL) were added4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane(120 mg, 472.9 umol) and Pd(dppf)Cl₂ (28 mg, 39.4 umol). The mixture wasstirred at 90° C. for 12 h under N₂, cooled to rt and concentrated togive a crude residue, which was purified by prep-TLC (SiO₂) to affordcompound 2A-3 (150 mg).

Step 4: tert-butyl4-((6-(3-amino-1-methyl-1H-pyrazol-5-yl)quinazolin-2-yl)(tert-butoxycarbonyl)amino)piperidine-1-carboxylate (2A)

To a solution of compound 2A-3 (150 mg, 270.5 umol) and K₂CO₃ (112 mg,811.5 umol) in dioxane (4 mL) and H₂O (400 uL) were added5-Bromo-1-methyl-1H-pyrazol-3-amine (47 mg, 270.5 umol) and Pd(dppf)Cl₂(19 mg, 27.0 umol). The mixture was stirred at 90° C. for 12 h under N₂.The mixture was cooled to rt and concentrated to give a residue, whichwas purified by prep-TLC (SiO₂) to afford compound 2A (100 mg).

Example A3: Synthesis of1-(5-bromo-1-methyl-1H-pyrazol-3-yl)-3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea(3A)

Step 1: 1-(bromomethyl)-4-nitro-2-(trifluoromethyl)benzene (3A-2)

To a solution of 1-methyl-4-nitro-2-(trifluoromethyl)benzene (8.0 g,39.0 mmol) in DCE (240 mL) was added AIBN (640 mg, 3.9 mmol) and NBS(6.9 g, 39.0 mmol). The mixture was stirred at 80° C. for 12 h, cooledto rt and concentrated. The residue was purified by columnchromatography (SiO₂) to afford compound 3A-2 (11.0 g).

Step 2: 1-methyl-4-(4-nitro-2-(trifluoromethyl)benzyl)piperazine (3A-3)

To a solution of compound 3A-2 (11.0 g, 38.7 mmol) in DCM (120 mL) wasadded 1-methylpiperazine (7.7 g, 77.4 mmol, 8.6 mL) and K₂CO₃ (5.3 g,38.7 mmol). The mixture was stirred at 25° C. for 1 h, washed with water(80 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated togive a residue. The residue was purified by column chromatography (SiO₂)to give compound 3A-3 (3.5 g).

Step 3: 4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)aniline(3A-4)

To a solution of compound 3A-3 (3.5 g, 11.5 mmol) in EtOH (40 mL) wasadded Pd/C (350 mg, 10%). The mixture was stirred under H₂ (1 atm) for 1h, filtered and concentrated to give compound 3A-4 (3.2 g), which wasused into the next step without further purification.

Step 4:1-(5-bromo-1-methyl-1H-pyrazol-3-yl)-3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea(3A)

To a solution of compound 3A-4 (400 mg, 1.4 mmol) in DCM (12 mL) wasadded DIEA (283 mg, 2.1 mmol, 382.4 uL) and triphosgene (143 mg, 481.8umol) at −20° C. The mixture was stirred at −20° C. for 0.5 h. Asolution of 5-Bromo-1-methyl-1H-pyrazol-3-amine (257 mg, 1.4 mmol) inDCM (4.0 mL) was added and the resulting mixture was stirred at 25° C.for 12 h. The reaction was quenched with MeOH (3.0 mL) and concentrated.The residue was purified by prep-TLC (SiO₂) to give compound 3A (500 mg,799.3 umol, 54.7% yield). M+H⁺=475.1 (LCMS)

Example A4: Synthesis of1-(1-methyl-5-(2-(piperidin-4-ylamino)quinazolin-6-yl)-1H-pyrazol-3-yl)-3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea(2)

Step 1: tert-butyl4-((6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazolin-2-yl)amino)piperidine-1-carboxylate (2-2)

A mixture of compound 2A-1 (131 mg, 321.6 umol), KOAc (95 mg, 964.9umol),4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane(98 mg, 386.0 umol), Pd(dppf)Cl₂ (24 mg, 32.2 umol) in dioxane (4.0 mL)was degassed and purged with N₂ for 3 times, and then the mixture wasstirred at 90° C. for 12 h under N₂. The reaction mixture wasconcentrated and the residue was purified by prep-TLC (SiO₂) to affordcompound 2-2 (100 mg).

Step 2: tert-butyl4-((6-(1-methyl-3-(3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)ureido)-1H-pyrazol-5-yl)quinazolin-2-yl)amino)piperidine-1-carboxylate(2-3)

To a solution of compound 2-2 (50 mg, 110.0 umol) in dioxane (1.8 mL)and H₂O (180 uL) was added K₂CO₃ (46 mg, 330.1 umol), compound 3A (52mg, 110.0 umol) and Pd(dppf)Cl₂ (8 mg, 11.0 umol). The mixture wasdegassed and purged with N₂ for 3 times and then stirred at 90° C. for12 h under N₂. The reaction mixture was concentrated and the residue waspurified by prep-TLC (SiO₂) to afford compound 2-3 (34 mg).

Step 3:1-(1-methyl-5-(2-(piperidin-4-ylamino)quinazolin-6-yl)-1H-pyrazol-3-yl)-3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea(2)

To a solution of compound 2-3 (34 mg, 69.2 umol) in DCM (2.0 mL) wasadded trifluoroacetic acid (1.0 mL). The mixture was stirred at 25° C.for 0.5 h. The reaction mixture was concentrated under reduced pressure.The residue was purified by prep-HPLC to give 2 (4.6 mg, 5.7 umol, 8.2%yield, TFA). M+H⁺=623.4 (LCMS); ¹H NMR (METHANOL-d₄, 400 MHz): δ 9.27(br s, 1H), 8.03 (br s, 1H), 7.93 (br s, 2H), 7.79-7.68 (m, 1H), 7.66(br s, 3H), 7.37 (br d, J=8.6 Hz, 1H), 6.48-6.32 (m, 1H), 5.87 (s, 1H),3.82 (br d, J=19.0 Hz, 3H), 3.72 (s, 2H), 3.58-3.34 (m, 4H), 3.25-3.08(m, 4H), 3.00 (br s, 1H), 2.88 (s, 3H), 2.47 (br s, 1H), 2.32 (br d,J=15.4 Hz, 2H), 1.89 (br d, J=11.9 Hz, 2H), 1.38-1.19 (m, 2H).

The following compounds were synthesized according to proceduresdescribed in example A⁴ above for the preparation of compound 2.

Comp Chemical Mass ¹H NMR ID Structure Name (M + H⁺) (MeOD, 400 MHz)  1

1-(1-methyl- 5-(2-(piperidin- 3-ylamino) quinazolin-6- yl)-1H-pyrazol-3-yl)-3-(4-((4- methylpiperazin- 1-yl)methyl)-3- (trifluoromethyl)Calc’d for C₃₁H₃₈F₃N₁₀O: 623.3; Found: 623.4 ¹H NMR (DMSO-d₆, 400 MHz) δ9.49 (s, 1H), 9.33-9.18 (m, 2H), 8.80 (br s, 2H), 8.03 (s, 2H), 7.87 (brd, J = 9.2 Hz, 1H), 7.76 (br s, 1H), 7.63-7.51 (m, 3H), 6.54 (s, 1H),3.79 (s, phenyl)urea, 3H), 3.64 (s, 2H), trifluoroacetate 3.40 (br d, J= 19.7 salt Hz, 3H), 3.25-3.12 (m, 2H), 3.09-2.72 (m, 9H), 2.45-2.26 (m,2H), 2.06-1.86 (m, 2H), 179-1.55 (m, 2H)  3

1-(5-(2-(((1r,4r)-4- aminocyclohexyl) amino)quinazolin-6-yl)-1-methyl-1H- pyrazol-3-yl)-3-(4- ((4- methylpiperazin-1-yl)methyl)-3- Calc’d for C₃₂H₄₀F₃N₁₀O: 637.3; Found: 637.4 ¹H NMR(DMSO-d₆, 400 MHz) δ 9.44 (br s, 1 H), 9.27 (s, 1 H), 9.19 (br s, 1 H),8.01 (s, 1 H), 7.88 (br s, 3 H), 7.53-7.61 (m, 3 H), 6.52 (s, 1 H), 3.78(s, 3 H), 3.62 (br s, (trifluoromethyl) 2H), 3.32-3.44 (m, 2phenyl)urea, H), 2.82-3.04 (m, 4 trifluoroacetate salt H), 2.77 (s, 3H), 2.26-2.45 (m, 4 H), 1.92-2.08 (m, 4 H), 1.31-1.52 (m, 4 H)  5

1-(5-(2- (cyclohexylamino) quinazolin-6-yl)-1- methyl-1H-pyrazol-3-yl)-3-(4-((4- methylpiperazin- 1-yl)methyl)-3- (trifluoromethyl)phenyl)urea Calc’d for C₃₂H₃₉F₃N₉O: 622.3; Found: 622.4 δ 9.32 (br s,1H), 9.13 (s, 2H), 7.98 (dd, J = 2.0, 19.6 Hz, 2H), 7.80 (dd, J = 2.0,8.8 Hz, 1H), 7.65-7.38 (m, 4H), 6.50 (s, 1H), 3.94-3.82 (m, 4H),3.57-3.48 (m, 2H), 2.43-2.29 (m, 7H), 2.19 (s, 3H), 1.94 (br s, 2H),1.79-1.70 (m, 2H), 1.61 (br d, J = 12.6 Hz, 1H), 1.45-1.07 (m, 6H) 15

(R)-1-(1-methyl- 5-(2-(piperidin-3- ylamino) quinazolin-6-yl)-1H-pyrazol-3-yl)- 3-(4-((4- methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl) Calc’d for C₃₁H₃₈F₃N₁₀O: 623.3; Found: 623.4 δ 9.13(s, 1H), 8.54 (br s, 1H), 7.98-7.87 (m, 2H), 7.82 (dd, J = 2.0, 8.8 Hz,1H), 7.69-7.57 (m, 3H), 6.41 (s, 1H),4.41- 4.29 (m, 1H), 3.83 (s, 3H),3.73-3.56 (m, 3H), 3.39-3.25 phenyl)urea, (m, 1H), 3.13 (br s, formatesalt 4H), 3.06-2.94 (m, 2H), 2.94-2.68 (m, 7H), 2.22-2.01 (m, 2H),1.98-1.64 (m, 2H) 17

(S)-1-(1-methyl- 5-(2-(piperidin-3- ylamino) quinazolin-6-yl)-1H-pyrazol-3-yl)- 3-(4-((4- methylpiperazin-1- yl)methyl)-3-(trifluoromethyl) Calc’d for C₃₁H₃₈F₃N₁₀O: 623.3; Found: 623.4 δ 9.17(s, 1 H), 7.95 (s, 2 H), 7 81-7.93 (m, 1 H), 7.61-7.71 (m, 3 H), 6.43(s, 1 H), 4.34-4.43 (m, 1 H), 3.85 (s, 3 H), 3.58-3.81 (m, 3 H), 3.37(br s, 1 H), 3.15- 3.24 (m, 4 H), 2.98- phenyl)urea, 3.10 (m, 2 H),2.56- formate salt 2.85 (m, 7H), 2.06-2.23 (m, 2 H), 1.73-1.98 (m, 2 H)26

1-(5-(2-(((1r,4r)-4- hydroxycyclohexyl) amino)quinazolin-6-yl)-1-methyl-1H- pyrazol-3-yl)-3-(4- ((4- methylpiperazin-1- Calc’dfor C₃₂H₃₉F₃N₉O₂: 638.3; Found: 638.4 δ 9.07 (br s, 1H), 8.43 (br s,1H), 7.90 (br d, J = 16.8 Hz, 2H), 7.80 (br, d, J = 8.8 Hz, 1H),7.70-7.58 (m, 3H) 6.38 (br s, 1H), 3.83 (s, 3H), 3.69 (s, yl)methyl)-3-2H), 3.59 (br d, J = (trifluoromethyl) 3.5 Hz, 1H), 3.14 (brphenyl)urea, s, 4H), 2.76 (s, 6H), formate salt 2.16-1.95 (m, 4H),1.52-1.33 (m, 4H) 29

1-(5-(2-(((1s,4s)-4- aminocyclohexyl) amino)quinazolin-6-yl)-1-methyl-1H- pyrazol-3-yl)-3- (4-((4- methylpiperazin-1-yl)methyl)-3- (trifluoromethyl) phenyl)urea, Calc’d for C₃₂H₄₀F₃N₁₀O:637.3; Found: 637.4 δ 9.13 (s, 1 H), 8.38- 8.50 (m, 2 H), 7.93 (br d, J= 6.62 Hz, 2 H), 7.83 (br d, J = 8.60 Hz, 1 H), 7.61- 7.69 (m, 3 H),6.41 (s, 1 H), 4.20 (br s, 1 H), 3.84 (s, 3 H), 3.69 (s, 2 H), 3.24-3.28 (m, 1 H), 3.16 formate salt (br s, 4 H), 2.55- 2.80 (m, 7 H), 2.00-2.10 (m, 2 H), 1.73- 1.95 (m, 6 H) 33

1-(5-(2-(((1R,3R)-3- aminocyclohexyl) amino)quinazolin-6-yl)-1-methyl-1H- pyrazol-3-yl)-3-(4- ((4- methylpiperazin-1-yl)methyl)-3- Calc’d for C₃₂H₄₀F₃N₁₀O: 637.3; Found: 637.0 δ 9.11 (s,1H), 8.49 (br s, 2H), 7.92 (br d, J = 12.8 Hz, 2H), 7.81 (br d, J = 8.6Hz, 1H), 7.71-7.49 (m, 3H), 6.41 (br s, 1H), 4.44 (br s, 1H), 3.83 (s,3H), 3.67 (br s, 2H), (trifluoromethyl) 3.49 (br s, 1H), 3.11phenyl)urea, (br s, 3H), 2.81-2.52 formate salt (m, 7H), 2.33 (br d, J =12.3 Hz, 1H), 2.00 (br d, J = 11.0 Hz,1H), 1.81 (br s, 5H), 1.56 (br s,1H) 34

1-(5-(2-(((1S,3R)-3- aminocyclohexyl) amino)quinazolin-6-yl)-1-methyl-1H- pyrazol-3-yl)-3- (4-((4- methylpiperazin-1-yl)methyl)-3- Calc’d for C₃₂H₄₀F₃N₁₀O: 637.3; Found: 637.3 δ 9.09 (s,1H), 8.58 (br s, 1H), 7.97-7.84 (m, 2H), 7.80 (br d, J = 9.0 Hz, 1H),7.69- 7.55 (m, 3H), 6.40 (br s, 1H), 4.06 (br t, J = 11.2 Hz, 1H), 3.83(s, 3H), 3.68 (trifluoromethyl) (br s, 2H), 3.28-3.03 phenyl)urea, (m,5H), 2.86-2.56 formate salt (m, 7H), 2.50 (br d, J = 10.6 Hz, 1H),2.14-1.90 (m, 3H), 1.55 (q, J = 13.0 Hz, 1H), 1.46-1.26 (m, 3H) 36

(R)-1-(1-methyl-5- (2-(pyrrolidin-3- ylamino)quinazolin-6-yl)-1H-pyrazol- 3-yl)-3-(4-((4- methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl) Calc’d for C₃₀H₃₆F₃N₁₀O: 609.3; Found: 609.0 δ 9.20(s, 1H), 8.53 (br s, 2H), 7.98 (dd, J = 1.8, 6.1 Hz, 2H), 7.89 (dd, J =2.0, 8.8 Hz, 1H), 7.75-7.65 (m, 3H), 6.46 (s, 1H), 4.79-4.71 (m, 1H),3.88 (s, 3H), 3.74- phenyl)urea, 3.56 (m, 4H), 3.53- formate salt 3.41(m, 2H), 3.22- 3.01 (m, 4H), 2.83- 2.58 (m, 7H), 2.53- 2.41 (m, 1H),2.30- 2.19 (m, 1H) 38

1-(5-(2-((3- aminopropyl) amino) quinazolin-6- yl)-1-methyl-1H-pyrazol-3-yl)-3- (4-((4- Calc’d for C₂₉H₃₆F₃N₁₀O: 597.3; Found: 597.2 δ9.15 (s, 1 H), 8.52 (br s, 2 H), 7.95 (s, 2 H), 7.86 (dd, J = 8.80, 1.96Hz, 1 H), 7.62- 7.72 (m, 3 H), 6.43 (s, 1 H), 3.85 (s, 3 H), 3.62-3.74(m, 4 H), methylpiperazin- 3.03-3.17 (m, 6 H), 1-yl)methyl)-3- 2.63-2.78(m, 7 H), (trifluoromethyl) 2.05 (m, J = 6.72 Hz, phenyl)urea, 2 H)formate salt 39

(S)-1-(1-methyl-5- (2-(pyrrolidin-3- ylamino)quinazolin-6-yl)-1H-pyrazol- 3-yl)-3-(4-((4- methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl) Calc’d for C₃₀H₃₆F₃N₁₀O: 609.3; Found: 609.2 δ 9.17(s, 1H), 7.96 (br d, J = 9.5 Hz, 2H), 7.86 (br d, J = 8.8 Hz, 1H),7.76-7.59 (m, 3H), 6.45 (br s, 1H), 4.74 (br s, 1H), 3.86 (s, 3H),3.76-3.67 (m, 2H), 3.64-3.53 (m, phenyl)urea, 2H), 3.52-3.45 (m, formatesalt 2H), 3.16 (br s, 4H), 2.78 (s, 3H), 2.71 (br s, 4H), 2.46 (qd, J =7.1, 13.9 Hz, 1H), 2.34-2.14 (m, 1H) 41

1-(5-(2-((4,4- difluorocyclohexyl) amino)quinazolin- 6-yl)-1-methyl-1H-pyrazol-3-yl)- 3-(4-((4- methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl) phenyl)urea, Calc’d for C₃₂H₃₇F₃N₉O: 658.3; Found:658.2 δ 9.10 (s, 1H), 7.91 (br d, J = 11.8 Hz, 2H), 7.82 (br d, J = 8.8Hz, 1H), 7.72- 7.57 (m, 3H), 6.40 (s, 1H), 4.12 (br s, 1H), 3.84 (s,3H), 3.67 (s, 2H), 2.92 (br s, 4H), 2.60 (s, 7H), 2.12 (br d, J = 9.2Hz, formate salt 4H), 2.03-1.87 (m, 2H), 1.81-1.61 (m, 2H) 50

1-(5-(2-((azetidin- 3-ylmethyl) amino)quinazolin- 6-yl)-1-methyl-1H-pyrazol-3-yl)- 3-(4-((4- methylpiperazin- Calc’d for C₃₀H₃₆F₃N₁₀O:609.3; Found: 609.3 δ 9.14 (s, 1H), 8.55 (br s, 1H), 7.94 (br d, J = 4.4Hz, 2H), 7.84 (br d, J= 9.2 Hz, 1H), 7.71-7.59 (m, 3H), 6.42 (br s, 1H),4.19- 4.01 (m, 3H), 3.92- 1-yl)methyl)-3- 3.62 (m, 7H), 3.33(trifluoromethyl) (br s, 2H), 3.13 (br s, phenyl)urea, 4H), 2.90-2.47(m, 7H) formate salt

Example A5: Synthesis of1-(5-(3-(cyclohexylamino)isoquinolin-7-yl)-1-methyl-1H-pyrazol-3-yl)-3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea(4)

Step 1: 7-bromoisoquinolin-3-yl trifluoromethanesulfonate (4-2)

A solution of compound 7-bromoisoquinolin-3(2H)-one (45.0 g, 200 mmol)in pyridine (500 mL) was cooled to 0° C. and Tf₂O (170.0 g, 602 mmol,99.4 mL) was added dropwise. The mixture was stirred at 25° C. for 2 h,concentrated, diluted with H₂O (200 mL) and extracted with ethyl acetate(300 mL×3). The combined organic layers were washed with brine (200mL×3), dried over Na₂SO₄, filtered and concentrated. The residue waspurified by column chromatography (SiO₂) to afford compound 4-2 (21.0 g,58.9 mmol, 29.3% yield). ¹H NMR (DMSO-d₆, 400 MHz): δ 9.25 (s, 1H), 8.57(s, 1H), 8.17 (s, 1H), 8.13-8.08 (m, 1H), 8.07-8.02 (m, 1H)

Step 2: 7-bromo-N-cyclohexylisoquinolin-3-amine (4-3)

To a solution of compound 4-2 (200 mg, 561 umol) in THF (10 mL) wereadded Cs₂CO₃ (548 mg, 1.6 mmol) and cyclohexanamine (835 mg, 8.4 mmol,960.2 uL). The mixture was stirred at 110° C. for 12 h. The mixture wasdiluted with H₂O (10 mL) and extracted with ethyl acetate (20 mL×3). Thecombined organic layers were washed with brine (10 mL×3), dried overNa₂SO₄, filtered and concentrated under reduced pressure to give aresidue. The residue was purified by column chromatography (SiO₂) toafford compound 4-3 (60 mg).

Step 2:N-cyclohexyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinolin-3-amine(4-4)

To a solution of compound 4-3 (60 mg, 196.5 umol) in dioxane (2 mL) wasadded4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane(59 mg, 235.9 umol), KOAc (28 mg, 294.8 umol), Pd(dppf)Cl₂ (14 mg, 19.6umol). The mixture was stirred at 90° C. for 12 h under N₂. The mixturewas concentrated. The residue was purified by prep-TLC (SiO₂) to affordcompound 4-4 (50 mg).

Step 3:1-(5-(3-(cyclohexylamino)isoquinolin-7-yl)-1-methyl-1H-pyrazol-3-yl)-3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea(4)

To a solution of compound 4-4 (50 mg, 141.9 umol) and K₂CO₃ (39 mg,283.8 umol) in dioxane (2 mL) and H₂O (200 uL) were added compound 3A(80 mg, 170.3 umol) and Pd(dppf)Cl₂ (10 mg, 14.1 umol). The mixture wasstirred at 90° C. for 12 h under N₂. The mixture was cooled to rt andconcentrated. The residue was purified by prep-TLC (SiO₂) followed byprep-HPLC to afford compound 4 (7.0 mg, 8.19 umol, 5.7% yield, TFA).M+H⁺=621.3 (LCMS); ¹H NMR (METHANOL-d₄, 400 MHz): δ 8.99 (s, 1H), 8.08(s, 1H), 7.93 (s, 1H), 7.85-7.79 (m, 2H), 7.66 (br d, J=4.2 Hz, 2H),7.32-7.26 (m, 1H), 6.50 (s, 1H), 3.86 (s, 3H), 3.73 (s, 2H), 3.66-3.57(m, 1H), 2.95-2.37 (m, 7H), 2.08 (br d, J=13.0 Hz, 2H), 1.93-1.64 (m,4H), 1.57-1.22 (m, 7H), 0.92 (dd, J=6.5, 13.3 Hz, 1H).

Example A6: Synthesis of5-((4-methylpiperazin-1-yl)methyl)-4-(trifluoromethyl)pyridin-2-amine(51-4)

Step 1: 6-amino-4-(trifluoromethyl)nicotinonitrile (51-2)

A mixture of 5-bromo-4-(trifluoromethyl)pyridin-2-amine (500 mg, 2.1mmol) and CuCN (556 mg, 6.2 mmol) in DMF (10.0 mL) was stirred at 170°C. for 4 h. The mixture was cooled to rt and concentrated. The residuewas purified by column chromatography (SiO₂) to afford compound 51-2(350 mg, 90%). ¹H NMR (CDCl₃, 400 MHz): δ 8.49 (s, 1H), 6.78 (s, 1H).

Step 2: 6-amino-4-(trifluoromethyl)nicotinaldehyde (51-3)

To a solution of compound 51-2 (240 mg, 1.2 mmol) in THF (10.0 mL) wasadded DIBAL-H (1 M, 5.9 mL) at 0° C. The mixture was warmed to 25° C.for 12 h, quenched with MeOH (191 mg, 5.9 mmol, 242.4 uL) at 25° C.,filtered and concentrated to give a residue. The residue was purified bycolumn chromatography (SiO₂) to afford compound 51-3 (100 mg, 41%). ¹HNMR (CDCl₃, 400 MHz): δ10.04 (d, J=1.7 Hz, 1H), 8.75 (s, 1H), 6.66 (s,1H).

Step 3:5-((4-methylpiperazin-1-yl)methyl)-4-(trifluoromethyl)pyridin-2-amine(51-4)

To a solution of compound 51-3 (110 mg, 289.2 umol) and1-methylpiperazine (34 mg, 347.1 umol, 38.6 uL) in MeOH (2.0 mL) wasadded AcOH (868 ug, 14.4 umol, 0.8 uL). After 2 h at 30° C., NaBH₃CN (90mg, 1.4 mmol) was added. The resulting mixture was stirred at 30° C. for12 h and concentrated. The residue was purified by prep-TLC (SiO₂) toafford compound 51-4 (60 mg).

Example A7: Synthesis of1-(4-((3-methyl-3,8-diazabicyclo[3.2.1]octan-8-yl)methyl)-3-(trifluoromethyl)phenyl)-3-(1-methyl-5-(2-(piperidin-4-ylamino)quinazolin-6-yl)-1H-pyrazol-3-yl)urea(19)

Step 1: tert-Butyl 3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carboxylate(19-2)

To a solution of tert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate(200 mg, 942.1 umol) and paraformaldehyde (254 mg, 2.8 mmol) in methanol(2 mL) was added AcOH (2 mg, 47.1 umol, 2.7 uL) (pH=5). The mixture wasstirred at 45° C. for 2 h. Then NaBH₃CN (296 mg, 4.7 mmol) was added andstirred at 45° C. for 12 h. The mixture was concentrated, diluted withNaHCO₃ (5 mL) and extracted with dichloromethane (5 mL×3). The combinedorganic layers were washed with brine (5 mL×2), dried over Na₂SO₄,filtered and concentrated. The residue was purified by prep-TLC (SiO₂)to afford compound 19-2 (200 mg). ¹H NMR (CDCl₃, 400 MHz): δ 4.28-4.00(m, 2H), 2.63 (dd, J=2.2, 10.5 Hz, 2H), 2.23 (s, 5H), 1.94-1.76 (m, 4H),1.47 (s, 9H).

Step 2: 3-methyl-3,8-diazabicyclo[3.2.1]octane (19-3)

A solution of compound 19-2 (200 mg, 883.7 umol) in dichloromethane (2mL) and trifluoroacetic acid (1 mL) was stirred at 25° C. for 10 min.The mixture was concentrated to get compound 19-3 (212 mg, TFA).

Step 3:3-methyl-8-(4-nitro-2-(trifluoromethyl)benzyl)-3,8-diazabicyclo[3.2.1]octane(19-4)

To a solution of compound 3A-2 (551 mg, 970.7 umol) and K₂CO₃ (365 mg,2.6 mmol) in DCM (2 mL) was added compound 19-3 (212 mg, 882.5 umol,TFA). The mixture was stirred at 25° C. for 12 h. The mixture wasconcentrated to get crude residue. The residue was purified by prep-TLC(SiO₂) to afford compound 19-4 (140 mg). ¹H NMR (CDCl₃, 400 MHz): δ 8.50(d, J=2.2 Hz, 1H), 8.43-8.38 (m, 1H), 8.37-8.33 (m, 1H), 3.76 (s, 2H),3.07 (br s, 2H), 2.79-2.53 (m, 2H), 2.35 (br d, J=9.9 Hz, 2H), 2.28 (s,3H), 2.07-1.85 (m, 4H).

Step 4:4-((3-methyl-3,8-diazabicyclo[3.2.1]octan-8-yl)methyl)-3-(trifluoromethyl)aniline(19-5)

To a solution of compound 19-4 (140 mg, 425.1 umol) in methanol (10 mL)was added Pd/C (10%, 0.1 g) under N₂. The suspension was degassed andpurged with H₂ 3 times. The mixture was stirred under H₂ (15 Psi) at 25°C. for 0.5 h, filtered and concentrated under reduced pressure to give aresidue. The residue was purified by prep-TLC (SiO₂) to afford compound19-5 (80 mg).

Step 5: tert-butyl4-((tert-butoxycarbonyl)(6-(1-methyl-3-(3-(4-((3-methyl-3,8-diazabicyclo[3.2.1]octan-8-yl)methyl)-3-(trifluoromethyl)phenyl)ureido)-1H-pyrazol-5-yl)quinazolin-2-yl)amino)piperidine-1-carboxylate(19-6)

To a solution of compound 19-5 (50 mg, 167 umol) and DIEA (32 mg, 250umol, 43.8 uL) in dichloromethane (2 mL) was cooled to −30° C. andtriphosgene (16 mg, 55.1 umol) was added. The mixture was stirred at−30° C. for 1 h. Then a solution of compound 2A (69 mg, 133.6 umol) indichloromethane (1 mL) was added. After 12 h at 25° C., MeOH (1 mL) wasadded and the resulting mixture was concentrated. The residue waspurified by prep-TLC (SiO₂) to afford compound 19-6 (50 mg).

Step 6:1-(4-((3-methyl-3,8-diazabicyclo[3.2.1]octan-8-yl)methyl)-3-(trifluoromethyl)phenyl)-3-(1-methyl-5-(2-(piperidin-4-ylamino)quinazolin-6-yl)-1H-pyrazol-3-yl)urea(19)

A solution of compound 19-6 (50 mg, 58.9 umol) in trifluoroacetic acid(1 mL) and dichloromethane (2 mL) was stirred at 25° C. for 10 min. Themixture was concentrated to get crude residue. The residue was dissolvedin MeOH (2.0 mL) and basified pH to 8 with NH₃.H₂O (25% purity). Theresidue was purified by prep-HPLC to get 19 (14.7 mg, 21.1 umol, 35.8%yield, FA). M+H+=649.4 (LCMS); ¹H NMR (METHANOL-d₄, 400 MHz): δ 9.13 (s,1H), 8.51 (br s, 1H), 7.92 (t, J=2.0 Hz, 2H), 7.85-7.80 (m, 2H), 7.64(t, J=9.4 Hz, 2H), 6.41 (s, 1H), 4.30-4.22 (m, 1H), 3.84 (s, 3H), 3.69(s, 2H), 3.47 (td, J=3.7, 13.1 Hz, 2H), 3.37-3.31 (m, 2H), 3.24-3.13 (m,4H), 2.97 (br d, J=11.5 Hz, 2H), 2.67 (s, 3H), 2.31 (br dd, J=3.3, 14.3Hz, 2H), 2.25-2.12 (m, 2H), 1.98-1.79 (m, 4H).

The following compounds were synthesized according to proceduresdescribed in example above for the preparation of compound 19.

Comp Chemical Mass ¹H NMR ID Structure Name (M + H⁺) (MeOD, 400 MHz) 23

1-(4-((5-methyl- 2,5-diazabicyclo [2.2.2]octan-2-yl) methyl)-3-(trifluoromethyl) phenyl)-3-(1-methyl- 5-(2-(piperidin-4-ylamino)quinazolin- Calc’d for C₃₃H₄₀F₃N₁₀O: 649.3; Found: 649.3 δ 9.12(s, 1H), 8.51 (br s, 2H), 7.92 (br d, J = 9.7 Hz, 2H), 7.82 (br d, J =8.8 Hz, 1H), 7.71- 7.58 (m, 3H), 6.41 (s, 1H), 4.31-4.18 (m, 1H),3.89-3.79 (m, 5H), 3.53- 3.39 (m, 4H), 3.37-3.23 6-yl)-1H-pyrazol- (m,2H), 3.17 (br t, J = 3-yl)urea, formate 11.1 Hz, 2H), 2.95-2.84 salt (m,4H), 2.78 (br d, J = 11.5 Hz, 1H), 2.30 (br d, J = 11.9 Hz, 2H), 2.23-2.06 (m, 2H), 2.03-1.77 (m, 3H), 1.77-1.58 (m, 1H) 51

1-(1-methyl-5-(2- (piperidin-4- ylamino)quinazolin- 6-yl)-1H-pyrazol-3-yl)-3-(5-((4- methylpiperazin-1- yl)methyl)-4- (trifluoromethyl)pyridin-2-yl)urea, Calc’d for C₃₀H₃₇F₃N₁₁O: 624.3; Found: 624.3 δ 9.06(s, 1H), 8.50 (s, 1H), 8.38 (br s, 2H), 7.87 (d, J = 1.7 Hz, 1H), 7.77(dd, J = 1.9, 8.7 Hz, 1H), 7.56 (d, J = 8.7 Hz, 1H), 7.36-7.19 (m, 3H),6.50 (br s, 1H), 4.26-4.12 (m, 1H), 3.77 (s, 3H), 3.68-3.61 (m, 2H),3.45- formate salt 3.30 (m, 3H), 3.17-3.03 (m, 5H), 3.00-2.87 (m, 2H),2.66 (s, 4H), 2.25 (br dd, J = 3.1, 14.2 Hz, 3H), 1.88-1.67 (m, 5H)

Example A8: Synthesis ofN-(5-(3-aminoisoquinolin-7-yl)-1-methyl-1H-pyrazol-3-yl)-2-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)acetamide(11)

Step 1: tert-butyl (7-bromoisoquinolin-3-yl)carbamate (11-2)

To a solution of 7-bromoisoquinolin-3-amine 11-1 (34.0 g, 53 mmol) andTEA (16.0 g, 160 mmol, 22 mL) in DMA (300 mL) was addedtert-butoxycarbonyl tert-butyl carbonate (34.9 g, 160 mmol, 36.7 mL) andDMAP (1.3 g, 10.6 mmol). The mixture was stirred at 20° C. for 12 h, andconcentrated to give a crude residue which was purified by columnchromatography (SiO₂) to afford compound 11-2 (7.0 g, crude).

Step 2: tert-butyl(7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinolin-3-yl)carbamate(11-3)

To a solution of 11-2 (7.0 g, 21.6 mmol) and KOAc (4.2 g, 43.3 mmol) indioxane (160 mL) were added4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane(6.6 g, 25.9 mmol) and Pd(dppf)Cl₂ (792 mg, 1 mmol). The mixture wasstirred at 90° C. for 12 h under N₂, cooled to rt and concentrated. Theresidue was purified by column chromatography (SiO₂) to afford compound11-3 (3.6 g).

Step 3: tert-butyl(7-(3-amino-1-methyl-1H-pyrazol-5-yl)isoquinolin-3-yl)carbamate (11-4)

To a solution of compound 11-3 (2.0 g, 5.4 mmol) and K₂CO₃ (2.2 g, 16.2mmol) in dioxane (40 mL) and H₂O (4 mL) were added5-bromo-1-methyl-1H-pyrazol-3-amine (1.0 g, 5.9 mmol) and Pd(dppf)Cl₂(395 mg, 540 umol). The mixture was stirred at 90° C. for 12 h under N₂,cooled to rt and concentrated. The residue was purified by prep-TLC(SiO₂) followed by prep-HPLC. The eluent was adjusted to pH=8 with sat.NaHCO₃ and extracted with ethyl acetate (20 mL×3). The combined organiclayers was dried over Na₂SO₄, filtered and concentrated under reducedpressure to afford 11-4 (114.9 mg, 337.0 umol, 6.2% yield). M+H⁺=340.2(LCMS); ¹H NMR (DMSO-d₆, 400 MHz): δ 9.89 (s, 1H), 9.12 (s, 1H), 8.17(s, 1H), 8.09 (s, 1H), 7.92 (d, J=8.6 Hz, 1H), 7.73 (dd, J=1.5, 8.6 Hz,1H), 5.67 (s, 1H), 4.63 (br s, 1H), 3.66 (s, 3H), 1.50 (s, 9H).

Step 4: tert-butyl(7-(1-methyl-3-(2-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)acetamido)-1H-pyrazol-5-yl)isoquinolin-3-yl)carbamate (11-5)

To a solution of compound 46-8 (30 mg, 88.4 umol) in pyridine (2.0 mL)was added compound 11-4 (30 mg, 88.4 umol) and EDCI (51 mg, 265.2 umol).The mixture was stirred at 45° C. for 12 h, cooled to rt andconcentrated to give a residue, which was purified by prep-TLC (SiO₂) togive compound 11-5 (40 mg).

Step 5:N-(5-(3-aminoisoquinolin-7-yl)-1-methyl-1H-pyrazol-3-yl)-2-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)acetamide(11)

To a solution of compound 11-5 (40 mg, 62.7 umol) in DCM (2.0 mL) wasadded TFA (1.0 mL). The mixture was stirred at 25° C. for 15 min andconcentrated. The residue was dissolved in MeOH (2.0 mL), basified to pH˜8 with NH₃.H₂O (25% purity) and concentrated. The residue was purifiedby prep-HPLC to afford 11 (16.9 mg, 28.6 umol, 45.7% yield, FA).M+H⁺=538.0 (LCMS); ¹H NMR (METHANOL-d₄, 400 MHz): δ δ 8.82 (s, 1H), 7.89(s, 1H), 7.78-7.66 (m, 2H), 7.63-7.47 (m, 3H), 6.80 (s, 1H), 6.64 (s,1H), 3.89-3.69 (m, 7H), 3.18 (br s, 4H), 2.87-2.58 (m, 7H).

Example A9: Synthesis of1-(1-methyl-5-(2-(piperidin-4-ylamino)quinazolin-6-yl)-1H-pyrazol-3-yl)-3-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)urea(21)

Step 1: 3-nitro-5-(trifluoromethyl)benzoyl chloride (21-2)

To a solution of 3-nitro-5-(trifluoromethyl)benzoic acid (2.0 g, 8.5mmol) in DCM (20 mL) was added oxalyl chloride (1.6 g, 12.8 mmol, 1.1mL) and DMF (6 mg, 85.1 umol, 6.6 uL) at 25° C. The mixture was stirredat 25° C. for 0.5 h. The reaction was concentrated to give compound 21-2(2.0 g, crude).

Step 2:(4-methylpiperazin-1-yl)(3-nitro-5-(trifluoromethyl)phenyl)methanone(21-3)

To a solution of compound 21-2 (948 mg, 9.5 mmol, 1.0 mL) in DCM (20.0mL) was added TEA (2.4 g, 23.6 mmol, 3.2 mL) and3-nitro-5-(trifluoromethyl)benzoyl chloride (2.0 g, 7.8 mmol) at 0° C.The mixture was stirred at 25° C. for 10 min and concentrated to give aresidue. The residue was purified by column chromatography (SiO₂) toafford compound 21-3 (2.0 g, 6.1 mmol, 77.5% yield). ¹H NMR(METHANOL-d₄, 400 MHz): δ 8.55 (s, 1H) 8.46 (t, J=1.65 Hz, 1H) 8.02 (s,1H) 3.84 (br s, 2H) 3.43 (br s, 2H) 2.29-2.67 (m, 7H).

Step 3: 3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)aniline(21-4)

To a solution of LAH (1.2 g, 31.5 mmol) in THF (20.0 mL) was addedcompound 21-3 (1.0 g, 3.1 mmol) in THF (15.0 mL) via syringe at 25° C.The mixture was stirred at 70° C. for 3 h, quenched with H₂O (2 mL),aqueous NaOH (2 mL 10%) and H₂O (6 mL). The mixture was filtered andwashed with methyl alcohol (20 mL×3), and concentrated to give aresidue. The residue was purified by prep-TLC (SiO₂) to afford compound21-4 (250 mg).

Step 4 and 5:1-(1-methyl-5-(2-(piperidin-4-ylamino)quinazolin-6-yl)-1H-pyrazol-3-yl)-3-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)urea(21)

Compound 21 (21.3 mg, 30.6 umol, 25.1% yield, FA) was prepared from 21-4(50 mg, 182.9 umol) according to similar procedures as described in thesynthesis of compound 19. M+H⁺=623.0 (LCMS); ¹H NMR (METHANOL-d₄, 400MHz): δ 9.10 (s, 1H), 8.55 (br s, 2H), 7.88 (s, 1H), 7.84-7.77 (m, 2H),7.68 (br s, 1H), 7.60 (br d, J=8.8 Hz, 1H), 7.29 (s, 1H), 6.41 (br s,1H), 4.23 (br s, 1H), 3.83 (s, 3H), 3.63 (s, 2H), 3.47 (br d, J=12.6 Hz,2H), 3.24-3.06 (m, 6H), 2.82-2.59 (m, 7H), 2.29 (br d, J=13.0 Hz, 2H),1.93-1.78 (m, 2H).

Example A10: Synthesis of1-(1-methyl-5-(2-(piperidin-4-ylamino)quinazolin-6-yl)-1H-pyrazol-3-yl)-3-(4-(1-(4-methylpiperazin-1l-yl)ethyl)-3-(trifluoromethyl)phenyl)urea (22)

Step 1: 1-(1-ethoxyvinyl)-4-nitro-2-(trifluoromethyl)benzene (22-2)

A mixture of tributyl(1-ethoxyvinyl)stannane (5.4 g, 14.8 mmol, 5.0 mL)and 1-bromo-4-nitro-2-(trifluoromethyl)benzene (4.0 g, 14.8 mmol),Pd(PPh₃)₄(1.7 g, 1.4 mmol) in toluene (100 mL) was stirred at 100° C.for 5 h under N₂. The mixture was cooled to rt and concentrated. Theresidue was purified by column chromatography (SiO₂) to give compound22-2 (7.0 g).

Step 2: 1-(4-nitro-2-(trifluoromethyl)phenyl)ethan-1-one (22-3)

A solution of compound 22-2 (7.0 g, 13.4 mmol) in HCl (20 mL) (6M) andTHF (20 mL) was stirred at 25° C. for 10 min, diluted with H₂O (20 mL)and extracted with ethyl acetate (20 mL×3). The combined organic layerswere washed with brine (20 mL×3), dried over Na₂SO₄, filtered andconcentrated. The residue was purified by column chromatography (SiO₂)to give compound 22-3 (3.0 g, 86%). ¹H NMR (CDCl₃, 400 MHz): δ 8.59 (d,J=1.8 Hz, 1H), 8.48 (dd, J=1.8, 8.3 Hz, 1H), 7.65 (d, J=8.3 Hz, 1H),2.63 (s, 3H).

Step 3:1-methyl-4-(1-(4-nitro-2-(trifluoromethyl)phenyl)ethyl)piperazine (22-4)

To a solution of compound 22-3 (500 mg, 2.14 mmol) and1-methylpiperazine (322 mg, 3.2 mmol, 357.2 uL) in DCM (20 mL) was addedTi(i-PrO)₄ (1.2 g, 4.2 mmol, 1.2 mL). After the mixture was stirred at45° C. for 12 h, NaBH₃CN (1.1 g, 17.1 mmol) was added and the mixturewas stirred at 45° C. for 12 h. The reaction was filtered andconcentrated to give a residue, which was purified by columnchromatography (SiO₂) to afford compound 22-4 (300 mg).

Step 4: 4-(1-(4-methylpiperazin-1-yl)ethyl)-3-(trifluoromethyl)aniline(22-5)

To a solution of compound 22-4 (200 mg, 630.3 umol) in EtOH (3.0 mL) andH₂O (600 uL) was added Fe (176 mg, 3.1 mmol) and NH₄Cl (101 mg, 1.8mmol). The mixture was stirred at 80° C. for 12 h, cooled to rt,filtered and concentrated. The residue was purified by prep-TLC (SiO₂)to afford compound 22-5 (80 mg).

Step 5: tert-butyl4-((tert-butoxycarbonyl)(6-(1-methyl-3-(3-(4-(1-(4-methylpiperazin-1-yl)ethyl)-3-(trifluoromethyl)phenyl)ureido)-1H-pyrazol-5-yl)quinazolin-2-yl)amino)piperidine-1-carboxylate (22-6)

To a solution of compound 22-5 (50 mg, 174.0 umol) and DIEA (34 mg,261.0 umol, 45.6 uL) in DCM (3.0 mL) was added triphosgene (17 mg, 57.4umol) at −20° C. After 1 h at −20° C., compound 2A (91 mg, 174.0 umol)in DCM (2.0 mL) was added and the resulting mixture was slowly warmed to25° C. and stirred at 25° C. for 12 h. The reaction was quenched withMeOH (1.0 mL) and concentrated to give a residue. The residue waspurified by prep-TLC (SiO₂) to afford compound 22-6 (50 mg).

Step 6:1-(1-methyl-5-(2-(piperidin-4-ylamino)quinazolin-6-yl)-1H-pyrazol-3-yl)-3-(4-(1-(4-methylpiperazin-1-yl)ethyl)-3-(trifluoromethyl)phenyl)urea(22)

To a solution of compound 22-6 (50 mg, 59.7 umol) in DCM (2.0 mL) wasadded TFA (1.0 mL). The mixture was stirred at 25° C. for 15 min. Thereaction was concentrated. The residue was dissolved in MeOH (2.0 mL),basified to pH ˜8 with NH₃.H₂O (25% purity), and concentrated to give aresidue. The residue was purified by prep-HPLC to afford 22 (10.1 mg,14.7 umol, 24.7% yield, FA). M+H⁺=637.3 (LCMS); ¹H NMR (METHANOL-d₄, 400MHz): δ 6 9.12 (s, 1H), 8.50 (br s, 2H), 7.91 (br s, 2H), 7.82 (br d,J=8.6 Hz, 1H), 7.76 (d, J=8.6 Hz, 1H), 7.69-7.60 (m, 2H), 6.41 (s, 1H),4.25 (br t, J=10.1 Hz, 1H), 3.83 (s, 3H), 3.69 (br d, J=6.0 Hz, 1H),3.47 (br d, J=12.8 Hz, 2H), 3.31-3.29 (m, 2H), 3.24-3.00 (m, 6H), 2.71(s, 3H), 2.53 (br s, 2H), 2.31 (br d, J=12.8 Hz, 2H), 1.94-1.75 (m, 2H),1.32 (d, J=6.4 Hz, 3H).

The following compounds were synthesized according to proceduresdescribed in example above for the preparation of compound 22.

Comp Chemical Mass ¹H NMR ID Structure Name (M + H⁺) (MeOD, 400 MHz) 40

1-(1-methyl-5-(2- (((S)-piperidin-3- yl)amino) quinazolin-6-yl)-1H-pyrazol- 3-yl)-3-(4-(1-(4- methylpiperazin- 1-yl)ethyl)-3-(trifluoromethyl) Calc’d for C₃₂H₄₀F₃N₁₀O: 637.3; Found: 637.2 δ 9.16(s, 1H), 8.52 (br s, 2H), 7.99-7.88 (m, 2H), 7.85 (br d, J = 8.8 Hz,1H), 7.81-7.74 (m, 1H), 7.66 (br t, J = 8.6 Hz, 2H), 6.43 (s, 1H), 4.38(br s, 1H), 3.84 (s, 3H), 3.75- phenyl)urea, 3.59 (m, 2H), 3.35 formatesalt (br s, 1H), 3.21-2.96 (m, 7H), 2.74 (s, 3H), 2.54 (br s, 3H),2.23-2.03 (m, 2H), 1.98-1.70 (m, 2H), 1.33 (br d, J = 6.1 Hz, 3H) 42

1-5-(2-(((1r,4r)-4- aminocyclohexyl) amino)quinazolin- 6-yl)-1-methyl-1H-pyrazol-3- yl)-3-(4-(1-(4- methylpiperazin- 1-yl)ethyl)-3-(trifluoromethyl) Calc’d for C₃₃H₄₂F₃N₁₀O: 651.3; Found: 651.3 δ 9.13(s, 1H), 8.51 (br s, 2H), 7.97-7.90 (m, 2H), 7.88-7.77 (m, 2H), 7.67 (brdd, J = 8.7, 18.6 Hz, 2H), 6.44 (s, 1H), 4.01 (br t, J = 11.3 Hz, 1H),3.87 (s, 3H), 3.79-3.69 (m, phenyl)urea, 1H), 3.18 (br s, 5H), formatesalt 2.95-2.47 (m, 7H), 2.30-2.12 (m, 4H), 1.71-1.44 (m, 4H), 1.36 (brd, J = 6.4 Hz, 3H)

Example A11: Synthesis of1-(4-(((2-aminoethyl)(methyl)amino)methyl)-3-(trifluoromethyl)phenyl)-3-(5-(2-aminoquinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)urea (9)

Step 1

To a solution of compound 1A-2 (4.0 g, 17.8 mmol) and TEA (5.4 g, 53.5mmol, 7.42 mL) in DMA (100.0 mL) were added Boc₂O (3.9 g, 17.8 mmol, 4.1mL) and DMAP (1.0 g, 8.9 mmol). The mixture was stirred at 25° C. for 12h, diluted with H₂O (100 mL) and extracted with ethyl acetate (100mL×3). The combined organic layers were washed with brine (50 mL×3),dried over Na₂SO₄, filtered and concentrated. The residue was purifiedby column chromatography (SiO₂) to afford compound 9-1 (1.4 g, 3.3 mmol,18.4% yield).

Step 2

A mixture of compound 9-1 (400 mg, 942.7 umol),4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane(287 mg, 1.1 mmol), KOAc (277 mg, 2.8 mmol), and Pd(dppf)Cl₂ (68 mg,94.2 umol) in dioxane (20 mL) was degassed and purged with N₂ threetimes, and heated at 90° C. for 12 h under N₂. The mixture was cooled tort and concentrated to give a residue. The residue was purified bycolumn chromatography (SiO₂) and prep-HPLC (TFA condition). The productwas basified with NaHCO₃ to PH=8 to afford compound 9-2 (150 mg, 385.4umol, 40.8% yield).

Step 3

A mixture of compound 9-2 (1.5 g, 3.1 mmol), compound5-bromo-1-methyl-1H-pyrazol-3-amine (672 mg, 3.8 mmol), K₂CO₃ (1.3 g,9.5 mmol) and Pd(dppf)Cl₂ (232 mg, 318.2 umol) in dioxane (30 mL) andH₂O (3.0 mL) was stirred at 90° C. for 12 h under N₂. The reaction wascooled to rt and concentrated to give a residue. The residue waspurified by column chromatography (SiO₂) to afford 9-3 (821.2 mg, 1.7mmol, 56.2% yield). M+H⁺=441.3 (LCMS); ¹H NMR (METHANOL-d₄, 400 MHz): δ9.63 (s, 1H), 8.28 (d, J=1.1 Hz, 1H), 8.18-8.11 (m, 1H), 8.10-8.03 (m,1H), 5.91 (s, 1H), 3.75 (s, 3H), 1.40 (s, 18H)

Step 4: tert-butyl(2-(methyl(4-nitro-2-(trifluoromethyl)benzyl)amino)ethyl)carbamate (9-4)

A mixture of tert-butyl N-[2-(methylamino)ethyl]carbamate (1.0 g, 5.7mmol), compound 3A-2 (1.6 g, 5.7 mmol), K₂CO₃ (1.1 g, 8.6 mmol) in DCM(20 mL) was stirred at 25° C. for 12 h under N₂. The reaction mixturewas concentrated and the residue was purified by column chromatography(SiO₂) to afford compound 9-4 (1.3 g, 2.2 mmol, 39.6% yield).

Step 5: tert-butyl(2-((4-amino-2-(trifluoromethyl)benzyl)(methyl)amino)ethyl)carbamate(9-5)

A mixture of compound 9-4 (1.1 g, 2.9 mmol), Pd/C (300 mg, 2.9 mmol,10.0% purity) in MeOH (20 mL) was degassed and purged with H₂ for 3times, and then the mixture was stirred at 20° C. for 0.5 h under H₂ (15psi). The reaction mixture was filtered and concentrated to affordcompound 9-5 (1.0 g, 2.5 mmol, 87.9% yield).

Step 6 and Step 7:1-(4-(((2-aminoethyl)(methyl)amino)methyl)-3-(trifluoromethyl)phenyl)-3-(5-(2-aminoquinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)urea (9)

Compound 9 (2.4 mg, 3.8 umol, 15.5% yield, FA) was prepared from 9-3(101 mg, 230.3 umol) and 9-5 (100 mg, 287.8 umol) according to similarprocedures as described in the synthesis of compound 22. M+H⁺=514.3(LCMS); ¹H NMR (METHANOL-d₄, 400 MHz): 9.18 (s, 1H), 7.97 (d, J=1.76 Hz,1H), 7.82-7.94 (m, 2H), 7.75-7.79 (m, 1H), 7.68-7.74 (m, 1H), 7.61 (d,J=8.60 Hz, 1H), 6.42 (s, 1H), 3.78-3.88 (m, 3H), 3.71 (s, 2H), 3.07 (t,J=5.84 Hz, 2H), 2.66-2.72 (m, 2H), 2.23-2.29 (m, 3H).

The following compounds were synthesized according to proceduresdescribed in example above for the preparation of compound 9.

Comp Chemical Mass ¹H NMR ID Structure Name (M + H⁺) (MeOD, 400 MHz) 10

1-(5-(2- aminoquinazolin- 6-yl)-1-methyl-1H- pyrazol-3-yl)-3-(4-((methyl(2- (methylamino)ethyl) amino)methyl)-3- (trifluoromethyl)phenyl) Calc’d for C₂₅H₂₉F₃N₉O: 528.2; Found: 528.3 δ 9.18 (s, 1 H),7.97 (d, J = 1.76 Hz, 1 H), 7.84-7.92 (m, 2 H), 7.70-7.80 (m, 2 H), 7.61(d, J = 8.82 Hz, 1 H), 6.42 (s, 1 H), 3.86 (s, 3 H), 3.71 (s, 2H), 3.15(t, J = 5.84 Hz, 2 H), 2.66- 2.72 (m, 5 H), 2.28 (s, 3 H) urea, formatesalt

Example A12: Synthesis of1-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)-3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea (31)

Step 1: 1-(5-bromo-2-fluorophenyl)ethan-1-ol (31-2)

A solution of 5-bromo-2-fluoro-benzaldehyde (55.0 g, 270.9 mmol) in THF(500.0 mL) was cooled to 0° C. Then MeMgBr (3 M, 94.8 mL) was added. Themixture was stirred at 0° C. for 0.5 h, quenched with NH₄Cl (500 mL) andextracted with ethyl acetate (500 mL×3).

The combined organic layers were washed with brine (500 mL×3), driedover Na₂SO₄, filtered and concentrated under reduced pressure to give aresidue. The residue was purified by column chromatography (SiO₂) toafford compound 31-2 (46.0 g).

Step 2: 4-bromo-2-ethyl-1-fluorobenzene (31-3)

To a solution of compound 31-2 (46.0 g, 210.0 mmol) and triethylsilane(48.8 g, 420.0 mmol, 66.9 mL) in DCM (500.0 mL) was added BF₃.Et₂O (59.6g, 420.0 mmol, 51.8 mL) at 0° C. The mixture was stirred at 25° C. for 2h, concentrated, quenched by addition of Sat. NaHCO₃ (200 mL) at 0° C.,and extracted with ethyl acetate (200 mL×3). The combined organic layerswere washed with brine (200 mL×3), dried over Na₂SO₄, filtered andconcentrated. The residue was purified by column chromatography (SiO₂)to afford compound 31-3 (24.0 g). ¹H NMR (CHLOROFORM-d, 400 MHz) δ 7.31(dd, J=2.2, 6.6 Hz, 1H), 7.27-7.21 (m, 1H), 6.87 (t, J=9.2 Hz, 1H), 2.62(q, J=7.5 Hz, 2H), 1.20 (t, J=7.6 Hz, 3H).

Step 3: 5-bromo-3-ethyl-2-fluorobenzaldehyde (31-4)

To a solution of compound 31-3 (24.0 g, 82.7 mmol) in THF (500 mL) wasadded LDA (2 M, 49.6 mL) at −78° C. The mixture was stirred at −78° C.for 1 h. Then dimethyl formamide (7.8 g, 107.5 mmol, 8.3 mL) was addedand stirred for 1 h at −78° C. The reaction mixture was quenched byaddition of NH₄Cl (100 mL) and the resulting mixture was extracted withethyl acetate (200 mL×3). The combined organic layers were washed withbrine (100 mL×3), dried over Na₂SO₄, filtered and concentrated underreduced pressure to give a residue. The residue was purified by columnchromatography (SiO₂) to afford compound 31-4 (13.0 g). ¹H NMR (CDCl₃,400 MHz) δ 10.30 (s, 1H), 7.81 (dd, J=2.6, 5.7 Hz, 1H), 7.58 (dd, J=2.6,6.4 Hz, 1H), 2.73 (q, J=7.6 Hz, 2H), 1.30-1.25 (m, 3H)

Step 4: 6-bromo-8-ethylquinazolin-2-amine (31-5)

To a solution of carbonic acid-guanidine (3.5 g, 19.4 mmol) and DIEA(5.0 g, 38.9 mmol, 6.8 mL) in DMA (20 mL) was added a solution ofcompound 31-4 (3.0 g, 12.98 mmol) in DMA (5 mL). The mixture was stirredat 160° C. for 1 h, poured into ice water (30 mL) and extracted withethyl acetate (40 mL×3). The combined organic layers were washed withbrine (30 mL×3), dried over Na₂SO₄, filtered and concentrated underreduced pressure to give a residue. The residue was purified by columnchromatography (SiO₂) to afford compound 31-5 (1.2 g). ¹H NMR (DMSO-d₆,400 MHz) δ 9.03 (s, 1H), 7.85 (d, J=2.4 Hz, 1H), 7.60 (d, J=2.4 Hz, 1H),6.94 (s, 2H), 2.98-2.88 (m, 2H), 1.22-1.17 (m, 3H)

Step 5: 6-bromo-8-ethyl-2-iodoquinazoline (31-6)

To a mixture of compound 31-5 (1.2 g, 4.76 mmol) and CH₂I₂(6.3 g, 23.8mmol, 1.92 mL) in tetrahydrofuran (24.0 mL) were added CuI (906 mg, 4.7mmol) and isoamyl nitrite (1.6 g, 14.3 mmol, 2.0 mL). After the mixturewas stirred at 80° C. for 2 h under N₂, NH₃.H₂O (30 mL) was added. Theresulting mixture was extracted with ethyl acetate (50 mL×3) and thecombined organic layers were washed with brine (50 mL×3), dried overNa₂SO₄, filtered and concentrated. The residue was purified by columnchromatography (SiO₂) to afford compound 31-6 (400 mg).

Step 6: tert-butyl((1r,4r)-4-((6-bromo-8-ethylquinazolin-2-yl)amino)cyclohexyl)carbamate(31-7)

To a mixture of compound 31-6 (350 mg, 964.2 umol) and DIEA (373 mg, 2.8mmol, 505.2 uL) in isopropanol (10 mL) was added tert-butyl((1r,4r)-4-aminocyclohexyl)carbamate (413 mg, 1.9 mmol). The mixture wasstirred at 80° C. for 12 h, cooled to rt and concentrated. The residuewas purified by prep-TLC (SiO₂) to afford compound 31-7 (350 mg).

Step 7: tert-butyl((1r,4r)-4-((8-ethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazolin-2-yl)amino)cyclohexyl)carbamate(31-8)

To a mixture of compound 31-7 (150 mg, 333.7 umol) and KOAc (98 mg, 1.0mmol) in dioxane (2 mL) were added4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane(101 mg, 400.5 umol) and Pd(dppf)Cl₂ (24 mg, 33.3 umol). The mixture wasstirred at 90° C. for 12 h under N₂, cooled to rt and concentrated. Theresidue was purified by prep-TLC (SiO₂) to afford compound 31-8 (100mg).

Step 8: tert-butyl((1r,4r)-4-((8-ethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazolin-2-yl)amino)cyclohexyl)carbamate(31-9)

To a mixture of compound 31-8 (100 mg, 201.4 umol) and K₂CO₃ (83 mg,604.2 umol) in dioxane (2 mL) and H₂O (200 uL) were added compound 3A(76 mg, 161.1 umol) and Pd(dppf)Cl₂ (14 mg, 20.1 umol). The mixture wasstirred at 90° C. for 12 h under N₂, cooled to rt and concentrated. Theresidue was purified by prep-TLC (SiO₂) to afford compound 31-9 (40 mg).

Step 9:1-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)-3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea (31)

A solution of compound 31-9 (40 mg, 52.3 umol) in TFA (1 mL) anddichloromethane (2 mL) was stirred at 20° C. for 10 min. The mixture wasconcentrated to get crude residue, adjusted to pH=7 with NH₃.H₂O (25%),and purified by prep-HPLC to give 31 (16.1 mg, 22.1 umol, 42.3% yield).M+H⁺=665.5 (LCMS); ¹H NMR (METHANOL-d₄, 400 MHz) δ 9.02 (s, 1H), 7.92(s, 1H), 7.68 (br d, J=11.9 Hz, 2H), 7.64-7.56 (m, 2H), 6.36 (br s, 1H),3.93 (br s, 1H), 3.83 (s, 3H), 3.60 (s, 2H), 3.07 (q, J=7.3 Hz, 2H),2.80 (br s, 1H), 2.49 (br s, 8H), 2.29-2.14 (m, 5H), 2.00 (br s, 2H),1.45-1.29 (m, 7H)

Example A13: Synthesis of1-(5-(2-amino-8-ethylquinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)-3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea(6)

Step 1:8-ethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazolin-2-amine(6-2)

To a mixture of compound 31-5 (150 mg, 594 umol) and KOAc (87 mg, 892umol) in dioxane (4 mL) were added4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane(181 mg, 713 umol) and Pd(dppf)Cl₂ (43 mg, 59.5 umol). The mixture wasstirred at 90° C. for 12 h under N₂. The mixture was concentrated andthe crude residue was purified by prep-TLC (SiO₂) to afford compound 6-2(100 mg).

Step 2:1-(5-(2-amino-8-ethylquinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)-3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea(6)

To a mixture of compound 6-2 (50 mg, 167 umol) and K₂CO₃ (69 mg, 501.3umol) in dioxane (2 mL) and H₂O (200 uL) were added compound 3A (79 mg,167.1 umol) and Pd(dppf)Cl₂ (6 mg, 8.3 umol). The mixture was stirred at90° C. for 12 h under N₂, cooled to rt 1H), 3.85 (s, 3H), 3.70 (s, 2H),3.18-3.01 (m, 6H), 2.82-2.55 (m, 7H), 1.33 (t, J=7.5 Hz, 3H).

Example A14: Synthesis of1-(5-(2-amino-8-methylquinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)-3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea(12)

Step 1: 5-bromo-2-fluoro-3-methylbenzaldehyde (12-2)

To a solution of 4-bromo-1-fluoro-2-methyl-benzene (2.0 g, 10.5 mmol) inTHF (20.0 mL) was added dropwise LDA (2 M, 6.3 mL) at −78° C. over 5min. After addition, the mixture was stirred at −78° C. for 1 h, and DMF(1.1 g, 15.8 mmol, 1.2 mL) was added dropwise. The resulting mixture wasstirred for 25 min, quenched by addition of NH₄Cl (30 mL) at 15° C., andthe resulting mixture was extracted with ethyl acetate (50 mL×3). Thecombined organic layers were washed with brine (50 mL), dried overNa₂SO₄, filtered and concentrated. The residue was purified by columnchromatography (SiO₂) to afford compound 12-2 (1.3 g, 5.2 mmol). ¹H NMR(CDCl₃, 400 MHz) δ 10.25 (s, 1H), 7.75 (dd, J=5.62, 2.54 Hz, 1H), 7.54(dd, J=6.50, 2.09 Hz, 1H), 2.30 (d, J=2.21 Hz, 3H).

Step 2: 6-bromo-8-methylquinazolin-2-amine (12-3)

To a solution of compound 12-2 (1.2 g, 5.8 mmol) in DMA (10.0 mL) wasadded carbonic acid-guanidine (1.5 g, 8.7 mmol). The mixture was stirredat 160° C. for 0.5 h, cooled to rt, diluted with water (10 mL) andextracted with ethyl acetate (50 mL×3). The combined organic layers werewashed with brine (50 mL), dried over Na₂SO₄, filtered and concentrated.The residue was washed with dichloromethane (50 mL×3) to give a productcompound 12-3 (120 mg).

Step 3 and step 4 are carried out according to similar procedures asdescribed in the synthesis of compound 6.

Compound 12 (4.8 mg, 8.3 umol, 1.8% yield) was obtained. M+H+=554.3(LCMS); ¹H NMR (METHANOL-d₄, 400 MHz) δ 9.11 (s, 1H), 7.94 (d, J=2.21Hz, 1H), 7.78 (d, J=1.54 Hz, 1H), 7.69-7.72 (m, 2H), 7.61-7.64 (m, 1H),6.39 (s, 1H), 3.86 (s, 3H), 3.63 (s, 2H), 2.39-2.66 (m, 11H), 2.29 (s,3H)

Example A15: Synthesis of1-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)quinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)-3-(4-((4-aminopiperidin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea (32)

Step 1: tert-butyl(1-(4-nitro-2-(trifluoromethyl)benzyl)piperidin-4-yl)carbamate (32-1)

To a solution of compound 3A-2 (1.0 g, 3.5 mmol) and K₂CO₃ (1.4 g, 10.5mmol) in DCM (30.0 mL) was added tert-butyl N-(4-piperidyl)carbamate(2.1 g, 10.5 mmol). The mixture was stirred at 25° C. for 12 h. Themixture was diluted with H₂O (10 mL) and extracted with ethyl acetate(10 mL×3). The combined organic layers were washed with brine (10 mL×3),dried over Na₂SO₄, filtered and concentrated. The residue was purifiedby column chromatography (SiO₂) to afford compound 32-1 (1.0 g).

Step 2: tert-butyl(1-(4-amino-2-(trifluoromethyl)benzyl)piperidin-4-yl)carbamate (32-2)

A solution of compound 32-1 (100 mg, 247.8 umol) in MeOH (10.0 mL) wasadded Pd/C (10 mg, 247.8 umol, purity 10%). The mixture was stirred at25° C. for 10 min under H₂ (15 psi). The reaction mixture was filteredand concentrated under reduced pressure to give compound 32-2 (70 mg).¹H NMR (CDCl₃, 400 MHz): δ 7.39 (d, J=8.3 Hz, 1H), 6.87-6.82 (m, 1H),6.72 (dd, J=2.3, 8.2 Hz, 1H), 4.36 (br s, 1H), 3.68 (br s, 1H), 3.42 (brd, J=2.2 Hz, 2H), 2.67 (br d, J=11.5 Hz, 2H), 2.06 (br t, J=10.6 Hz,1H), 1.82 (br d, J=11.0 Hz, 2H), 1.54 (br s, 2H), 1.41-1.33 (m, 9H)

Step 3: tert-butyl(1-(4-(3-(5-bromo-1-methyl-1H-pyrazol-3-yl)ureido)-2-(trifluoromethyl)benzyl)piperidin-4-yl)carbamate (32-3)

To a solution of compound 32-2 (70 mg, 187.4 umol) and DIEA (36 mg,281.1 umol, 49.1 uL) in DCM (3.0 mL) at −20° C. was added triphosgene(18 mg, 61.8 umol). The mixture was stirred at −20° C. for 1 h. Then asolution of 5-bromo-1-methyl-1H-pyrazol-3-amine (33 mg, 187.4 umol) inDCM (1.0 mL) was added. The resulting mixture was stirred at 25° C. for12 h and concentrated to get a crude residue which was purified byprep-TLC (SiO₂) to afford compound 32-3 (90 mg).

Step 4: tert-butyl(1-(4-(3-(5-(2-(((1r,4r)-4-((tert-butoxycarbonyl)amino)cyclohexyl)amino)quinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)ureido)-2-(trifluoromethyl)benzyl)piperidin-4-yl)carbamate (32-4)

To a solution of compound 1A (100 mg, 213.4 umol) and K₂CO₃ (88 mg,640.4 umol) in dioxane (2.0 mL) and H₂O (200 uL) were added compound32-3 (85 mg, 149.4 umol) and Pd(dppf)Cl₂ (15 mg, 21.3 umol). The mixturewas stirred at 90° C. for 12 h under N₂, cooled to rt and concentrated.The residue was purified by prep-TLC (SiO₂) to afford compound 32-4 (80mg).

Step 5:1-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)quinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)-3-(4-((4-aminopiperidin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea (32)

A solution of compound 32-4 (80 mg, 95.59 umol) in TFA (1.0 mL) and DCM(2.0 mL) was stirred at 25° C. for 5 min. The mixture was concentratedand the residue was dissolved in MeOH (2.0 mL), basified to pH-8 withNH₃.H₂O (25% purity) and concentrated to give a residue. The residue waspurified by prep-HPLC to afford 32(16.9 mg, 23.9 umol, 25.0% yield, FA).M+H⁺=637.1 (LCMS); ¹H NMR (METHANOL-d₄, 400 MHz) δ 9.09 (br s, 1H), 8.49(br s, 1H), 7.90 (br d, J=5.7 Hz, 2H), 7.81 (br d, J=8.6 Hz, 1H),7.70-7.56 (m, 3H), 6.40 (br s, 1H), 3.96 (br s, 1H), 3.83 (s, 3H), 3.61(br s, 2H), 3.12 (br d, J=18.7 Hz, 2H), 2.91 (br d, J=11.9 Hz, 2H),2.29-2.05 (m, 6H), 1.95 (br d, J=12.1 Hz, 2H), 1.72-1.38 (m, 6H).

The following compounds were synthesized according to proceduresdescribed in example above for the preparation of compound 32.

Comp Chemical Mass ¹H NMR ID Structure Name (M + H⁺) (MeOD, 400 MHz) 43

1-5-(2-(((1r,4r)-4- aminocyclohexyl) amino)quinazolin- 6-yl)-1-methyl-1H-pyrazol-3-yl)- 3-(4-((methyl(2- (methylamino)ethyl) amino)methyl)-3-Calc’d for C₃₁H₄₀F₃N₁₀O: 625.3; Found: 625.2 δ 9.13 (s, 1H), 8.51 (br s,2H), 7.94 (br d, J = 16.1 Hz, 2H), 7.88-7.75 (m, 2H), 7.74-7.60 (m, 2H),6.44 (br s, 1H), 4.00 (br t, J = 11.0 Hz, 1H), 3.87 (s, 3H),(trifluoromethyl) 3.72 (s, 2H), 3.24- phenyl)urea, 3.10 (m, 3H), 2.78-formate salt 2.66 (m, 5H), 2.34- 2.23 (m, 5H), 2.16 (br d, J = 10.8 Hz,2H), 1.70-1.44 (m, 4H) 44

1-(5-(2-(((1r,4r)-4- aminocyclohexyl) amino)quinazolin-6-yl)-1-methyl-1H- pyrazol-3-yl)-3-(4- ((4-(methylamino) piperidin-1-yl)methyl)-3- (trifluoromethyl) Calc’d for C₃₃H₄₂F₃N₁₀O: 651.3; Found:651.3 δ 9.10 (br s, 1H), 8.42 (br s, 3H), 7.91 (br s, 2H), 7.82(br d, J= 8.8 Hz, 1H), 7.71-7.54 (m, 3H), 6.40 (br s, 1H), 3.97 (br s, 1H), 3.84(s, 3H), 3.62 (br s, 2H), 3.22-2.88 (m, phenyl)urea, 4H), 2.67 (s, 3H),forrnate salt 2.28-1.98 (m, 8H), 1.72-1.39 (m, 6H)

Example A16: Synthesis of1-(4-((2-(dimethylamino)ethyl-methyl-amino)methyl]-3-(trifluoromethyl)phenyl)-3-(1-methyl-5-(2-(4-piperidylamino)quinazolin-6-yl)pyrazol-3-yl)urea(35)

Step 1:1-(5-bromo-1-methyl-1H-pyrazol-3-yl)-3-(4-((methyl(2-(methylamino)ethyl)amino)methyl)-3-(trifluoromethyl)phenyl)urea (35-2)

A solution of compound 35-1 (110 mg, 195.2 umol, prepared from 3A-2according to similar procedures as described in the synthesis of 3A inexample 2) in dichloromethane (2.0 mL) was added trifluoroacetic acid(1.0 mL). The mixture was stirred at 25° C. for 3 h and concentratedunder reduced pressure to afford compound 35-2 (100 mg, TFA).

Step 2:1-(5-bromo-1-methyl-1H-pyrazol-3-yl)-3-(4-(((2-(dimethylamino)ethyl)(methyl)amino)methyl)-3-(trifluoromethyl)phenyl)urea (35-3)

To a solution of compound 35-2 (100 mg, TFA) in methanol (2.0 mL) wasadded triethylamine (50.0 uL) to pH ˜7, then paraformaldehyde (58 mg,647.5 umol) and HOAc (100.0 uL) were added to pH ˜5. The resultingmixture was stirred at 25° C. for 2 h, and NaBH₃CN (67 mg, 1.1 mmol) wasadded. The mixture was stirred at 25° C. for 12 h and concentrated underreduced pressure. The residue was diluted with H₂O (5 mL) and extractedwith dichloromethane (5 mL×3). The combined organic layers were washedwith brine (5 mL×3), dried over anhydrous Na₂SO₄, filtered andconcentrated to give a residue which was purified by prep-TLC (SiO₂) toafford compound 35-3 (30 mg).

Step 3: tert-butyl4-((tert-butoxycarbonyl)(6-(3-(3-(4-(((2-(dimethylamino)ethyl)(methyl)amino)methyl)-3-(trifluoromethyl)phenyl)ureido)-1-methyl-1H-pyrazol-5-yl)quinazolin-2-yl)amino)piperidine-1-carboxylate(35-4)

A mixture of compound 35-3 (30 mg, 62.9 umol), compound 2A-3 (34 mg,62.9 umol), K₂CO₃ (26 mg, 188.6 umol), Pd(dppf)Cl₂ (5 mg, 6.3 umol) andin dioxane (2.0 mL) and H₂O (200 uL) was degassed and purged with N₂ for3 times, and heated at 90° C. for 12 h under N₂. The reaction mixturewas cooled to rt and filtered. The filtrate was concentrated and theresidue was purified by prep-TLC (SiO₂) to afford compound 35-4 (13 mg).

Step 4:1-(4-((2-(dimethylamino)ethyl-methyl-amino)methyl]-3-(trifluoromethyl)phenyl)-3-(1-methyl-5-(2-(4-piperidylamino)quinazolin-6-yl)pyrazol-3-yl)urea(35)

To a solution of compound 35-4 (13 mg, 15.8 umol) in dichloromethane(2.0 mL) was added trifluoroacetic acid (1.0 mL). The mixture wasstirred at 25° C. for 30 min and concentrated. The residue was purifiedby prep-HPLC to give 35 (3.6 mg, 4.9 umol, 30.8% yield, FA). M+H⁺=625.3(LCMS); ¹H NMR (METHANOL-d₄, 400 MHz) δ 9.18 (s, 1H), 8.54 (br s, 2H),7.97 (br s, 2H), 7.88 (d, J=8.7 Hz, 1H), 7.80-7.70 (m, 2H), 7.68 (d,J=8.8 Hz, 1H), 6.45 (s, 1H), 4.30 (br t, J=10.3 Hz, 1H), 3.88 (s, 3H),3.75 (s, 2H), 3.51 (br d, J=13.0 Hz, 2H), 3.28 (br t, J=5.9 Hz, 2H),3.24-3.13 (m, 2H), 2.83 (s, 6H), 2.78 (br t, J=5.8 Hz, 2H), 2.43-2.27(m, 5H), 1.98-1.81 (m, 2H).

Example A17: Synthesis of1-(4-((dimethylamino)methyl)-3-(trifluoromethyl)phenyl)-3-(1-methyl-5-(2-(piperidin-4-ylamino)quinazolin-6-yl)-1H-pyrazol-3-yl)urea(45)

Step 1: N-methyl-1-(4-nitro-2-(trifluoromethyl)phenyl)methanamine (45-1)

To a solution of compound 3A-2 (1.0 g, 3.5 mmol) was added methanamine(2 M, 8.80 mL) in THF. The mixture was stirred at 25° C. for 12 h andconcentrated under reduced pressure to give compound 45-1 (1.2 g).

Step 2: tert-butyl methyl(4-nitro-2-(trifluoromethyl)benzyl)carbamate(45-2)

To a solution of compound 45-1 (1.2 g, 5.1 mmol) in DCM (30 mL) wasadded TEA (1.6 g, 15.4 mmol, 2.1 mL) and tert-butoxycarbonyl tert-butylcarbonate (3.4 g, 15.4 mmol, 3.5 mL). The mixture was stirred at 30° C.for 12 h and concentrated to give a crude residue which was purified bycolumn chromatography (SiO₂) to afford compound 45-2 (1.3 g).

Step 3: tert-butyl (4-amino-2-(trifluoromethyl)benzyl)(methyl)carbamate(45-3)

To a solution of compound 45-2 (500 mg, 1.5 mmol) in EtOH (10 mL) andH₂O (2.0 mL) were added Fe (419 mg, 7.5 mmol) and NH₄C₁ (240 mg, 4.5mmol, 157.3 uL). The mixture was stirred at 80° C. for 2 h, cooled tort, filtered and concentrated. The residue was purified by columnchromatography (SiO₂) to afford compound 45-3 (190 mg).

Step 4: tert-butyl(4-(3-(5-bromo-1-methyl-1H-pyrazol-3-yl)ureido)-2-(trifluoromethyl)benzyl)(methyl)carbamate (45-4)

To a solution of compound 45-3 (190 mg, 624.3 umol) in DCM (6.0 mL) wasadded DIEA (121 mg, 936.5 umol, 163.6 uL). The mixture was cooled to−20° C. for 0.5 h and then added bis(trichloromethyl) carbonate (61 mg,206.0 umol) quickly avoiding water. The mixture was stirred at −20° C.for 0.5 h, and 5-bromo-1-methyl-1H-pyrazol-3-amine (109 mg, 624.3 umol)in DCM (4.0 mL) was added dropwise. The resulting mixture was stirred at25° C. for 12 h and concentrated. The residue was purified by columnchromatography (SiO₂) to afford compound 45-4 (62 mg).

Step 5:1-(5-bromo-1-methyl-1H-pyrazol-3-yl)-3-(4-((methylamino)methyl)-3-(trifluoromethyl)phenyl)urea(45-5)

To a solution of compound 45-4 (62 mg, 122.4 umol) in DCM (2.0 mL) wasadded TFA (1.0 mL). The mixture was stirred at 25° C. for 0.5 h andconcentrated under reduced pressure to afford compound 45-5 (120 mg,TFA).

Step 6:1-(5-bromo-1-methyl-1H-pyrazol-3-yl)-3-(4-((dimethylamino)methyl)-3-(trifluoromethyl)phenyl)urea (45-6)

To a solution of compound 45-5 (120 mg, 230.7 umol TFA) in MeOH (2.0 mL)was added TEA (50.0 uL) to pH ˜7, then paraformaldehyde (62 mg, 692.0umol) and CH₃COOH (100 uL) were added to pH ˜5. The resulting mixturewas stirred at 25° C. for 2 h, NaBH₃CN (72 mg, 1.1 mmol) was added andthe mixture was stirred at 25° C. for 12 h. The reaction mixture wasconcentrated, diluted with H₂O (5 mL), and extracted with DCM (5 mL×3).The combined organic layers were washed with brine (5 mL), dried overNa₂SO₄, filtered and concentrated to give a residue, which was purifiedby prep-TLC (SiO₂) to afford compound 45-6 (15 mg).

Step 7 and step 8:1-(4-((dimethylamino)methyl)-3-(trifluoromethyl)phenyl)-3-(1-methyl-5-(2-(piperidin-4-ylamino)quinazolin-6-yl)-1H-pyrazol-3-yl)urea(45)

Compound 45 (4.5 mg, 7.1 umol, 20.2% yield, FA) was prepared from 45-6(15 mg, 35.7 umol) according to similar procedures as described in thesynthesis of compound 31. M+H=568.2 (LCMS); ¹H NMR (METHANOL-d₄, 400MHz): δ 9.06 (s, 1H), 8.38 (br s, 2H), 7.98 (s, 1H), 7.85 (s, 1H), 7.76(dd, J=1.7, 8.8 Hz, 1H), 7.69-7.61 (m, 1H), 7.61-7.51 (m, 2H), 6.35 (s,1H), 4.25-4.10 (m, 1H), 3.96 (s, 2H), 3.76 (s, 3H), 3.40 (br d, J=13.0Hz, 2H), 3.17-3.02 (m, 2H), 2.53 (s, 6H), 2.24 (br d, J=11.6 Hz, 2H),1.90-1.66 (m, 2H).

Example A18: Synthesis ofN-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)-2-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)acetamide (46)

Step 1: (4-methyl-3-(trifluoromethyl)phenyl)methanol (46-2)

To a solution of LAH (223 mg, 5.9 mmol) in THF (5.0 mL) was added4-methyl-3-(trifluoromethyl)benzoic acid (1.0 g, 4.9 mmol) in THF (10.0mL) dropwise at 0° C. The mixture was stirred at 25° C. for 12 h, andquenched with H₂O (1.0 ml) and NaOH (10%, 1.0 ml).

The mixture was filtered and concentrated. The residue was purified bycolumn chromatography (SiO₂) to give compound 46-2 (900 mg, 3.7 mmol,77.2% yield). ¹H NMR (CDCl₃, 400 MHz): δ 7.59 (s, 1H), 7.40 (br d, J=7.9Hz, 1H), 7.24 (s, 1H), 4.69 (d, J=5.1 Hz, 2H), 2.46 (s, 3H)

Step 2: 4-methyl-3-(trifluoromethyl)benzyl methanesulfonate (46-3)

To a solution of compound 46-2 (800 mg, 4.2 mmol) in DCM (20 mL) wasadded TEA (1.3 g, 12.6 mmol, 1.8 mL) and MsCl (723 mg, 6.3 mmol, 488.4uL) at 0° C. The mixture was stirred at 25° C. for 1 h, added water (20mL) and extracted with DCM (20 mL×3). The combined organic phase waswashed with brine (30 mL×3), dried over anhydrous Na₂SO₄, filtered andconcentrated to give compound 46-3 (900 mg, crude).

Step 3: 2-(4-methyl-3-(trifluoromethyl)phenyl)acetonitrile (46-4)

To a solution of compound 46-3 (900 mg, 3.3 mmol) in DMF (15.0 mL) wasadded NaCN (198 mg, 4.0 mmol). The mixture was stirred at 25° C. for 1h, diluted with water (15 mL) and extracted with ethyl acetate (15mL×3). The combined organic layers were washed with brine (15 mL×3),dried over anhydrous Na₂SO₄, filtered and concentrated. The residue waspurified by column chromatography (SiO₂) to afford compound 46-4 (600mg). ¹H NMR (CDCl₃, 400 MHz): δ 7.53 (s, 1H), 7.40 (br d, J=7.9 Hz, 1H),7.30 (d, J=7.9 Hz, 1H), 3.75 (s, 2H), 2.47 (s, 3H)

Step 4: methyl 2-(4-methyl-3-(trifluoromethyl)phenyl)acetate (46-5)

The mixture of compound 46-4 (500 mg, 2.5 mmol) in HCl/MeOH (5.0 mL) (12M) was stirred at 25° C. for 0.5 h and concentrated to give a residue.The residue was purified by prep-TLC (SiO₂) to give compound 46-5 (460mg).

Step 5: methyl 2-(4-(bromomethyl)-3-(trifluoromethyl)phenyl)acetate(46-6)

To a solution of compound 46-5 (460 mg, 1.9 mmol) in CCl₄ (15.0 mL) wasadded BPO (48 mg, 198.0 umol) and NBS (388 mg, 2.2 mmol). The mixturewas stirred at 80° C. for 12 h, cooled to rt and concentrated to give aresidue which was purified by column chromatography (SiO₂) to givecompound 46-6 (450 mg).

Step 6: methyl2-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)acetate(46-7)

To a solution of compound 46-6 (450 mg, 578.6 umol) in DCM (5.0 mL) wasadded K₂CO₃ (120 mg, 868.0 umol) and 1-methylpiperazine (116 mg, 1.2mmol, 128.8 uL). The mixture was stirred at 25° C. for 1 h andconcentrated to give a residue. The residue was purified by columnchromatography (SiO₂) followed by prep-HPLC (TFA condition). The productwas basified to pH ˜8 with saturated NaHCO₃ and extracted with Ethylacetate (40 mL×3), dried over anhydrous Na₂SO₄, filtered andconcentrated to give compound 46-7 (110 mg, 299.6 umol, 51.7% yield). ¹HNMR (CDCl₃, 400 MHz): δ 7.73 (d, J=8.3 Hz, 1H), 7.51 (s, 1H), 7.42 (d,J=7.9 Hz, 1H), 3.70 (s, 3H), 3.67-3.60 (m, 4H), 2.51 (br s, 8H), 2.30(s, 3H)

Step 7:2-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)aceticacid (46-8)

The mixture of compound 46-7 (200 mg, 605.4 umol) in HCl (4.0 mL) (6 M)was stirred at 100° C. for 12 h. The reaction was cooled to rt andconcentrated to give compound 46-8 (100 mg).

Step 8:N-(5-bromo-1-methyl-1H-pyrazol-3-yl)-2-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)acetamide(46-9)

To a solution of compound 46-8 (140 mg, 442.5 umol) in pyridine (2.0 mL)were added 5-bromo-1-methyl-1H-pyrazol-3-amine (77 mg, 442.5 umol) andEDCI (254 mg, 1.3 mmol). The mixture was stirred at 45° C. for 12 h,cooled to rt and concentrated to give a residue. The residue waspurified by prep-TLC (SiO₂) to afford compound 46-9 (77 mg, 30% yield).M+H+=472.0 (LCMS).

Step 9: tert-butyl((1r,4r)-4-((8-ethyl-6-(1-methyl-3-(2-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)acetamido)-1H-pyrazol-5-yl)quinazolin-2-yl)amino)cyclohexyl)carbamate (46-10)

A mixture of compound 31-8 (67 mg, 162.3 umo), compound 46-9 (77 mg, 162umol), K₂CO₃ (67 mg, 487.0 umol) and Pd(dppf)Cl₂ (11 mg, 16.2 umol) inH₂O (300.0 uL) and dioxane (3.0 mL) was degassed and purged with N₂ for3 times, and then heated at 90° C. for 12 h under N₂. The reaction wascooled to rt and concentrated. The residue was purified by prep-TLC(SiO₂) to afford compound 46-10 (100 mg). M+H⁺=764.4 (LCMS).

Step 10:N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)-2-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)acetamide (46)

To a solution of compound 46-10 (100 mg, 130.9 umol) in DCM (2.0 mL) wasadded TFA (1.0 mL). The mixture was stirred at 20° C. for 15 min andconcentrated to give a residue. The residue was dissolved in MeOH (1mL), basified pH to 8 with NH₃.H₂O (25%), concentrated and purified byprep-HPLC to afford compound 46 (27.1 mg, 34.6 umol, 26.5% yield, FA).M+H⁺=664.3 (LCMS); ¹H NMR (METHANOL-d₄, 400 MHz): δ 9.03 (s, 1H), 8.54(br s, 2H), 7.80-7.66 (m, 3H), 7.65-7.59 (m, 2H), 6.66 (s, 1H),4.05-3.93 (m, 1H), 3.85-3.74 (m, 7H), 3.25-3.03 (m, 7H), 2.81-2.66 (m,7H), 2.31 (br d, J=11.2 Hz, 2H), 2.17 (br d, J=11.1 Hz, 2H), 1.70-1.43(m, 4H), 1.34 (t, J=7.5 Hz, 3H).

The following compounds were synthesized according to proceduresdescribed in example above for the preparation of compound 46.

Comp Chemical Mass ¹H NMR ID Structure Name (M + H⁺) (MeOD, 400 MHz) 14

N-(1-methyl-5-(2- (piperidin-4- ylamino) quinazolin- 6-yl)-1H-pyrazol-3-yl)-2-(4-((4- methylpiperazin-1- yl)methyl)-3- (trifluoromethyl)phenyl)acetamide, Calc’d for C₃₂H₃₉F₃N₉O: 622.3; Found: 622.0 δ 9.08 (s,1H), 8.50 (br s, 1H), 7.85 (d, J = 1.1 Hz, 1H), 7.80- 7.68 (m, 3H),7.63- 7.56 (m, 2H), 6.66 (s, 1H), 4.29-4.19 (m, 1H), 3.85-3.70 (m, 7H),3.48 (br d, J = 12.8 Hz, 2H), 3.26- 3.12 (m, 6H), 2.86-2.61 formate salt(m, 7H), 2.35-2.25 (m, 2H), 1.93-1.80 (m, 2H)

Example A19: Synthesis of1-(5-(8-ethyl-2-(((1r,4r)-4-hydroxycyclohexyl)amino)quinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)-3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea (49)

Step 1: (1r,4r)-4-((6-bromo-8-ethylquinazolin-2-yl)amino)cyclohexan-1-ol(49-1)

To a solution of compound 31-6 (240 mg, 661.1 umol) in IPA (12.0 mL)were added DIEA (256 mg, 1.9 mmol, 346.4 uL) and 4-aminocyclohexanol(152 mg, 1.3 mmol). The mixture was stirred at 80° C. for 12 h, cooledto rt and concentrated. The residue was purified by columnchromatography (SiO₂) to afford compound 49-1 (150 mg).

Step 2:(1r,4r)-4-((8-ethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazolin-2-yl)amino)cyclohexan-1-ol (49-2)

A mixture of compound 49-1 (150 mg, 428.2 umol), AcOK (126 mg, 1.3mmol),4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane(120 mg, 471.1 umol) and Pd(dppf)Cl₂ (31 mg, 42.8 umol) in dioxane (8.0mL) was degassed and purged with N₂ three times, and stirred at 90° C.for 12 h. The reaction mixture was cooled to rt and concentrated to givea residue which was purified by prep-TLC (SiO₂) to give compound 49-2(200 mg).

Step 3:1-(5-(8-ethyl-2-(((1r,4r)-4-hydroxycyclohexyl)amino)quinazolin-6-yl)-1-methyl-1H-pyrazol-3-yl)-3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea (49)

A mixture of compound 49-2 (100 mg, 251.6 umol), compound 3A (120 mg,251.7 umol), K₂CO₃ (104 mg, 755.0 umol) and Pd(dppf)Cl₂ (18 mg, 25.1umol) in dioxane (3.0 mL) and H₂O (300 uL) was degassed and purged withN₂ three times before it was stirred at 90° C. for 12 h under N₂. Thereaction mixture was concentrated and the crude residue was purified byprep-TLC (SiO₂) followed by prep-HPLC to afford 49 (27.6 mg, 37.6 umol,14.9% yield, FA). M+H⁺=666.3 (LCMS); ¹H NMR (METHANOL-d₄, 400 MHz) δ9.03 (s, 1H), 8.53 (br dd, J=1.9, 3.7 Hz, 1H), 7.96 (s, 1H), 7.76-7.61(m, 4H), 6.39 (s, 1H), 4.00-3.91 (m, 1H), 3.86 (s, 3H), 3.72 (s, 2H),3.68-3.59 (m, 1H), 3.29-3.03 (m, 6H), 2.94-2.56 (m, 7H), 2.21 (br s,2H), 2.09-1.98 (m, 2H), 1.53-1.41 (m, 4H), 1.37 (t, J=7.5 Hz, 3H).

Example B1: In Vitro FRET Assay

In vitro FRET assay was performed to evaluate the ability of selectcompounds to inhibit IRE1, the results of which are summarized in Table5. To perform the in vitro FRET assay, 1× complete assay buffer (CAB; 1MDTT, 50 mM sodium citrate pH 7.15, 1 mM magnesium acetate, 0.02% tween20) was used to dilute SignalChem IRE1α protein to a final concentrationof 2 nM. Selected compounds were serially diluted with DMSO in anon-binding black 384-well plate for a total of 15 ul in each well. 2 ulof the serially diluted compound or DMSO control were then added to newwells containing 98 ul of 1×CAB, for a total volume of 100 ul, 10 ul ofwhich were then transferred to wells of a new plate. 5 ul of the dilutedIRE1α was then added to each well. 5 ul of a 400 mM XBP1 RNA probe wasthen added to each well. Fluorescence was then read over 30 minutes inkinetic mode (485/515 nm).

Two RNA probes were used, XBP1 wildtype (SEQ ID NO: 2) which is able tobe spliced by active IRE1α or XBP1 mutant (SEQ ID NO: 3) which is unableto be spliced. Each probe contained a 5′ 6-FAM modification and a 3′IOWA Black FQ modification.

A second FRET assay was performed to assess ATP-mediated inhibition. Inthis case, compounds and IRE1α were prepared and combined as discussedabove, with the addition of ATP up to 1 mM final concentration. Thismixture was incubated at room temperature for 60 minutes and then 5 ulof 400 nM XBP1 wildtype or mutant RNA probe was added. Plates were thenread over 30 minutes in kinetic mode (485/515 nm).

TABLE 5 Compound Ref. No. Mean EC₅₀  1; TFA A  2; TFA A  3; TFA A  4;TFA D  5 D  6; Formic Acid B  9; Formic Acid D 10; Formic Acid B 11;Formic Acid D 12 B 14; Formic Acid D 15; Formic Acid A 17; Formic Acid A19; Formic Acid B 20; Formic Acid D 21; Formic Acid D 22; Formic Acid A23; Formic Acid D 26; Formic Acid A 29; Formic Acid A 31 A 32; FormicAcid A 33; Formic Acid A 34; Formic Acid A 35; Formic Acid C 36; FormicAcid A 38; Formic Acid A 39; Formic Acid A 40; Formic Acid A 41; FormicAcid D 42; Formic Acid A 43; Formic Acid A 44; Formic Acid A 45; FormicAcid D 46; Formic Acid D 49; Formic Acid A 50; Formic Acid B 51; FormicAcid C Note: Biochemical assay Mean EC₅₀ data are designated within thefollowing ranges: A: ≤5 nM; B: >5 nM to ≤50 nM; C: >50 nM to ≤100 nM;and D: >100 nM.

Example B2: In Vitro Luciferase Assay

Compounds disclosed herein were assessed for disruption of IRE-1signaling using a IRE1α Endoribonuclease Nanoluciferase Assay. Briefly,2.5×10⁶ 293T cells were seeded in in a 10 cm² tissue culture plate.About 24 hours later, the cells were transfected with Effectene. In a 15mL Tube, the following was added: 2 μg XBP1 luciferase reporter plasmid(PGK-Luc2-P2A-XBP1u-Nanoluciferase-PEST); 300 μl EC buffer; and 16 μlEnhancer, followed by incubation at room temp for 5 minutes. Next, 60 μlEffectene (Qiagen 301427) was added, followed by incubation at roomtemperature for 10 minutes. 2.6 mL cDMEM media was added. Old media wasaspirated from the cells, followed by addition of 7 mL fresh media. Fulltransfection mixture was added dropwise to cells. Cells were incubatedfor 6 hours, followed by tripsinization, centrifugation and resuspensionin 11 mL media. 100 uL of cells were plated per a well in a 96 wellplate. A day later, stressors of choice +/− inhibitors were added. Toharvest, media was aspirated from cells completely, then 50 uL 1×passive lysis buffer (Promega: E1941) was added per well and put onshaker (300 rpm) for 30 minutes at room temperature. Cells werecentrifuged, and 15 uL sample per well was added to a new, opaque white384 well plate (Corning 3570). 15 uL OneGlo (nanoluciferase kit, PromegaN1630) was added. Plates were spun down, placed on shaker (300 rpm) for10 minutes. Plates were read on luminometer, 1000 ms integration timeper well. 15 uL Stop and Glo (nanoluciferase kit) was added. Plates werespun down, placed on shaker (300 rpm) for 10 minutes. Plates were readon luminometer, 1000 ms second integration time per well. Recordings areprovided below in Table 6.

TABLE 6 Compound Ref. No. Mean EC₅₀  1; TFA B  2; TFA D  3; TFA B  5 D 6; Formic Acid C  9; Formic Acid D 10; Formic Acid D 12 D 15; FormicAcid D 17; Formic Acid B 19; Formic Acid D 21; Formic Acid D 22; FormicAcid D 23; Formic Acid D 26; Formic Acid A 29; Formic Acid B 31 A 32;Formic Acid C 33; Formic Acid D 34; Formic Acid D 35; Formic Acid D 36;Formic Acid D 38; Formic Acid D 39; Formic Acid D 40; Formic Acid A 41;Formic Acid D 42; Formic Acid A 43; Formic Acid B Note: Biochemicalassay Mean EC₅₀ data are designated within the following ranges: A: ≤5nM; B: >5 nM to ≤50 nM; C: >50 nM to ≤100 nM; and D: >100 nM.

Example B3: ELISA Assay

Total human of mouse CD4 T cells are isolated with Miltenyl MACS beads.Mouse CD4 T cells are isolated from mouse spleen while human CD4 T cellswere isolated from human PBMCs. CD4 T cells are washed and then mixedwith CD3/CD28 activator Dynabeads at 8 pm. After a 36 hour incubation,select IRE1α inhibitor compounds or IRE1α inhibitor controls are addedand incubated for 2 hours.

After the two hour incubation, mouse or human ascites supernatants orcRPMI control are added. After a 10 hour incubation, supernatants areisolated and used in an IFN-g ELISA assay. Trizol is added to each ELISAwell containing T Cells for isolating RNA. ELISA assay is performedaccording to eBioscience Ready-Set-Go IFN-g ELISA kit protocol.

Example B4: DC Lipid Accumulation Assay

Approximately 3×10⁶ bone marrow cells (after RBC lysis) are seeded in 10mL cRPMI with 20 ng/mL GM-CSF in a petri dish. On culture day 3, 10 mLof cRPMI+20 ng/mL GM-CSF is added. On culture day 6, non-adherent cellsfrom each plate are collected and resuspended in 20 mL of fresh cRPMI+20ng/mL GM-CSF. On culture day 7, suspension cells are harvested, counted,and the resuspended at 500,000 cells per 180 microliters in freshcRPMI+20 ng/mL GM-CSF+110% final concentration of IRE1α inhibitorcompounds or DMSO as a control. 180 microliters of cell suspension areadded to each well of a 96 well flat bottom TC-treated plate andincubated for 2 hours. 20 ul of 10×LPS (1 ug/mL) prepared in cRPMI+20ng/mL GM-CSF is added to indicated wells and incubated for another 6hours. Cells are spun down and supernatant was stored in a new 96-wellV-bottom plate. 200 microliters of trizol is added to pelleted cells tosubsequent RNA analysis.

While preferred embodiments of the present invention have been shown anddescribed herein, it will be obvious to those skilled in the art thatsuch embodiments are provided by way of example only. Numerousvariations, changes, and substitutions will now occur to those skilledin the art without departing from the invention. It should be understoodthat various alternatives to the embodiments of the invention describedherein may be employed in practicing the invention. It is intended thatthe following claims define the scope of the invention and that methodsand structures within the scope of these claims and their equivalents becovered thereby.

SEQUENCE LISTING SEQ ID NO: 1MPARRLLLLLTLLLPGLGIFGSTSTVTLPETLLFVSTLDGSLHAVSKRTGSIKWTLKEDPVLQVPTHVEEPAFLPDPNDGSLYTLGSKNNEGLTKLPFTIPELVQASPCRSSDGILYMGKKQDIWYVIDLLTGEKQQTLSSAFADSLCPSTSLLYLGRTEYTITMYDTKTRELRWNATYFDYAASLPEDDVDYKMSHFVSNGDGLVVTVDSESGDVLWIQNYASPVVAFYVWQREGLRKVMHINVAVETLRYLTFMSGEVGRITKWKYPFPKETEAKSKLTPTLYVGKYSTSLYASPSMVHEGVAVVPRGSTLPLLEGPQTDGVTIGDKGECVITPSTDVKFDPGLKSKNKLNYLRNYWLLIGHHETPLSASTKMLERFPNNLPKHRENVIPADSEKKSFEEVINLVDQTSENAPTTVSRDVEEKPAHAPARPEAPVDSMLKDMATIILSTFLLIGWVAFIITYPLSMHQQQQLQHQQFQKELEKIQLLQQQQQQLPFHPPGDTAQDGELLDTSGPYSESSGTSSPSTSPRASNHSLCSGSSASKAGSSPSLEQDDGDEETSVVIVGKISFCPKDVLGHGAEGTIVYRGMFDNRDVAVKRILPECFSFADREVQLLRESDEHPNVIRYFCTEKDRQFQYIAIELCAATLQEYVEQKDFAHLGLEPITLLQQTTSGLAHLHSLNIVHRDLKPHNILISMPNAHGKIKAMISDFGLCKKLAVGRHSFSRRSGVPGTEGWIAPEMLSEDCKENPTYTVDIFSAGCVFYYVISEGSHPFGKSLQRQANILLGACSLDCLHPEKHEDVIARELIEKMIAMDPQKRPSAKHVLKHPFFWSLEKQLQFFQDVSDRIEKESLDGPIVKQLERGGRAVVKMDWRENITVPLQTDLRKFRTYKGGSVRDLLRAMRNKKHHYRELPAEVRETLGSLPDDFVCYFTSRFPHLLAHTYRAMELCSHERLFQPYYFHEPPEPQPPVTPDAL SEQ ID NO: 2 CAUGUCCGCAGCACAUG SEQ ID NO: 3CAUGUCCCCAGCACAUG

What is claimed is:
 1. A compound of Formula (I), or a pharmaceuticallyacceptable salt, or solvate thereof:

wherein,

is an optionally substituted C₃-C₁₀ heterocyclyl containing at least oneN, O, S, S(═O), or S(═O)₂; wherein if

is substituted, then

is substituted with 0-3 R⁵;

is a substituted C₃-C₁₀ cycloalkyl that is substituted with 1-3R⁴ and0-3R⁵; each R⁴ is independently —OR⁶, —SR⁶, —S(═O)R⁷, —S(═O)₂R⁷, or—N(R⁶)₂; each R⁵ is independently halogen, —CN, —OR⁸, —SR⁸, —S(═O)R⁹,—S(═O)₂R⁹, —S(═O)₂N(R⁸)₂, —NR⁸S(═O)₂R⁹, —C(═O)R⁹, —OC(═O)R⁹, —CO₂R⁸,—OCO₂R⁹, —N(R⁸)₂, —OC(═O)N(R⁸)₂, —NR⁸C(═O)R⁹, —NR⁸C(═O)OR⁹, optionallysubstituted C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl,optionally substituted C₁-C₆heteroalkyl, optionally substitutedC₃-C₆cycloalkyl, optionally substituted aryl, or optionally substitutedheteroaryl; A¹ is N or CR^(A); A² is N or CR^(A); A³ is N or CR^(A); A⁴is N or CR^(A); A⁵ is N or CR^(A); each R^(A) is independently H oroptionally substituted C₁-C₆alkyl; R¹ and R² are each independently H oroptionally substituted C₁-C₆alkyl; L¹ and L² are each independently—CHY—, —CH₂— or —NH—; Y is optionally substituted C₁-C₆alkyl;

is optionally substituted aryl or optionally substituted heteroaryl,wherein if

is substituted, then

is substituted with 0-4 R^(c); each R^(c) is independently H, halogen,—CN, —OR¹⁰, —SR¹⁰, —S(═O)R¹¹, —S(═O)₂R¹¹, —S(═O)₂N(R¹⁰)₂,—NR¹⁰S(═O)₂R¹¹, —C(═O)R¹¹, —OC(═O)R¹¹, —CO₂R¹⁰, —OCO₂R¹¹, —N(R¹⁰)₂,—OC(═O)N(R¹⁰)₂, —NR¹⁰C(═O)R¹¹, —NR¹⁰C(═O)OR¹¹, optionally substitutedC₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl, optionallysubstituted C₁-C₆heteroalkyl, optionally substituted C₃-C₆cycloalkyl,optionally substituted aryl, or optionally substituted heteroaryl; eachR³ is independently H or optionally substituted C₁-C₆alkyl;

or L^(D);

is optionally substituted heterocyclyl containing at least one N atom;wherein if

is substituted, then

is substituted with 0-4 R^(D); L^(D) is —N(R¹²)-(optionally substitutedC₁-C₆ alkyl), —N(R¹³)-(optionally substituted C₁-C₆ alkylene)—N(R¹⁴)₂ or-(optionally substituted C₁-C₆ alkylene)—N(R¹⁴)₂; wherein if L^(D) issubstituted, then L^(D) is substituted with 0-4 R^(D); each R^(D) isindependently halogen, —CN, —OR¹⁵, —SR¹⁵, —S(═O)R¹⁶, —S(═O)₂R¹⁶,—S(═O)₂N(R¹⁵)₂, —NR¹⁵S(═O)₂R¹⁶, —C(═O)R¹⁶, —OC(═O)R¹⁶, —CO₂R¹⁵,—OCO₂R¹⁶, —N(R¹⁵)₂, —OC(═O)N(R¹)₂, —NR¹⁵C(═O)R¹⁶, —NR¹⁵C(═O)OR¹⁶,optionally substituted C₁-C₆alkyl, optionally substitutedC₁-C₆fluoroalkyl, optionally substituted C₁-C₆heteroalkyl, optionallysubstituted C₃-C₆cycloalkyl, optionally substituted aryl, or optionallysubstituted heteroaryl; each R⁶ is independently hydrogen, optionallysubstituted C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl,optionally substituted C₁-C₆heteroalkyl, optionally substitutedC₃-C₁₀cycloalkyl, optionally substituted C₂-C₁₀heterocycloalkyl,optionally substituted aryl, or optionally substituted heteroaryl; ortwo R⁶ are taken together with the N atom to which they are attached toform an optionally substituted heterocycle; each R⁷ is independentlyoptionally substituted C₁-C₆alkyl, optionally substitutedC₁-C₆fluoroalkyl, optionally substituted C₁-C₆heteroalkyl, optionallysubstituted C₃-C₁₀cycloalkyl, optionally substitutedC₂-C₁₀heterocycloalkyl, optionally substituted aryl, or optionallysubstituted heteroaryl; each R⁸ is independently hydrogen, optionallysubstituted C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl,optionally substituted C₁-C₆heteroalkyl, optionally substitutedC₃-C₁₀cycloalkyl, optionally substituted C₂-C₁₀heterocycloalkyl,optionally substituted aryl, or optionally substituted heteroaryl; ortwo R⁸ are taken together with the N atom to which they are attached toform an optionally substituted heterocycle; each R⁹ is independentlyoptionally substituted C₁-C₆alkyl, optionally substitutedC₁-C₆fluoroalkyl, optionally substituted C₁-C₆heteroalkyl, optionallysubstituted C₃-C₁₀cycloalkyl, optionally substitutedC₂-C₁₀heterocycloalkyl, optionally substituted aryl, or optionallysubstituted heteroaryl; each R¹⁰ is independently hydrogen, optionallysubstituted C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl,optionally substituted C₁-C₆heteroalkyl, optionally substitutedC₃-C₁₀cycloalkyl, optionally substituted C₂-C₁₀heterocycloalkyl,optionally substituted aryl, or optionally substituted heteroaryl; ortwo R¹⁰ are taken together with the N atom to which they are attached toform an optionally substituted heterocycle; each R¹¹ is independentlyoptionally substituted C₁-C₆alkyl, optionally substitutedC₁-C₆fluoroalkyl, optionally substituted C₁-C₆heteroalkyl, optionallysubstituted C₃-C₁₀cycloalkyl, optionally substitutedC₂-C₁₀heterocycloalkyl, optionally substituted aryl, or optionallysubstituted heteroaryl; each R¹² and R¹³ is independently H oroptionally substituted C₁-C₆alkyl; each R¹⁴ is independently H oroptionally substituted C₁-C₆alkyl; or two R¹⁴ are taken together withthe N atom to which they are attached to form an optionally substitutedheterocycle; each R¹⁵ is independently hydrogen, optionally substitutedC₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl, optionallysubstituted C₁-C₆heteroalkyl, optionally substituted C₃-C₁₀cycloalkyl,optionally substituted C₂-C₁₀heterocycloalkyl, optionally substitutedaryl, or optionally substituted heteroaryl; or two R¹⁵ are takentogether with the N atom to which they are attached to form anoptionally substituted heterocycle; and each R¹⁶ is independentlyoptionally substituted C₁-C₆alkyl, optionally substitutedC₁-C₆fluoroalkyl, optionally substituted C₁-C₆heteroalkyl, optionallysubstituted C₃-C₁₀cycloalkyl, optionally substitutedC₂-C₁₀heterocycloalkyl, optionally substituted aryl, or optionallysubstituted heteroaryl.
 2. The compound of claim 1, or apharmaceutically acceptable salt, or solvate thereof, wherein


3. The compound of claim 2, or a pharmaceutically acceptable salt, orsolvate thereof, wherein

is optionally substituted C₄-C₇ heterocyclyl containing at least one N,O, S, S(═O), or S(═O)₂; wherein if

is substituted, then

is substituted with 0-3 R⁵.
 4. The compound of claim 2, or apharmaceutically acceptable salt, or solvate thereof, wherein

o is 0, 1, or 2; and p is 0, 1, 2, or
 3. 5. The compound of claim 4, ora pharmaceutically acceptable salt, or solvate thereof, wherein

and o is 0, 1, or
 2. 6. The compound of claim 1, or a pharmaceuticallyacceptable salt, or solvate thereof, wherein


7. The compound of claim 6, or a pharmaceutically acceptable salt, orsolvate thereof, wherein

is substituted C₄-C₇ cycloalkyl that is substituted with 1-3R⁴ and0-3R⁵.
 8. The compound of claim 6, or a pharmaceutically acceptablesalt, or solvate thereof, wherein

and q is 0, 1, 2, or
 3. 9. The compound of claim 8, or apharmaceutically acceptable salt, or solvate thereof, wherein

and q is 0, 1, 2, or
 3. 10. The compound of any one of claims 1-9, or apharmaceutically acceptable salt, or solvate thereof, wherein A¹ is CH;A² is N or CR^(A); A³ is N or CR^(A); A⁴ is CH; and A⁵ is CH.
 11. Thecompound of claim 10, or a pharmaceutically acceptable salt, or solvatethereof, wherein A² is N.
 12. The compound of claim 10, or apharmaceutically acceptable salt, or solvate thereof, wherein A² isCR^(A).
 13. The compound of any one of claims 10-12, or apharmaceutically acceptable salt, or solvate thereof, wherein A³ isCR^(A).
 14. The compound of claim 13, or a pharmaceutically acceptablesalt, or solvate thereof, wherein R^(A) is optionally substitutedC₁-C₆alkyl.
 15. The compound of claim 14, or a pharmaceuticallyacceptable salt, or solvate thereof, wherein R^(A) is methyl, ethyl,propyl or butyl.
 16. The compound of claim 14, or a pharmaceuticallyacceptable salt, or solvate thereof, wherein R^(A) is ethyl, propyl orbutyl.
 17. The compound of any one of claims 1-16, or a pharmaceuticallyacceptable salt, or solvate thereof, wherein R¹ is optionallysubstituted C₁-C₆alkyl.
 18. The compound of claim 17, or apharmaceutically acceptable salt, or solvate thereof, wherein R¹ ismethyl.
 19. The compound of any one of claims 1-18, or apharmaceutically acceptable salt, or solvate thereof, wherein R² is H.20. The compound of any one of claims 1-19, or a pharmaceuticallyacceptable salt, or solvate thereof, wherein L¹ and L² are each —NH—.21. The compound of any one of claims 1-19, or a pharmaceuticallyacceptable salt, or solvate thereof, wherein L¹ is —CH₂— and L² is —NH—.22. The compound of any one of claims 1-19, or a pharmaceuticallyacceptable salt, or solvate thereof, wherein L¹ is —NH— and L² is —CH₂—.23. The compound of any one of claims 1-22, or a pharmaceuticallyacceptable salt, or solvate thereof, wherein

is optionally substituted aryl, wherein if

is substituted, then

is substituted with 0-4R^(c).
 24. The compound of any one of claims1-22, or a pharmaceutically acceptable salt, or solvate thereof, wherein

is optionally substituted heteroaryl wherein if

is substituted, then

is substituted with 0-4 R^(c).
 25. The compound of any one of claims1-22, or a pharmaceutically acceptable salt, or solvate thereof, wherein

C¹ is N or CR^(C); C² is N or CR^(C); C³ is N or CR^(C); and C⁴ is N orCR^(C).
 26. The compound of claim 25, or a pharmaceutically acceptablesalt, or solvate thereof, wherein C¹ is CR^(C); C² is CR^(C); C³ isCR^(C); and C⁴ is CR^(C).
 27. The compound of claim 26, or apharmaceutically acceptable salt, or solvate thereof, wherein C¹ isCR^(C); C² is CH; C³ is CH; and C⁴ is CH.
 28. The compound of claim 27,or a pharmaceutically acceptable salt, or solvate thereof, wherein R^(C)is optionally substituted C₁-C₆fluoroalkyl.
 29. The compound of claim28, or a pharmaceutically acceptable salt, or solvate thereof, whereinR^(C) is —CF₃.
 30. The compound of any one of claims 1-29, or apharmaceutically acceptable salt, or solvate thereof, wherein each R³ isindependently H.
 31. The compound of any one of claims 1-30, or apharmaceutically acceptable salt, or solvate thereof, wherein


32. The compound of claim 31, or a pharmaceutically acceptable salt, orsolvate thereof, wherein

is optionally substituted heterocyclyl containing at least one N atom;and if

is substituted, then

is substituted with 0-4 R^(D).
 33. The compound of claim 31, or apharmaceutically acceptable salt, or solvate thereof, wherein

is optionally substituted heterocyclyl containing one N atom; and if

is substituted, then

is substituted with 0-4 R^(D).
 34. The compound of claim 31, or apharmaceutically acceptable salt, or solvate thereof, wherein

is optionally substituted heterocyclyl containing two N atoms; and if

is substituted, then

is substituted with 0-4 R^(D).
 35. The compound of claim 31, or apharmaceutically acceptable salt, or solvate thereof, wherein

and r is 0, 1, or
 2. 36. The compound of claim 35, or a pharmaceuticallyacceptable salt, or solvate thereof, wherein

and r is 0, 1, or
 2. 37. The compound of any one of claims 1-30, or apharmaceutically acceptable salt, or solvate thereof, wherein

is L^(D).
 38. The compound of claim 37, or a pharmaceutically acceptablesalt, or solvate thereof, wherein L^(D) is —N(R¹²)-(optionallysubstituted C₁-C₆ alkyl), —N(R¹³)-(optionally substituted C₁-C₆alkylene)—N(R¹⁴)₂ or -(optionally substituted C₁-C₆ alkylene)—N(R¹⁴)₂;and if L^(D) is substituted, then L^(D) is substituted with 0-4 R^(D).39. The compound of claim 38, or a pharmaceutically acceptable salt, orsolvate thereof, wherein L^(D) is —N(R¹²)-(optionally substituted C₁-C₆alkyl), and if L^(D) is substituted, then L^(D) is substituted with 0-4R^(D).
 40. The compound of claim 39, or a pharmaceutically acceptablesalt, or solvate thereof, wherein L^(D) is —N(R¹²)—CH₂—CH₂—CH₂—CH₃,—N(R¹²)—CH₂—CH₂—CH₃, —N(R¹²)—CH₂—CH₃, or —N(R¹²)—CH₃.
 41. The compoundof claim 39 or 40, or a pharmaceutically acceptable salt, or solvatethereof, wherein R¹² is H or C₁-C₄alkyl.
 42. The compound of claim 39 or40, or a pharmaceutically acceptable salt, or solvate thereof, whereinR¹² is H or C₃-C₄alkyl.
 43. The compound of claim 38, or apharmaceutically acceptable salt, or solvate thereof, wherein L^(D) is—N(R¹³)-(optionally substituted C₁-C₆ alkylene)—N(R¹⁴)₂, and if L^(D) issubstituted, then L^(D) is substituted with 0-4 R^(D).
 44. The compoundof claim 43, or a pharmaceutically acceptable salt, or solvate thereof,wherein L^(D) is —N(R¹³)—CH₂—CH₂—CH₂—CHCH₂—N(R¹⁴)₂,—N(R¹³)—CH₂—CH₂—CH₂—N(R¹⁴)₂, —N(R¹³)—CH₂—CH₂—N(R¹⁴)₂, or—N(R¹³)—CH₂—N(R¹⁴)₂.
 45. The compound of claim 43 or 44, or apharmaceutically acceptable salt, or solvate thereof, wherein each R¹³and R¹⁴ is independently H or C₁-C₄alkyl.
 46. The compound of claim 38,or a pharmaceutically acceptable salt, or solvate thereof, wherein L^(D)is or -(optionally substituted C₁-C₆ alkylene)—N(R¹⁴)₂; and if L^(D) issubstituted, then L^(D) is substituted with 0-4 R^(D).
 47. The compoundof claim 46, or a pharmaceutically acceptable salt, or solvate thereof,wherein L^(D) is —CH₂—CH₂—CH₂—CH₂—N(R¹⁴)₂, —CH₂—CH₂—CH₂—N(R¹⁴)₂,—CH₂—CH₂—N(R¹⁴)₂, or —CH₂—N(R¹⁴)₂.
 48. The compound of claim 46 or 47,or a pharmaceutically acceptable salt, or solvate thereof, wherein eachR¹⁴ is independently H or C₁-C₄alkyl.
 49. The compound of claim 1, or apharmaceutically acceptable salt, or solvate thereof, wherein thecompound has the structure of formula (Ia)

wherein, C¹ is N or CR^(C); C² is N or CR^(C); C³ is N or CR^(C); and C⁴is N or CR^(C).
 50. The compound of claim 1, or a pharmaceuticallyacceptable salt, or solvate thereof, wherein the compound has thestructure of formula (Ib)

wherein, C¹ is N or CR^(C); C² is N or CR^(C); C³ is N or CR^(C); and C⁴is N or CR^(C).
 51. The compound of claim 1, or a pharmaceuticallyacceptable salt, or solvate thereof, wherein the compound has thestructure of formula (Ic)

wherein, C¹ is N or CR^(C); C² is N or CR^(C); C³ is N or CR^(C); and C⁴is N or CR^(C).
 52. The compound of claim 1, or a pharmaceuticallyacceptable salt, or solvate thereof, wherein the compound has thestructure of formula (Id)

wherein, C¹ is N or CR^(C); C² is N or CR^(C); C³ is N or CR^(C); and C⁴is N or CR^(C).
 53. The compound of claim 1, or a pharmaceuticallyacceptable salt, or solvate thereof, wherein the compound has thestructure of formula (Ie)

wherein, C¹ is N or CR^(C); C² is N or CR^(C); C³ is N or CR^(C); and C⁴is N or CR^(C).
 54. The compound of claim 1, or a pharmaceuticallyacceptable salt, or solvate thereof, wherein the compound has thestructure of formula (If)


55. The compound of claim 1, or a pharmaceutically acceptable salt, orsolvate thereof, wherein the compound has the structure of formula (Ig)


56. The compound of claim 1, or a pharmaceutically acceptable salt, orsolvate thereof, wherein the compound has the structure of formula (Ih)


57. The compound of claim 1, or a pharmaceutically acceptable salt, orsolvate thereof, wherein the compound has the structure of formula (Ii)


58. A compound of Formula (II), or a pharmaceutically acceptable salt,or solvate thereof:

wherein Z is H,

is an optionally substituted C₃-C₁₀ heterocyclyl containing at least oneN, O, S, S(═O), or S(═O)₂; wherein if

is substituted, then

is substituted with 0-3 R⁵;

is a substituted C₃-C₁₀ cycloalkyl that is substituted with 1-3R⁴ and0-3R⁵; each R⁴ is independently —OR⁶, —SR⁶, —S(═O)R⁷, —S(═O)₂R⁷, or—N(R⁶)₂; each R⁵ is independently halogen, —CN, —OR⁸, —SR⁸, —S(═O)R⁹,—S(═O)₂R⁹, —S(═O)₂N(R⁸)₂, —NR⁸S(═O)₂R⁹, —C(═O)R⁹, —OC(═O)R⁹, —CO₂R⁸,—OCO₂R⁹, —N(R⁸)₂, —OC(═O)N(R⁸)₂, —NR⁸C(═O)R⁹, —NR⁸C(═O)OR⁹, optionallysubstituted C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl,optionally substituted C₁-C₆heteroalkyl, optionally substitutedC₃-C₆cycloalkyl, optionally substituted aryl, or optionally substitutedheteroaryl; A¹ is N or CR^(A); A² is N or CR^(A); A⁴ is N or CR^(A); A⁵is N or CR^(A); each R^(A) is independently H or optionally substitutedC₁-C₆alkyl; R^(A′) is optionally substituted C₁-C₆alkyl; R¹ and R² areeach independently H or optionally substituted C₁-C₆alkyl; L¹ and L² areeach independently —CHY—, —CH₂— or —NH—; Y is optionally substitutedC₁-C₆alkyl;

is optionally substituted aryl or optionally substituted heteroaryl,wherein if

is substituted, then

is substituted with 0-4 R^(c); each R^(c) is independently H, halogen,—CN, —OR¹⁰, —SR¹⁰, —S(═O)R¹¹, —S(═O)₂R¹¹, —S(═O)₂N(R¹⁰)₂,—NR¹⁰S(═O)₂R¹¹, —C(═O)R¹¹, —OC(═O)R¹¹, —CO₂R¹⁰, —OCO₂R¹¹, —N(R¹⁰)₂,—OC(═O)N(R¹⁰)₂, —NR¹⁰C(═O)R¹¹, —NR¹⁰C(═O)OR¹¹, optionally substitutedC₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl, optionallysubstituted C₁-C₆heteroalkyl, optionally substituted C₃-C₆cycloalkyl,optionally substituted aryl, or optionally substituted heteroaryl; eachR³ is independently H or optionally substituted C₁-C₆alkyl;

or L^(D);

is optionally substituted heterocyclyl containing at least one N atom;wherein if

is substituted, then

is substituted with 0-4 R^(D); L^(D) is —N(R¹²)-(optionally substitutedC₁-C₆ alkyl), —N(R¹³)-(optionally substituted C₁-C₆ alkylene)—N(R¹⁴)₂ or-(optionally substituted C₁-C₆ alkylene)—N(R¹⁴)₂; wherein if L^(D) issubstituted, then L^(D) is substituted with 0-4 R^(D); each R^(D) isindependently halogen, —CN, —OR¹⁵, —SR¹⁵, —S(═O)R¹⁶, —S(═O)₂R¹⁶,—S(═O)₂N(R¹⁵)₂, —NR¹⁵S(═O)₂R¹⁶, —C(═O)R¹⁶, —OC(═O)R¹⁶, —CO₂R¹⁵,—OCO₂R¹⁶, —N(R¹⁵)₂, —OC(═O)N(R¹)₂, —NR¹⁵C(═O)R¹⁶, —NR¹⁵C(═O)OR¹⁶,optionally substituted C₁-C₆alkyl, optionally substitutedC₁-C₆fluoroalkyl, optionally substituted C₁-C₆heteroalkyl, optionallysubstituted C₃-C₆cycloalkyl, optionally substituted aryl, or optionallysubstituted heteroaryl; each R⁶ is independently hydrogen, optionallysubstituted C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl,optionally substituted C₁-C₆heteroalkyl, optionally substitutedC₃-C₁₀cycloalkyl, optionally substituted C₂-C₁₀heterocycloalkyl,optionally substituted aryl, or optionally substituted heteroaryl; ortwo R⁶ are taken together with the N atom to which they are attached toform an optionally substituted heterocycle; each R⁷ is independentlyoptionally substituted C₁-C₆alkyl, optionally substitutedC₁-C₆fluoroalkyl, optionally substituted C₁-C₆heteroalkyl, optionallysubstituted C₃-C₁₀cycloalkyl, optionally substitutedC₂-C₁₀heterocycloalkyl, optionally substituted aryl, or optionallysubstituted heteroaryl; each R⁸ is independently hydrogen, optionallysubstituted C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl,optionally substituted C₁-C₆heteroalkyl, optionally substitutedC₃-C₁₀cycloalkyl, optionally substituted C₂-C₁₀heterocycloalkyl,optionally substituted aryl, or optionally substituted heteroaryl; ortwo R⁸ are taken together with the N atom to which they are attached toform an optionally substituted heterocycle; each R⁹ is independentlyoptionally substituted C₁-C₆alkyl, optionally substitutedC₁-C₆fluoroalkyl, optionally substituted C₁-C₆heteroalkyl, optionallysubstituted C₃-C₁₀cycloalkyl, optionally substitutedC₂-C₁₀heterocycloalkyl, optionally substituted aryl, or optionallysubstituted heteroaryl; each R¹⁰ is independently hydrogen, optionallysubstituted C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl,optionally substituted C₁-C₆heteroalkyl, optionally substitutedC₃-C₁₀cycloalkyl, optionally substituted C₂-C₁₀heterocycloalkyl,optionally substituted aryl, or optionally substituted heteroaryl; ortwo R¹⁰ are taken together with the N atom to which they are attached toform an optionally substituted heterocycle; each R¹¹ is independentlyoptionally substituted C₁-C₆alkyl, optionally substitutedC₁-C₆fluoroalkyl, optionally substituted C₁-C₆heteroalkyl, optionallysubstituted C₃-C₁₀cycloalkyl, optionally substitutedC₂-C₁₀10heterocycloalkyl, optionally substituted aryl, or optionallysubstituted heteroaryl; each R¹² and R¹³ is independently H oroptionally substituted C₁-C₆alkyl; each R¹⁴ is independently H oroptionally substituted C₁-C₆alkyl; or two R¹⁴ are taken together withthe N atom to which they are attached to form an optionally substitutedheterocycle; each R¹⁵ is independently hydrogen, optionally substitutedC₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl, optionallysubstituted C₁-C₆heteroalkyl, optionally substituted C₃-C₁₀cycloalkyl,optionally substituted C₂-C₁₀10heterocycloalkyl, optionally substitutedaryl, or optionally substituted heteroaryl; or two R¹⁵ are takentogether with the N atom to which they are attached to form anoptionally substituted heterocycle; and each R¹⁶ is independentlyoptionally substituted C₁-C₆alkyl, optionally substitutedC₁-C₆fluoroalkyl, optionally substituted C₁-C₆heteroalkyl, optionallysubstituted C₃-C₁₀cycloalkyl, optionally substitutedC₂-C₁₀heterocycloalkyl, optionally substituted aryl, or optionallysubstituted heteroaryl.
 59. The compound of claim 58, or apharmaceutically acceptable salt, or solvate thereof, wherein Z is H.60. The compound of claim 58, or a pharmaceutically acceptable salt, orsolvate thereof, wherein Z


61. The compound of claim 58, or a pharmaceutically acceptable salt, orsolvate thereof, wherein

is optionally substituted C₄-C₇ heterocyclyl containing at least one N,O, S, S(═O), or S(═O)₂; wherein if

is substituted, then

is substituted with 0-3 R⁵.
 62. The compound of claim 60, or apharmaceutically acceptable salt, or solvate thereof, wherein

o is 0, 1, or 2; and p is 0, 1, 2, or
 3. 63. The compound of claim 62,or a pharmaceutically acceptable salt, or solvate thereof, wherein

and o is 0, 1, or
 2. 64. The compound of claim 58, or a pharmaceuticallyacceptable salt, or solvate thereof, wherein Z is


65. The compound of claim 64, or a pharmaceutically acceptable salt, orsolvate thereof, wherein

is substituted C₄-C₇ cycloalkyl that is substituted with 1-3R⁴ and0-3R⁵.
 66. The compound of claim 64, or a pharmaceutically acceptablesalt, or solvate thereof, wherein

and q is 0, 1, 2, or
 3. 67. The compound of claim 66, or apharmaceutically acceptable salt, or solvate thereof, wherein

and q is 0, 1, 2, or
 3. 68. The compound of any one of claims 58-67, ora pharmaceutically acceptable salt, or solvate thereof, wherein A¹ isCH; A² is N or CR^(A); A⁴ is CH; and A⁵ is CH.
 69. The compound of claim68, or a pharmaceutically acceptable salt, or solvate thereof, whereinA² is N.
 70. The compound of claim 68, or a pharmaceutically acceptablesalt, or solvate thereof, wherein A² is CR^(A).
 71. The compound of anyone of claims 58-70, or a pharmaceutically acceptable salt, or solvatethereof, wherein R^(A′) is optionally substituted C₁-C₄alkyl.
 72. Thecompound of any one of claims 58-70, or a pharmaceutically acceptablesalt, or solvate thereof, wherein R^(A′) is methyl, ethyl, propyl, andbutyl.
 73. The compound of any one of claims 58-70, or apharmaceutically acceptable salt, or solvate thereof, wherein R^(A′)ethyl, propyl, and butyl.
 74. The compound of any one of claims 58-73,or a pharmaceutically acceptable salt, or solvate thereof, wherein R¹ isoptionally substituted C₁-C₆alkyl.
 75. The compound of claim 74, or apharmaceutically acceptable salt, or solvate thereof, wherein R¹ ismethyl.
 76. The compound of any one of claims 58-75, or apharmaceutically acceptable salt, or solvate thereof, wherein R² is H.77. The compound of any one of claims 58-76, or a pharmaceuticallyacceptable salt, or solvate thereof, wherein L¹ and L² are each —NH—.78. The compound of any one of claims 58-76, or a pharmaceuticallyacceptable salt, or solvate thereof, wherein L¹ is —CH₂— and L² is —NH—.79. The compound of any one of claims 58-76, or a pharmaceuticallyacceptable salt, or solvate thereof, wherein L¹ is —NH— and L² is —CH₂—.80. The compound of any one of claims 58-79, or a pharmaceuticallyacceptable salt, or solvate thereof, wherein

is optionally substituted aryl, wherein if

is substituted, then

is substituted with 0-4 R^(c).
 81. The compound of any one of claims58-79, or a pharmaceutically acceptable salt, or solvate thereof,wherein

is optionally substituted heteroaryl wherein if

is substituted, then

is substituted with 0-4R^(c).
 82. The compound of any one of claims58-79, or a pharmaceutically acceptable salt, or solvate thereof,wherein

C¹ is N or CR^(C); C² is N or CR^(C); C³ is N or CR^(C); and C⁴ is N orCR^(C).
 83. The compound of claim 82, or a pharmaceutically acceptablesalt, or solvate thereof, wherein C¹ is CR^(C); C² is CR^(C); C³ isCR^(C); and C⁴ is CR^(C).
 84. The compound of claim 83, or apharmaceutically acceptable salt, or solvate thereof, wherein C¹ isCR^(C); C² is CH; C³ is CH; and C⁴ is CH.
 85. The compound of claim 84,or a pharmaceutically acceptable salt, or solvate thereof, wherein R^(C)is optionally substituted C₁-C₆fluoroalkyl.
 86. The compound of claim85, or a pharmaceutically acceptable salt, or solvate thereof, whereinR^(C) is —CF₃.
 87. The compound of any one of claims 58-86, or apharmaceutically acceptable salt, or solvate thereof, wherein each R³ isindependently H.
 88. The compound of any one of claims 58-87, or apharmaceutically acceptable salt, or solvate thereof, wherein


89. The compound of claim 88, or a pharmaceutically acceptable salt, orsolvate thereof, wherein

is optionally substituted heterocyclyl containing at least one N atom;and if

is substituted, then

is substituted with 0-4 R^(D).
 90. The compound of claim 88, or apharmaceutically acceptable salt, or solvate thereof, wherein

is optionally substituted heterocyclyl containing one N atom; and if

is substituted, then

is substituted with 0-4 R^(D).
 91. The compound of claim 88, or apharmaceutically acceptable salt, or solvate thereof, wherein

is optionally substituted heterocyclyl containing two N atoms; and if

is substituted, then

is substituted with 0-4 R^(D).
 92. The compound of claim 88, or apharmaceutically acceptable salt, or solvate thereof, wherein

and r is 0, 1, or
 2. 93. The compound of claim 92, or a pharmaceuticallyacceptable salt, or solvate thereof, wherein

and r is 0, 1, or
 2. 94. The compound of any one of claims 58-93, or apharmaceutically acceptable salt, or solvate thereof, wherein

is L^(D).
 95. The compound of claim 94, or a pharmaceutically acceptablesalt, or solvate thereof, wherein L^(D) is —N(R¹²)-(optionallysubstituted C₁-C₆ alkyl), —N(R¹³)-(optionally substituted C₁-C₆alkylene)—N(R¹⁴)₂ or -(optionally substituted C₁-C₆ alkylene)—N(R¹⁴)₂;and if L^(D) is substituted, then L^(D) is substituted with 0-4 R^(D).96. The compound of claim 95, or a pharmaceutically acceptable salt, orsolvate thereof, wherein L^(D) is —N(R¹²)-(optionally substituted C₁-C₆alkyl), and if L^(D) is substituted, then L^(D) is substituted with 0-4R^(D).
 97. The compound of claim 96, or a pharmaceutically acceptablesalt, or solvate thereof, wherein L^(D) is —N(R¹²)—CH₂—CH₂—CH₂—CH₃,—N(R¹²)—CH₂—CH₂—CH₃, —N(R¹²)—CH₂—CH₃, or —N(R¹²)—CH₃.
 98. The compoundof claim 96 or 97, or a pharmaceutically acceptable salt, or solvatethereof, wherein R¹² is H or C₁-C₄alkyl.
 99. The compound of claim 96 or97, or a pharmaceutically acceptable salt, or solvate thereof, whereinR¹² is H or C₃-C₄alkyl.
 100. The compound of claim 95, or apharmaceutically acceptable salt, or solvate thereof, wherein L^(D) is—N(R¹³)-(optionally substituted C₁-C₆ alkylene)—N(R¹⁴)₂, and if L^(D) issubstituted, then L^(D) is substituted with 0-4 R^(D).
 101. The compoundof claim 100, or a pharmaceutically acceptable salt, or solvate thereof,wherein L^(D) is —N(R¹³)—CH₂—CH₂—CH₂—CH₂—CH₂—N(R¹⁴)₂,—N(R¹³)—CH₂—CH₂—CH₂—N(R¹⁴)₂, —N(R¹³)—CH₂—CH—N(R¹⁴)₂, or—N(R¹³)—CH₂—N(R¹⁴)₂.
 102. The compound of claim 100 or 101, or apharmaceutically acceptable salt, or solvate thereof, wherein each R¹³and R¹⁴ is independently H or C₁-C₄alkyl.
 103. The compound of claim 95,or a pharmaceutically acceptable salt, or solvate thereof, wherein L^(D)is or -(optionally substituted C₁-C₆ alkylene)—N(R¹⁴)₂; and if L^(D) issubstituted, then L^(D) is substituted with 0-4 R^(D).
 104. The compoundof claim 103, or a pharmaceutically acceptable salt, or solvate thereof,wherein L^(D) is —CH₂—CH₂—CH₂—CH₂—N(R¹⁴)₂, —CH₂—CH₂—CH₂—N(R¹⁴)₂,—CH₂—CH₂—N(R¹⁴)₂, or —CH₂—N(R¹⁴)₂.
 105. The compound of claim 103 or104, or a pharmaceutically acceptable salt, or solvate thereof, whereineach R¹⁴ is independently H or C₁-C₄alkyl.
 106. The compound of claim58, or a pharmaceutically acceptable salt, or solvate thereof, whereinthe compound has the structure of formula (IIa)

wherein, C¹ is N or CR^(C); C² is N or CR^(C); C³ is N or CR^(C); and C⁴is N or CR^(C).
 107. The compound of claim 58, or a pharmaceuticallyacceptable salt, or solvate thereof, wherein the compound has thestructure of formula (IIb)

wherein, C¹ is N or CR^(C); C² is N or CR^(C); C³ is N or CR^(C); and C⁴is N or CR^(C).
 108. The compound of claim 58, or a pharmaceuticallyacceptable salt, or solvate thereof, wherein the compound has thestructure of formula (IIc)

wherein, C¹ is N or CR^(C); C² is N or CR^(C); C³ is N or CR^(C); and C⁴is N or CR^(C).
 109. The compound of claim 58, or a pharmaceuticallyacceptable salt, or solvate thereof, wherein the compound has thestructure of formula (IId)

wherein, C¹ is N or CR^(C); C² is N or CR^(C); C³ is N or CR^(C); and C⁴is N or CR^(C).
 110. The compound of claim 58, or a pharmaceuticallyacceptable salt, or solvate thereof, wherein the compound has thestructure of formula (IIe)

wherein, C¹ is N or CR^(C); C² is N or CR^(C); C³ is N or CR^(C); and C⁴is N or CR^(C).
 111. The compound of claim 58, or a pharmaceuticallyacceptable salt, or solvate thereof, wherein the compound has thestructure of formula (IIf)

wherein, C¹ is N or CR^(C); C² is N or CR^(C); C³ is N or CR^(C); and C⁴is N or CR^(C).
 112. The compound of claim 58, or a pharmaceuticallyacceptable salt, or solvate thereof, wherein the compound has thestructure of formula (IIg)

wherein, C¹ is N or CR^(C); C² is N or CR^(C); C³ is N or CR^(C); and C⁴is N or CR^(C).
 113. The compound of claim 58, or a pharmaceuticallyacceptable salt, or solvate thereof, wherein the compound has thestructure of formula (IIh)


114. The compound of claim 58, or a pharmaceutically acceptable salt, orsolvate thereof, wherein the compound has the structure of formula (IIi)


115. The compound of claim 58, or a pharmaceutically acceptable salt, orsolvate thereof, wherein the compound has the structure of formula (IIj)


116. The compound of claim 58, or a pharmaceutically acceptable salt, orsolvate thereof, wherein the compound has the structure of formula (IIk)


117. The compound of claim 58, or a pharmaceutically acceptable salt, orsolvate thereof, wherein the compound has the structure of formula (IIl)


118. The compound of claim 58, or a pharmaceutically acceptable salt, orsolvate thereof, wherein the compound has the structure of formula (IIm)


119. A compound of Formula (III), or a pharmaceutically acceptable salt,or solvate thereof:

wherein, Z is H,

is an optionally substituted C₃-C₁₀ heterocyclyl containing at least oneN, O, S, S(═O), or S(═O)₂; wherein if

is substituted, then

is substituted with 0-3 R⁵;

is a substituted C₃-C₁₀ cycloalkyl that is substituted with 1-3R⁴ and0-3R⁵; each R⁴ is independently —OR⁶, —SR⁶, —S(═O)R⁷, —S(═O)₂R⁷, or—N(R⁶)₂; each R⁵ is independently halogen, —CN, —OR⁸, —SR⁸, —S(═O)R⁹,—S(═O)₂R⁹, —S(═O)₂N(R⁸)₂, —NR⁸S(═O)₂R⁹, —C(═O)R⁹, —OC(═O)R⁹, —CO₂R⁸,—OCO₂R⁹, —N(R⁸)₂, —OC(═O)N(R⁸)₂, —NR⁸C(═O)R⁹, —NR⁸C(═O)OR⁹, optionallysubstituted C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl,optionally substituted C₁-C₆heteroalkyl, optionally substitutedC₃-C₆cycloalkyl, optionally substituted aryl, or optionally substitutedheteroaryl; A¹ is N or CR^(A); A² is N or CR^(A); A³ is N or CR^(A); A⁴is N or CR^(A); A⁵ is N or CR^(A); each R^(A) is independently H oroptionally substituted C₁-C₆alkyl; R¹ and R² are each independently H oroptionally substituted C₁-C₆alkyl; L¹ and L² are each independently—CHY—, —CH₂— or —NH—; Y is optionally substituted C₁-C₆alkyl;

is optionally substituted aryl or optionally substituted heteroaryl,wherein if

is substituted, then

is substituted with 0-4 R^(c); each R^(c) is independently H, halogen,—CN, —OR¹⁰, —SR¹⁰, —S(═O)R¹¹, —S(═O)₂R¹¹, —S(═O)₂N(R¹⁰)₂,—NR¹⁰S(═O)₂R¹¹, —C(═O)R¹¹, —OC(═O)R¹¹, —CO₂R¹⁰, —OCO₂R¹¹, —N(R¹⁰)₂,—OC(═O)N(R¹⁰)₂, —NR¹⁰C(═O)R¹¹, —NR¹¹C(═O)OR¹¹, optionally substitutedC₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl, optionallysubstituted C₁-C₆heteroalkyl, optionally substituted C₃-C₆cycloalkyl,optionally substituted aryl, or optionally substituted heteroaryl; eachR³ is independently H or optionally substituted C₁-C₆alkyl; L^(D) is—N(R¹²)-(optionally substituted C₁-C₆ alkyl), —N(R¹³)-(optionallysubstituted C₁-C₆ alkylene)—N(R¹⁴)₂ or -(optionally substituted C₁-C₆alkylene)—N(R¹⁴)₂; wherein if L^(D) is substituted, then L^(D) issubstituted with 0-4 R^(D); each R^(D) is independently halogen, —CN,—OR¹⁵, —SR¹⁵, —S(═O)R¹⁶, —S(═O)₂R¹⁶, —S(═O)₂N(R¹⁵)₂, —NR¹⁵S(═O)₂R¹⁶,—C(═O)R¹⁶, —OC(═O)R¹⁶, —CO₂R¹⁵, —OCO₂R¹⁶, —N(R¹⁵)₂, —OC(═O)N(R¹⁵)₂,—NR¹⁵C(═O)R¹⁶, —NR¹⁵C(═O)OR¹⁶, optionally substituted C₁-C₆alkyl,optionally substituted C₁-C₆fluoroalkyl, optionally substitutedC₁-C₆heteroalkyl, optionally substituted C₃-C₆cycloalkyl, optionallysubstituted aryl, or optionally substituted heteroaryl; each R⁶ isindependently hydrogen, optionally substituted C₁-C₆alkyl, optionallysubstituted C₁-C₆fluoroalkyl, optionally substituted C₁-C₆heteroalkyl,optionally substituted C₃-C₁₀cycloalkyl, optionally substitutedC₂-C₁₀heterocycloalkyl, optionally substituted aryl, or optionallysubstituted heteroaryl; or two R⁶ are taken together with the N atom towhich they are attached to form an optionally substituted heterocycle;each R⁷ is independently optionally substituted C₁-C₆alkyl, optionallysubstituted C₁-C₆fluoroalkyl, optionally substituted C₁-C₆heteroalkyl,optionally substituted C₃-C₁₀cycloalkyl, optionally substitutedC₂-C₁₀heterocycloalkyl, optionally substituted aryl, or optionallysubstituted heteroaryl; each R⁸ is independently hydrogen, optionallysubstituted C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl,optionally substituted C₁-C₆heteroalkyl, optionally substitutedC₃-C₁₀cycloalkyl, optionally substituted C₂-C₁₀heterocycloalkyl,optionally substituted aryl, or optionally substituted heteroaryl; ortwo R⁸ are taken together with the N atom to which they are attached toform an optionally substituted heterocycle; each R⁹ is independentlyoptionally substituted C₁-C₆alkyl, optionally substitutedC₁-C₆fluoroalkyl, optionally substituted C₁-C₆heteroalkyl, optionallysubstituted C₃-C₁₀cycloalkyl, optionally substitutedC₂-C₁₀heterocycloalkyl, optionally substituted aryl, or optionallysubstituted heteroaryl; each R¹⁰ is independently hydrogen, optionallysubstituted C₁-C₆alkyl, optionally substituted C₁-C₆fluoroalkyl,optionally substituted C₁-C₆heteroalkyl, optionally substitutedC₃-C₁₀cycloalkyl, optionally substituted C₂-C₁₀heterocycloalkyl,optionally substituted aryl, or optionally substituted heteroaryl; ortwo R¹⁰ are taken together with the N atom to which they are attached toform an optionally substituted heterocycle; each R¹¹ is independentlyoptionally substituted C₁-C₆alkyl, optionally substitutedC₁-C₆fluoroalkyl, optionally substituted C₁-C₆heteroalkyl, optionallysubstituted C₃-C₁₀cycloalkyl, optionally substitutedC₂-C₁₀heterocycloalkyl, optionally substituted aryl, or optionallysubstituted heteroaryl; R¹² is independently H or optionally substitutedC₃-C₆alkyl; R¹³ is H or optionally substituted C₁-C₆alkyl; each R¹⁴ isindependently H or optionally substituted C₁-C₆alkyl; or two R¹⁴ aretaken together with the N atom to which they are attached to form anoptionally substituted heterocycle; each R¹⁵ is independently hydrogen,optionally substituted C₁-C₆alkyl, optionally substitutedC₁-C₆fluoroalkyl, optionally substituted C₁-C₆heteroalkyl, optionallysubstituted C₃-C₁₀cycloalkyl, optionally substitutedC₂-C₁₀heterocycloalkyl, optionally substituted aryl, or optionallysubstituted heteroaryl; or two R¹⁵ are taken together with the N atom towhich they are attached to form an optionally substituted heterocycle;and each R¹⁶ is independently optionally substituted C₁-C₆alkyl,optionally substituted C₁-C₆fluoroalkyl, optionally substitutedC₁-C₆heteroalkyl, optionally substituted C₃-C₁₀cycloalkyl, optionallysubstituted C₂-C₁₀heterocycloalkyl, optionally substituted aryl, oroptionally substituted heteroaryl.
 120. The compound of claim 119, or apharmaceutically acceptable salt, or solvate thereof, wherein Z is H.121. The compound of claim 119, or a pharmaceutically acceptable salt,or solvate thereof, wherein Z is


122. The compound of claim 121, or a pharmaceutically acceptable salt,or solvate thereof, wherein

is optionally substituted C₄-C₇ heterocyclyl containing at least one N,O, S, S(═O), or S(═O)₂; wherein if

is substituted, then

is substituted with 0-3 R⁵.
 123. The compound of claim 121, or apharmaceutically acceptable salt, or solvate thereof, wherein

o is 0, 1, or 2; and p is 0, 1, 2, or
 3. 124. The compound of claim 123,or a pharmaceutically acceptable salt, or solvate thereof, wherein

and o is 0, 1, or
 2. 125. The compound of claim 119, or apharmaceutically acceptable salt, or solvate thereof, wherein Z is


126. The compound of claim 125, or a pharmaceutically acceptable salt,or solvate thereof, wherein

is substituted C₄-C₇ cycloalkyl that is substituted with 1-3R⁴ and0-3R⁵.
 127. The compound of claim 125, or a pharmaceutically acceptablesalt, or solvate thereof, wherein

and q is 0, 1, 2, or
 3. 128. The compound of claim 127, or apharmaceutically acceptable salt, or solvate thereof, wherein

and q is 0, 1, 2, or
 3. 129. The compound of any one of claims 119-128,or a pharmaceutically acceptable salt, or solvate thereof, wherein A¹ isCH; A² is N or CR^(A); A³ is N or CR^(A); A⁴ is CH; and A⁵ is CH. 130.The compound of claim 129, or a pharmaceutically acceptable salt, orsolvate thereof, wherein A² is N.
 131. The compound of claim 129, or apharmaceutically acceptable salt, or solvate thereof, wherein A² isCR^(A).
 132. The compound of any one of claims 129-131, or apharmaceutically acceptable salt, or solvate thereof, wherein A³ isCR^(A).
 133. The compound of claim 132, or a pharmaceutically acceptablesalt, or solvate thereof, wherein R^(A) is optionally substitutedC₁-C₆alkyl.
 134. The compound of claim 133, or a pharmaceuticallyacceptable salt, or solvate thereof, wherein R^(A) is methyl, ethyl,propyl or butyl.
 135. The compound of claim 133, or a pharmaceuticallyacceptable salt, or solvate thereof, wherein R^(A) is methyl, propyl orbutyl.
 136. The compound of any one of claims 119-135, or apharmaceutically acceptable salt, or solvate thereof, wherein R¹ isoptionally substituted C₁-C₆alkyl.
 137. The compound of claim 136, or apharmaceutically acceptable salt, or solvate thereof, wherein R¹ ismethyl.
 138. The compound of any one of claims 119-137, or apharmaceutically acceptable salt, or solvate thereof, wherein R² is H.139. The compound of any one of claims 119-138, or a pharmaceuticallyacceptable salt, or solvate thereof, wherein L¹ and L² are each —NH—.140. The compound of any one of claims 119-138, or a pharmaceuticallyacceptable salt, or solvate thereof, wherein L¹ is —CH₂— and L² is —NH—.141. The compound of any one of claims 119-138, or a pharmaceuticallyacceptable salt, or solvate thereof, wherein L¹ is —NH— and L² is —CH₂—.142. The compound of any one of claims 119-141, or a pharmaceuticallyacceptable salt, or solvate thereof, wherein

is optionally substituted aryl, wherein if

is substituted, then

is substituted with 0-4R^(c).
 143. The compound of any one of claims119-141, or a pharmaceutically acceptable salt, or solvate thereof,wherein

is optionally substituted heteroaryl wherein if

is substituted, then

is substituted with 0-4 R^(c).
 144. The compound of any one of claims119-141, or a pharmaceutically acceptable salt, or solvate thereof,wherein

C¹ is N or CR^(C); C² is N or CR^(C); C³ is N or CR^(C); and C⁴ is N orCR^(C).
 145. The compound of claim 144, or a pharmaceutically acceptablesalt, or solvate thereof, wherein C¹ is CR^(C); C² is CR^(C); C³ isCR^(C); and C⁴ is CR^(C).
 146. The compound of claim 145, or apharmaceutically acceptable salt, or solvate thereof, wherein C¹ isCR^(C); C² is CH; C³ is CH; and C⁴ is CH.
 147. The compound of claim146, or a pharmaceutically acceptable salt, or solvate thereof, whereinR^(C) is optionally substituted C₁-C₆fluoroalkyl.
 148. The compound ofclaim 147, or a pharmaceutically acceptable salt, or solvate thereof,wherein R^(C) is —CF₃.
 149. The compound of any one of claims 119-148,or a pharmaceutically acceptable salt, or solvate thereof, wherein eachR³ is independently H.
 150. The compound of any one of claims 119-149,or a pharmaceutically acceptable salt, or solvate thereof, wherein L^(D)is —N(R¹²)-(optionally substituted C₁-C₆ alkyl), —N(R¹³)-(optionallysubstituted C₁-C₆ alkylene)—N(R¹⁴)₂ or -(optionally substituted C₁-C₆alkylene)—N(R¹⁴)₂; and if L^(D) is substituted, then L^(D) issubstituted with 0-4 R^(D).
 151. The compound of claim 150, or apharmaceutically acceptable salt, or solvate thereof, wherein L^(D) is—N(R¹²)-(optionally substituted C₁-C₆ alkyl), and if L^(D) issubstituted, then L^(D) is substituted with 0-4 R^(D).
 152. The compoundof claim 151, or a pharmaceutically acceptable salt, or solvate thereof,wherein L^(D) is —N(R¹²)—CH₂—CH₂—CH₂—CH₃, —N(R¹²)—CH₂—CH₂—CH₃,—N(R¹²)—CH₂—CH₃, or —N(R₁₂)—CH₃.
 153. The compound of claim 151 or 152,or a pharmaceutically acceptable salt, or solvate thereof, wherein R¹²is H or C₃-C₄alkyl.
 154. The compound of claim 150, or apharmaceutically acceptable salt, or solvate thereof, wherein L^(D) is—N(R¹³)-(optionally substituted C₁-C₆ alkylene)—N(R¹⁴)₂, and if L^(D) issubstituted, then L^(D) is substituted with 0-4 R^(D).
 155. The compoundof claim 154, or a pharmaceutically acceptable salt, or solvate thereof,wherein L^(D) is —N(R¹³)—CH₂—CH₂—CH₂—CH₂CH—N(R¹⁴)₂,—N(R¹³)—CH₂—CH₂—CH₂—N(R¹⁴)₂, —N(R¹³)—CH₂—CH₂—N(R¹⁴)₂, or—N(R¹³)—CH₂—N(R¹⁴)₂.
 156. The compound of claim 154 or 155, or apharmaceutically acceptable salt, or solvate thereof, wherein each R¹³and R¹⁴ is independently H or C₁-C₄alkyl.
 157. The compound of claim150, or a pharmaceutically acceptable salt, or solvate thereof, whereinL^(D) is or -(optionally substituted C₁-C₆ alkylene)—N(R¹⁴)₂; and ifL^(D) is substituted, then L^(D) is substituted with 0-4 R^(D).
 158. Thecompound of claim 157, or a pharmaceutically acceptable salt, or solvatethereof, wherein L^(D) is —CH₂—CH₂—CH₂—CH₂—N(R¹⁴)₂,—CH₂—CH₂—CH₂—N(R¹⁴)₂, —CH₂—CH₂—N(R¹⁴)₂, or —CH₂—N(R¹⁴)₂.
 159. Thecompound of claims 157-158, or a pharmaceutically acceptable salt, orsolvate thereof, wherein each R¹⁴ is independently H or C₁-C₄alkyl. 160.The compound of claim 119, or a pharmaceutically acceptable salt, orsolvate thereof, wherein the compound has the structure of formula(IIIa)

wherein, C¹ is N or CR^(C); C² is N or CR^(C); C³ is N or CR^(C); and C⁴is N or CR^(C).
 161. The compound of claim 119, or a pharmaceuticallyacceptable salt, or solvate thereof, wherein the compound has thestructure of formula (IIIb)

wherein, C¹ is N or CR^(C); C² is N or CR^(C); C³ is N or CR^(C); and C⁴is N or CR^(C).
 162. The compound of claim 119, or a pharmaceuticallyacceptable salt, or solvate thereof, wherein the compound has thestructure of formula (IIIc)

wherein, C¹ is N or CR^(C); C² is N or CR^(C); C³ is N or CR^(C); and C⁴is N or CR^(C).
 163. The compound of claim 119, or a pharmaceuticallyacceptable salt, or solvate thereof, wherein the compound has thestructure of formula (IIId)

wherein, C¹ is N or CR^(C); C² is N or CR^(C); C³ is N or CR^(C); and C⁴is N or CR^(C).
 164. The compound of claim 119, or a pharmaceuticallyacceptable salt, or solvate thereof, wherein the compound has thestructure of formula (IIIe)


165. The compound of claim 119, or a pharmaceutically acceptable salt,or solvate thereof, wherein the compound has the structure of formula(IIIf)


166. The compound of claim 119, or a pharmaceutically acceptable salt,or solvate thereof, wherein the compound has the structure of formula(IIIg)


167. The compound of claim 119, or a pharmaceutically acceptable salt,or solvate thereof, wherein the compound has the structure of formula(IIIh)


168. The compound of any one of claims 1-167, or a pharmaceuticallyacceptable salt, or solvate thereof, wherein the compound orpharmaceutically acceptable salt, or solvate thereof, selectively bindsto IRE1α at one or more binding sites.
 169. The compound of claim 168,wherein the IRE1α comprises an RNase domain, a kinase domain, or anycombination thereof.
 170. The compound of claim 169, wherein the kinasedomain is an auto-transphosphorylation kinase domain.
 171. The compoundof claim 169 or 170, wherein the kinase domain comprises an ATP-bindingpocket.
 172. The compound of any one of claims 168-171, wherein thekinase domain comprises an activation loop.
 173. The compound of any oneof claims 168-172, wherein at least one binding site is within the RNasedomain.
 174. The compound of any one of claims 168-173, where at leastone binding site is within the kinase domain.
 175. The compound of claim174, wherein the at least one binding site is within the ATP-bindingpocket of the kinase domain.
 176. The compound of claim 174, wherein theat least one binding site is within the activation loop of the kinasedomain.
 177. The compound of any one of claims 168-176, wherein bindingoccurs at a first binding site.
 178. The compound of claim 177, whereinthe first binding site is located within the RNase domain, kinasedomain, ATP-binding pocket, or activation loop.
 179. The compound of anyone of claims 177-178, wherein the first binding site comprises at leastone amino acid residue of within amino acid residues 465-977 of SEQ IDNO:
 1. 180. The compound of claim 179, wherein the first binding sitecomprises at least one amino acid residue within amino acid residues568-833 of SEQ ID NO:
 1. 181. The compound of claim 179, wherein thefirst binding site comprises at least one amino acid residue withinamino acid residues 577-586, 597, 599, 626, 642-643, 645, 648, 688,692-693, 695, or 711 of SEQ ID NO:
 1. 182. The compound of claim 179,wherein the first binding site comprises at least one amino acid residuewithin amino acid residues 710-725 or 729-736 of SEQ ID NO:
 1. 183. Thecompound of claim 179, wherein the first binding site comprises at leastone amino acid residue within amino acid residues 835-963 of SEQ IDNO:
 1. 184. The compound of any one of claims 177-183, wherein bindingfurther occurs at a second binding site.
 185. The compound of claim 184,wherein the second binding site is located within the RNase domain, thekinase domain, the ATP-binding pocket, or the activation loop.
 186. Thecompound of claim 184, wherein the second binding site comprises atleast one amino acid residue of within amino acid residues 465-977 ofSEQ ID NO:
 1. 187. The compound of claim 184, wherein the second bindingsite comprises at least one amino acid residue within amino acidresidues 568-833 of SEQ ID NO:
 1. 188. The compound of claim 184,wherein the second binding site comprises at least one amino acidresidue within amino acid residues 577-586, 597, 599, 626, 642-643, 645,648, 688, 692-693, 695, or 711 of SEQ ID NO:
 1. 189. The compound ofclaim 184, wherein the second binding site comprises at least one aminoacid residue within amino acid residues 710-725 or 729-736 of SEQ IDNO:
 1. 190. The compound of claim 184, wherein the second binding sitecomprises at least one amino acid residue within amino acid residues835-963 of SEQ ID NO:
 1. 191. The compound of any one of claims 168-190,wherein binding occurs when the IRE1α is in a homo-dimerizedconformation.
 192. The compound of any one of claims 168-190, whereinbinding occurs when the IRE1α is in an oligomerized conformation. 193.The compound of any one of claims 168-190, wherein binding occurs whenthe IRE1α is in a non-oligomerized or non-dimerized conformation. 194.The compound of any one of claims 168-193, wherein binding occurs whenthe IRE1α is in an ATP-bound state.
 195. The compound of any one ofclaims 168-193, wherein binding occurs when the IRE1α is in anon-ATP-bound state.
 196. The compound of any one of claims 168-195,wherein the compound selectively binds to a first IRE1α.
 197. Thecompound of claim 196, wherein selectively binding to the first IRE1αblocks dimerization of the first IRE1α to a second IRE1α.
 198. Thecompound of claim 196, wherein selectively binding to the first IRE1αblocks auto-transphosphorylation of the first IRE1α.
 199. The compoundof claim 196, wherein selectively binding to the first IRE1α blocksauto-transphosphorylation of a second IRE1α to which the first IRE1α isdimerized.
 200. The compound of claim 196, wherein selectively bindingto the first IRE1α blocks activation of the first IRE1α.
 201. Thecompound of claim 196, wherein selectively binding to the first IRE1αblocks activation a second IRE1α to which the first IRE1α is dimerized.202. The compound of claim 196, wherein selectively binding to the firstIRE1α blocks kinase activity of the first IRE1α.
 203. The compound ofclaim 196, wherein selectively binding to the first IRE1α blocks kinaseactivity of a second IRE1α to which the first IRE1α is dimerized. 204.The compound of claim 196, wherein selectively binding to the firstIRE1α blocks RNase activity of the first IRE1α.
 205. The compound ofclaim 196, wherein selectively binding to the first IRE1α blocks RNaseactivity of a second IRE1α to which the first IRE1α is dimerized.
 206. Acompound that selectively binds a first IRE1α at two or more sites,wherein when the compound is bound to the first IRE1α protein, thecompound binds to an ATP-binding pocket of the first IRE1α and blocksthe binding of ATP to the first IRE1α.
 207. The compound of claim 206,wherein the ATP binding pocket is comprised within a kinase domain. 208.The compound of claim 206 or 207, wherein the ATP binding pocket iscomprised within amino acid residues 465-977 of SEQ ID NO: 1
 209. Thecompound of any one of claims 206-208, wherein the ATP binding pocket iscomprised within amino acid residues 568-833 of SEQ ID NO:
 1. 210. Thecompound of any one of claims 206-209, wherein the ATP binding pocketcomprises one or more of amino acid resides 577-586, 597, 599, 626,642-643, 645, 648, 688, 692-693, 695, or 711 of SEQ ID NO:
 1. 211. Apharmaceutical composition comprising a compound according to any one ofclaims 1-196, or a pharmaceutically acceptable salt or solvate thereof.212. The pharmaceutical composition of claim 211, comprising one or morepharmaceutically acceptable excipients.
 213. A method for treating orameliorating the effects of a disease associated with altered IRE1signaling, the method comprising administering to a subject in needthereof a pharmaceutical composition, wherein the pharmaceuticalcomposition comprises the compound of any one of claims 1-210.
 214. Themethod of claim 213, wherein the disease is cancer.
 215. The method ofclaim 214, wherein the cancer is a solid cancer or a hematologic cancer.216. The method of claim 214, wherein the cancer is ovarian cancer,breast cancer, or triple negative breast cancer (TNBC).
 217. A methodfor treating or ameliorating a cell proliferative disorder, the methodcomprising administering a pharmaceutical composition comprising acompound, or a pharmaceutically acceptable salt, or solvate thereof,that selectively binds to at least one amino acid residue of a IRE1family protein comprising an RNase domain and kinase domain.
 218. Themethod of claim 217, wherein the IRE1 family protein is IRE1α.
 219. Themethod of claim 218, wherein the compound binds to an ATP-binding siteof IRE1α.
 220. The method of any one of claims 217-219, wherein the cellproliferative disorder is cancer.
 221. The method of claim 220, whereinthe cancer is a solid cancer or a hematologic cancer.
 222. The method ofany one of claims 217-221, wherein the pharmaceutical compositioncomprises the compound of any one of claims 1-210.